Publications: Prof Thomas Powles

Capitanio U, Bedke J, Albiges L, Volpe A, Giles RH, Hora M, Marconi L, Klatte T et al. ( 2023 ) . Reply to Yaxiong Tang, Xu Hu, Kan Wu, Yanxiang Shao, and Xiang Li's Letter to the Editor re: Umberto Capitanio, Jens Bedke, Laurence Albiges, et al. A Renewal of the TNM Staging System for Patients with Renal Cancer To Comply with Current Decision-making: Proposal from the European Association of Urology Guidelines Panel. Eur Urol. 2022;83:3–5 . European Urology vol. 83 , ( 3 ) e74 - e75 .

Chhaya S, Watts I, Ng K, Mustapha R, Powles T, Sharma A, Vasdev N ( 2023 ) . Role of Perioperative Immune Checkpoint Inhibitors in Muscle Invasive Bladder Cancer . Oncology and Therapy vol. 11 , ( 1 ) 49 - 64 .

Navani V, Wells JC, Boyne DJ, Cheung WY, Brenner DM, McGregor BA, Labaki C, Schmidt AL et al. ( 2023 ) . CABOSEQ: The Effectiveness of Cabozantinib in Patients With Treatment Refractory Advanced Renal Cell Carcinoma: Results From the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) . Clinical Genitourinary Cancer vol. 21 , ( 1 ) 106.e1 - 106.e8 .

Hora M, Albiges L, Bedke J, Campi R, Capitanio U, Giles RH, Ljungberg B, Marconi L et al. ( 2023 ) . European Association of Urology Guidelines Panel on Renal Cell Carcinoma Update on the New World Health Organization Classification of Kidney Tumours 2022: The Urologist's Point of View . European Urology vol. 83 , ( 2 ) 97 - 100 .

Huseni MA, Wang L, Klementowicz JE, Yuen K, Breart B, Orr C, Liu LF, Li Y et al. ( 2023 ) . CD8⁺ T cell-intrinsic IL-6 signaling promotes resistance to anti-PD-L1 immunotherapy . Cell Reports Medicine vol. 4 , ( 1 )

Davies CR, Guo T, Burke E, Stankiewicz E, Xu L, Mao X, Scandura G, Rajan P et al. ( 2023 ) . The potential of using circulating tumour cells and their gene expression to predict docetaxel response in metastatic prostate cancer . Frontiers in Oncology vol. 12 ,

Crabb SJ, Hussain S, Soulis E, Hinsley S, Dempsey L, Trevethan A, Song Y, Barber J et al. ( 2023 ) . A Randomized, Double-Blind, Biomarker-Selected, Phase II Clinical Trial of Maintenance Poly ADP-Ribose Polymerase Inhibition with Rucaparib Following Chemotherapy for Metastatic Urothelial Carcinoma . Journal of Clinical Oncology vol. 41 , ( 1 ) 54 - 64 .

Capitanio U, Bedke J, Albiges L, Volpe A, Giles RH, Hora M, Marconi L, Klatte T et al. ( 2023 ) . A Renewal of the TNM Staging System for Patients with Renal Cancer To Comply with Current Decision-making: Proposal from the European Association of Urology Guidelines Panel . European Urology vol. 83 , ( 1 ) 3 - 5 .

Powles T, Burgents JE, Xu L, Choueiri TK ( 2023 ) . Clarification needed for pembrolizumab as adjuvant therapy in clear cell renal cell carcinoma – Authors' reply . The Lancet Oncology vol. 24 , ( 1 ) e1 - e2 .

Balar AV, Castellano DE, Grivas P, Vaughn DJ, Powles T, Vuky J, Fradet Y, Lee JL et al. ( 2023 ) . Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up . Annals of Oncology

Brown JE, Royle KL, Gregory W, Ralph C, Maraveyas A, Din O, Eisen T, Nathan P et al. ( 2023 ) . Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial . The Lancet Oncology

Bedke J, Albiges L, Capitanio U, Giles RH, Hora M, Ljungberg B, Marconi L, Klatte T et al. ( 2023 ) . The 2022 Updated European Association of Urology Guidelines on the Use of Adjuvant Immune Checkpoint Inhibitor Therapy for Renal Cell Carcinoma . European Urology vol. 83 , ( 1 ) 10 - 14 .

Rini BI, Signoretti S, Choueiri TK, McDermott DF, Motzer RJ, George S, Powles T, Donskov F et al. ( 2022 ) . Long-Term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma . Journal for ImmunoTherapy of Cancer vol. 10 , ( 12 )

Choueiri TK, Porta C, Suárez C, Hainsworth J, Voog E, Duran I, Reeves J, Czaykowski P et al. ( 2022 ) . Randomized Phase II Trial of Sapanisertib ± TAK-117 vs. Everolimus in Patients With Advanced Renal Cell Carcinoma After VEGF-Targeted Therapy . The oncologist vol. 27 , ( 12 ) 1048 - 1057 .

Grant M, Hockings H, Lapuente M, Adeniran P, Saud RA, Sivajothi A, Amin J, Crusz SM et al. ( 2022 ) . Learning from Crisis: a Multicentre Study of Oncology Telemedicine Clinics Introduced During COVID-19 . Journal of Cancer Education vol. 37 , ( 6 ) 1861 - 1869 .

Apolo AB, Powles T, Escudier B, Burotto M, Zhang J, Simsek B, Scheffold C, Motzer RJ et al. ( 2022 ) . Nivolumab plus ipilimumab plus cabozantinib triplet combination for patients with previously untreated advanced renal cell carcinoma: Results from a discontinued arm of the phase III CheckMate 9ER trial . European Journal of Cancer vol. 177 , 63 - 71 .

van der Heijden MS, Powles T, Petrylak D, de Wit R, Necchi A, Sternberg CN, Matsubara N, Nishiyama H et al. ( 2022 ) . Predictive biomarkers for survival benefit with ramucirumab in urothelial cancer in the RANGE trial . Nature Communications vol. 13 , ( 1 )

Tannir NM, Agarwal N, Porta C, Lawrence NJ, Motzer R, McGregor B, Lee RJ, Jain RK et al. ( 2022 ) . Efficacy and Safety of Telaglenastat Plus Cabozantinib vs Placebo Plus Cabozantinib in Patients with Advanced Renal Cell Carcinoma: The CANTATA Randomized Clinical Trial . JAMA Oncology vol. 8 , ( 10 ) 1411 - 1418 .

Ljungberg B, Albiges L, Abu-Ghanem Y, Bedke J, Capitanio U, Dabestani S, Fernández-Pello S, Giles RH et al. ( 2022 ) . European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update . European Urology vol. 82 , ( 4 ) 399 - 410 .

Bedke J, Rini BI, Plimack ER, Stus V, Gafanov R, Waddell T, Nosov D, Pouliot F et al. ( 2022 ) . Health-related Quality of Life Analysis from KEYNOTE-426: Pembrolizumab plus Axitinib Versus Sunitinib for Advanced Renal Cell Carcinoma . European Urology vol. 82 , ( 4 ) 427 - 439 .

Szabados B, Ponz-Sarvisé M, Machado R, Saldana D, Kadel EE, Banchereau R, Bouquet F, Garmhausen M et al. ( 2022 ) . Clinico-Genomic Characterization of Patients with Metastatic Urothelial Carcinoma in Real-World Practice Identifies a Novel Bladder Immune Performance Index (BIPI) . Clinical Cancer Research vol. 28 , ( 18 ) 4083 - 4091 .

Powles T, Tomczak P, Park SH, Venugopal B, Ferguson T, Symeonides SN, Hajek J, Gurney H et al. ( 2022 ) . Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial . The Lancet Oncology vol. 23 , ( 9 ) 1133 - 1144 .

Szabados B, Kockx M, Assaf ZJ, van Dam PJ, Rodriguez-Vida A, Duran I, Crabb SJ, Van Der Heijden MS et al. ( 2022 ) . Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder . European Urology vol. 82 , ( 2 ) 212 - 222 .

Abu-Ghanem Y, van Thienen JV, Blank C, Aarts MJB, Jewett M, de Jong IJ, Lattouf JB, van Melick HHE et al. ( 2022 ) . Cytoreductive nephrectomy and exposure to sunitinib – a post hoc analysis of the Immediate Surgery or Surgery After Sunitinib Malate in Treating Patients With Metastatic Kidney Cancer (SURTIME) trial . BJU International vol. 130 , ( 1 ) 68 - 75 .

de Wit R, Powles T, Castellano D, Necchi A, Lee JL, van der Heijden MS, Matsubara N, Bamias A et al. ( 2022 ) . Exposure-response relationship of ramucirumab in RANGE, a randomized phase III trial in advanced urothelial carcinoma refractory to platinum therapy . British Journal of Clinical Pharmacology vol. 88 , ( 7 ) 3182 - 3192 .

Motzer RJ, Powles T, Burotto M, Escudier B, Bourlon MT, Shah AY, Suárez C, Hamzaj A et al. ( 2022 ) . Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial . The Lancet Oncology vol. 23 , ( 7 ) 888 - 898 .

Powles T, Yuen KC, Gillessen S, Kadel EE, Rathkopf D, Matsubara N, Drake CG, Fizazi K et al. ( 2022 ) . Re: Atezolizumab with Enzalutamide versus Enzalutamide Alone in Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase 3 Trial . Journal of Urology vol. 208 , ( 1 ) 214 - 215 .

Navani V, Ernst M, Wells JC, Yuasa T, Takemura K, Donskov F, Basappa NS, Schmidt A et al. ( 2022 ) . Imaging Response to Contemporary Immuno-oncology Combination Therapies in Patients with Metastatic Renal Cell Carcinoma . JAMA Network Open vol. 5 , ( 6 )

Motzer RJ, McDermott DF, Escudier B, Burotto M, Choueiri TK, Hammers HJ, Barthélémy P, Plimack ER et al. ( 2022 ) . Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma . Cancer vol. 128 , ( 11 ) 2085 - 2097 .

Filicevas A, Powles TB ( 2022 ) . Patient and Healthcare Professional Perspectives from ESMO 2021 on Bladder and Kidney Cancer: A Podcast . Oncology and Therapy vol. 10 , ( 1 ) 1 - 11 .

Powles T, Park SH, Voog E, Caserta C, Valderrama BP, Gurney H, Kalofonos H, Radulovic S et al. ( 2022 ) . Plain language summary of results from the JAVELIN Bladder 100 study: Avelumab maintenance treatment for advanced urothelial cancer . Future Oncology vol. 18 , ( 19 )

Graafland NM, Szabados B, Tanabalan C, Kuusk T, Mumtaz F, Barod R, Nicol D, Boleti E et al. ( 2022 ) . Surgical Safety of Deferred Cytoreductive Nephrectomy Following Pretreatment with Immune Checkpoint Inhibitor-based Dual Combination Therapy . European urology oncology vol. 5 , ( 3 ) 373 - 374 .

Bellmunt J, de Wit R, Fradet Y, Climent MA, Petrylak DP, Lee JL, Fong L, Necchi A et al. ( 2022 ) . Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials . Clinical Cancer Research vol. 28 , ( 10 ) 2050 - 2060 .

Hussain SA, Lester JF, Jackson R, Gornall M, Qureshi M, Elliott A, Crabb SJ, Huddart RA et al. ( 2022 ) . Addition of nintedanib or placebo to neoadjuvant gemcitabine and cisplatin in locally advanced muscle-invasive bladder cancer (NEOBLADE): a double-blind, randomised, phase 2 trial . The Lancet Oncology vol. 23 , ( 5 ) 650 - 658 .

Rini BI, Atkins MB, Plimack ER, Soulières D, McDermott RS, Bedke J, Tartas S, Alekseev B et al. ( 2022 ) . Characterization and Management of Treatment-emergent Hepatic Toxicity in Patients with Advanced Renal Cell Carcinoma Receiving First-line Pembrolizumab plus Axitinib. Results from the KEYNOTE-426 Trial . European urology oncology vol. 5 , ( 2 ) 225 - 234 .

Oldenburg J, Berney DM, Bokemeyer C, Climent MA, Daugaard G, Gietema JA, De Giorgi U, Haugnes HS et al. ( 2022 ) . Testicular seminoma and non-seminoma: ESMO-EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up ^☆ . Annals of Oncology vol. 33 , ( 4 ) 362 - 375 .

Motzer RJ, Choueiri TK, McDermott DF, Powles T, Vano YA, Gupta S, Yao J, Han C et al. ( 2022 ) . Biomarker analysis from CheckMate 214: Nivolumab plus ipilimumab versus sunitinib in renal cell carcinoma . Journal for ImmunoTherapy of Cancer vol. 10 , ( 3 )

Powles T, Bellmunt J, Comperat E, De Santis M, Huddart R, Loriot Y, Necchi A, Valderrama BP et al. ( 2022 ) . Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up ^☆ . Annals of Oncology vol. 33 , ( 3 ) 244 - 258 .

Albiges L, Tannir NM, Burotto M, McDermott D, Plimack ER, Barthélémy P, Porta C, Powles T et al. ( 2022 ) . First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and With an Evaluable Primary Renal Tumor in the CheckMate 214 Trial . European Urology vol. 81 , ( 3 ) 266 - 271 .

Choueiri TK, Albiges L, Atkins MB, Bakouny Z, Bratslavsky G, Braun DA, Haas NB, Haanen JBAG et al. ( 2022 ) . From Basic Science to Clinical Translation in Kidney Cancer: A Report from the Second Kidney Cancer Research Summit . Clinical Cancer Research vol. 28 , ( 5 ) 831 - 839 .

Martini A, Raggi D, Fallara G, Nocera L, Schultz JG, Belladelli F, Marandino L, Salonia A et al. ( 2022 ) . Immunotherapy versus chemotherapy as first-line treatment for advanced urothelial cancer: A systematic review and meta-analysis . Cancer Treatment Reviews vol. 104 ,

Sonpavde GP, Sternberg CN, Loriot Y, Marabelle A, Lee JL, Fléchon A, Roubaud G, Pouessel D et al. ( 2022 ) . Primary results of STRONG: An open-label, multicenter, phase 3b study of fixed-dose durvalumab monotherapy in previously treated patients with urinary tract carcinoma . European Journal of Cancer vol. 163 , 55 - 65 .

Powles T, Park H, Voog E, Caserta C, Pérez-Valderrama B, Gurney H, Loriot Y, Sridhar SS et al. ( 2022 ) . Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): Long-term follow-up results from the JAVELIN Bladder 100 trial . Journal of Clinical Oncology vol. 40 , ( 6_suppl ) 487 - 487 .

Powles T, Choueiri TK, Burotto M, Escudier B, Bourlon MT, Shah AY, Suárez C, Hamzaj A et al. ( 2022 ) . Final overall survival analysis and organ-specific target lesion assessments with two-year follow-up in CheckMate 9ER: Nivolumab plus cabozantinib versus sunitinib for patients with advanced renal cell carcinoma . Journal of Clinical Oncology vol. 40 , ( 6_suppl ) 350 - 350 .

Choueiri TK, Tomczak P, Park H, Venugopal B, Ferguson T, Symeonides SN, Hajek J, Chang Y-H et al. ( 2022 ) . Pembrolizumab as post nephrectomy adjuvant therapy for patients with renal cell carcinoma: Results from 30-month follow-up of KEYNOTE-564 . Journal of Clinical Oncology vol. 40 , ( 6_suppl ) 290 - 290 .

Jackson-Spence F, Toms C, Yang Y-H, Walshaw L, Riddell A, Cutino-Moguel M-T, Szabados B, Propper D et al. ( 2022 ) . The effect of anti-cancer therapy on immunological response to COVID-19 vaccination . Journal of Clinical Oncology vol. 40 , ( 6_suppl ) 319 - 319 .

Bedke J, Albiges L, Capitanio U, Giles RH, Hora M, Lam TB, Ljungberg B, Marconi L et al. ( 2022 ) . 2021 Updated European Association of Urology Guidelines on the Use of Adjuvant Pembrolizumab for Renal Cell Carcinoma . European Urology vol. 81 , ( 2 ) 134 - 137 .

Tomita Y, Yamamoto Y, Tsuchiya N, Kanayama H, Eto M, Miyake H, Powles T, Yoshida M et al. ( 2022 ) . Avelumab first-line maintenance plus best supportive care (BSC) vs BSC alone for advanced urothelial carcinoma: JAVELIN Bladder 100 Japanese subgroup analysis . International Journal of Clinical Oncology vol. 27 , ( 2 ) 383 - 395 .

Venugopal B, Pillai M, Powles T, Savage P, Michael A, Fife K, Klair B, Perrot V et al. ( 2022 ) . Early Clinical Experience with Cabozantinib for Advanced Renal Cell Carcinoma in the UK: Real-World Treatment Pathways and Clinical Outcomes . Clinical Genitourinary Cancer vol. 20 , ( 1 ) 94 - 94.e10 .

Motzer RJ, Powles T, Atkins MB, Escudier B, McDermott DF, Alekseev BY, Lee JL, Suarez C et al. ( 2022 ) . Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients with Previously Untreated Metastatic Renal Cell Carcinoma . JAMA Oncology vol. 8 , ( 2 ) 275 - 280 .

Huang J, Leung DKW, Chan EOT, Lok V, Leung S, Wong I, Lao XQ, Zheng ZJ et al. ( 2022 ) . A Global Trend Analysis of Kidney Cancer Incidence and Mortality and Their Associations with Smoking, Alcohol Consumption, and Metabolic Syndrome . European Urology Focus vol. 8 , ( 1 ) 200 - 209 .

Stewart GD, Welsh SJ, Ursprung S, Gallagher FA, Jones JO, Shields J, Smith CG, Mitchell TJ et al. ( 2022 ) . A Phase II study of neoadjuvant axitinib for reducing the extent of venous tumour thrombus in clear cell renal cell cancer with venous invasion (NAXIVA) . British Journal of Cancer

Powles T, Yuen KC, Gillessen S, Kadel EE, Rathkopf D, Matsubara N, Drake CG, Fizazi K et al. ( 2022 ) . Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial . Nature Medicine vol. 28 , ( 1 ) 144 - 153 .

Jackson-Spence F, Szabados B, Toms C, Yang YH, Sng C, Powles T ( 2022 ) . Avelumab in locally advanced or metastatic urothelial carcinoma . Expert Review of Anticancer Therapy vol. 22 , ( 2 ) 135 - 140 .

Matsubara N, Yonese J, Kojima T, Azuma H, Matsumoto H, Powles T, Rosenberg JE, Petrylak DP et al. ( 2022 ) . Japanese subgroup analysis of EV-301: An open-label, randomized phase 3 study to evaluate enfortumab vedotin versus chemotherapy in subjects with previously treated locally advanced or metastatic urothelial carcinoma . Cancer Medicine

Grivas P, Kopyltsov E, Su PJ, Parnis FX, Park SH, Yamamoto Y, Fong PC, Tournigand C et al. ( 2022 ) . Patient-reported Outcomes from JAVELIN Bladder 100: Avelumab First-line Maintenance Plus Best Supportive Care Versus Best Supportive Care Alone for Advanced Urothelial Carcinoma . European Urology

Meerveld-Eggink A, Graafland N, Wilgenhof S, Van Thienen JV, Lalezari F, Grant M, Szabados B, Abu-Ghanem Y et al. ( 2022 ) . Primary Renal Tumour Response in Patients Treated with Nivolumab and Ipilimumab for Metastatic Renal Cell Carcinoma: Real-world Data Assessment . European Urology Open Science vol. 35 , 54 - 58 .

Jackson-Spence F, Toms C, Yang YH, Jurascheck L, Choy J, Flanders L, Szabados B, Powles T ( 2022 ) . The role of modern immunotherapy in metastatic urothelial cancer: mini review . Journal of Cancer Metastasis and Treatment vol. 8 ,

Regan MM, Jegede OA, Mantia CM, Powles T, Werner L, Motzer RJ, Tannir NM, Lee CH et al. ( 2021 ) . Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial . Clinical Cancer Research vol. 27 , ( 24 ) 6687 - 6695 .

Powles T, Sridhar SS, Loriot Y, Bellmunt J, Mu XJ, Ching KA, Pu J, Sternberg CN et al. ( 2021 ) . Avelumab maintenance in advanced urothelial carcinoma: biomarker analysis of the phase 3 JAVELIN Bladder 100 trial . Nature Medicine vol. 27 , ( 12 ) 2200 - 2211 .

Powles T, Choueiri TK, Motzer RJ, Jonasch E, Pal S, Tannir NM, Signoretti S, Kaldate R et al. ( 2021 ) . Correction to: Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma (BMC Cancer, (2021), 21, 1, (904), 10.1186/s12885-021-08630-w) . BMC Cancer vol. 21 , ( 1 )

Powles T, Albiges L, Bex A, Grünwald V, Porta C, Procopio G, Schmidinger M, Suárez C et al. ( 2021 ) . ESMO Clinical Practice Guideline update on the use of immunotherapy in early stage and advanced renal cell carcinoma . Annals of Oncology vol. 32 , ( 12 ) 1511 - 1519 .

Szabados B, Prendergast A, Jackson-Spence F, Choy J, Powles T ( 2021 ) . Immune Checkpoint Inhibitors in Front-line Therapy for Urothelial Cancer . European urology oncology vol. 4 , ( 6 ) 943 - 947 .

Kuusk T, Cullen D, Neves JB, Campain N, Barod R, Boleti E, El-Sheihk S, Grant L et al. ( 2021 ) . Impact of the first surge of the COVID-19 pandemic on a tertiary referral centre for kidney cancer . BJU International vol. 128 , ( 6 ) 752 - 758 .

Banchereau R, Leng N, Zill O, Sokol E, Liu G, Pavlick D, Maund S, Liu LF et al. ( 2021 ) . Molecular determinants of response to PD-L1 blockade across tumor types . Nature Communications vol. 12 , ( 1 )

Powles T, Choueiri TK, Motzer RJ, Jonasch E, Pal S, Tannir NM, Signoretti S, Kaldate R et al. ( 2021 ) . Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma . BMC Cancer . vol. 21 ,

Kanesvaran R, Porta C, Wong A, Powles T, Ng QS, Schmidinger M, Ye D, Malhotra H et al. ( 2021 ) . Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with renal cell carcinoma . ESMO Open vol. 6 , ( 6 )

Choueiri TK, Powles T ( 2021 ) . Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma. Reply . The New England journal of medicine vol. 385 , ( 20 )

Lumba S, Powles T, Petrylak DP, Park SH, Sridhar SS, Caserta C, Thiery-Vuillemin A, Lee HJ et al. ( 2021 ) . Avelumab first-line maintenance for advanced urothelial carcinoma: analysis of clinical and genomic subgroups from the phase 3 JAVELIN Bladder 100 trial . ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY . vol. 17 , 126 - 127 .

Lumba S, Grivas P, Park SH, Voog E, Caserta C, Valderrama BP, Gurney H, Kalofonos H et al. ( 2021 ) . Avelumab first-line maintenance plus best supportive care vs best supportive care alone for advanced urothelial carcinoma not progressed with first-line chemotherapy: Prespecified subgroup analyses from JAVELIN Bladder 100 . ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY . vol. 17 , 126 - 126 .

Powles T, Loriot Y, Duran MAC, Sridhar S, Bellmunt J, Petrylak DP, Wang J, Costa N et al. ( 2021 ) . Avelumab first-line maintenance plus best supportive care vs best supportive care alone for advanced urothelial carcinoma: JAVELIN Bladder 100 subgroup analysis based on duration and cycles of first-line chemotherapy . ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY . vol. 17 , 132 - 133 .

Escudier B, Porta C, Burotto M, Suarez C, Bourlon M, Hsieh J, Shah A, Hamzaj A et al. ( 2021 ) . Nivolumab + Cabozantinib (N+C) vs Sunitinib (S) en première ligne (1L) de traitement chez des patients atteints d’un carcinome rénal avancé (ACCR) dans l’essai de phase III checkmate 9ER : analyse en sous-groupes basée sur l’absence ou présence de néphrectomie antérieure . Progrès en Urologie vol. 31 , ( 13 )

Pook D, Powles T, Burotto M, Bourlon MT, Hsieh JJ, Basso U, Shah AY, Suarez C et al. ( 2021 ) . Nivolumab plus cabozantinib (N plus C) vs sunitinib for advanced renal cell carcinoma (aRCC): Outcomes by baseline disease characteristics in the phase 3 CheckMate 9ER trial . ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY . vol. 17 , 131 - 131 .

Loriot Y, Vuillet M, Mamtani R, Rosenberg J, Powles T, Sonpavde G, Duran I, Lee J et al. ( 2021 ) . Qualité de vie et symptômes chez les patients atteints d’un carcinome urothélial localement avancé ou métastatique précédemment traité de l’étude Ev-301 : une étude randomisée de phase 3 comparant enfortumab vedotin à la chimiothérapie . Progrès en Urologie vol. 31 , ( 13 ) 813 - 814 .

Escudier B, Tannir N, Mcdermott D, Burotto M, Choueiri T, Hammers H, Plimack E, Porta C et al. ( 2021 ) . Survie conditionnelle et suivi à 5 ans dans l’étude checkmate 214 : Nivolumab+Ipilimumab (N+I) versus Sunitinib (S) dans le traitement de première ligne du carcinome rénal avancé (ACCR) . Progrès en Urologie vol. 31 , ( 13 )

Powles T, Petrylak DP, Rosenberg JE ( 2021 ) . Beyond chemotherapy and checkpoint inhibitors: Weighing the risks and benefits of the novel therapies for metastatic urothelial carcinoma . Journal of Clinical Oncology vol. 39 , ( 30 ) 3411 - 3412 .

Pook D, Sridhar S, Powles T, Loriot Y, Duran CM, Gupta S, Tsuchiya N, Bamias A et al. ( 2021 ) . Avelumab first-line maintenance for advanced urothelial carcinoma in the phase 3 JAVELIN Bladder 100 trial: subgroup analysis by duration of treatment-free interval from end of chemotherapy to start of maintenance . ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY . vol. 17 , 43 - 44 .

Lumba S, Powles T, Petrylak DP, Park SH, Sridhar SS, Caserta C, Thiery-Vuillemin A, Lee HJ et al. ( 2021 ) . Avelumab first-line maintenance for advanced urothelial carcinoma: analysis of clinical and genomic subgroups from the phase 3 JAVELIN Bladder 100 trial . ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY . vol. 17 , 44 - 45 .

Bedke J, Albiges L, Capitanio U, Giles RH, Hora M, Lam TB, Ljungberg B, Marconi L et al. ( 2021 ) . The 2021 Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibitor–based Combination Therapies for Treatment-naive Metastatic Clear-cell Renal Cell Carcinoma Are Standard of Care . European Urology vol. 80 , ( 4 ) 393 - 397 .

Porta CG, Burotto M, Rodriguez CS, Bourlon MT, Hsieh J, Shah AY, Hamzaj A, Bedke J et al. ( 2021 ) . 663P First-line nivolumab + cabozantinib vs sunitinib in patients (pts) with advanced renal cell carcinoma (aRCC) in subgroups based on prior nephrectomy in the CheckMate 9ER trial . Annals of Oncology vol. 32 , s688 - s689 .

Gafanov R, Powles TB, Bedke J, Stus V, Waddell TS, Nosov D, Pouliot F, Soulieres D et al. ( 2021 ) . 669P Subsequent therapy following pembrolizumab + axitinib or sunitinib treatment for advanced renal cell carcinoma (RCC) in the phase III KEYNOTE-426 study . Annals of Oncology vol. 32 ,

Rosenberg JE, Powles T, Sonpavde GP, Loriot Y, Duran I, Lee JL, Matsubara N, Vulsteke C et al. ( 2021 ) . 698P Analysis of hard-to-treat subgroups from EV-301: A phase III trial of enfortumab vedotin (EV) vs chemotherapy for previously treated advanced urothelial carcinoma . Annals of Oncology vol. 32 , s710 - s711 .

Bellmunt J, Powles TB, van der Heijden MS, Galsky MD, He P, Wang Z, Xiao F, Jones F et al. ( 2021 ) . 708P PD-L1 as a predictor of survival in patients with metastatic urothelial carcinoma (mUC) from the phase III DANUBE trial of durvalumab (D) or durvalumab plus tremelimumab (D+T) versus standard of care chemotherapy (SoC) . Annals of Oncology vol. 32 , s716 - s717 .

Powles TB, Gschwend JE, Bracarda S, Castellano D, Gross-Goupil M, Jensen JB, Kann A, Nishiyama H et al. ( 2021 ) . 716TiP IMvigor011: A global, double-blind, randomised phase III study of atezolizumab (atezo; anti–PD-L1) vs placebo (pbo) as adjuvant therapy in patients (pts) with high-risk muscle-invasive bladder cancer (MIBC) who are circulating tumour (ct)DNA+ post cystectomy . Annals of Oncology vol. 32 ,

Rini BI, Plimack ER, Powles TB, Voss MH, Gurney HP, Silverman R, Perini R, Rodriguez-Lopez K et al. ( 2021 ) . 717TiP Randomized, open-label, 3-arm phase III study comparing MK-1308A + lenvatinib and pembrolizumab (pembro) + belzutifan + lenvatinib versus pembro + lenvatinib as first-line (1L) treatment for advanced clear cell renal cell carcinoma (ccRCC) . Annals of Oncology vol. 32 , s722 - s723 .

de Vries-Brilland M, McDermott DF, Suárez C, Powles T, Gross-Goupil M, Ravaud A, Flippot R, Escudier B et al. ( 2021 ) . Checkpoint inhibitors in metastatic papillary renal cell carcinoma . Cancer Treatment Reviews vol. 99 ,

Mori K, Pradere B, Quhal F, Katayama S, Mostafaei H, Laukhtina E, Schuettfort VM, D'Andrea D et al. ( 2021 ) . Differences in oncological and toxicity outcomes between programmed cell death-1 and programmed cell death ligand-1 inhibitors in metastatic renal cell carcinoma: A systematic review and meta-analysis . Cancer Treatment Reviews vol. 99 ,

Powles TB, Chistyakov V, Beliakouski V, Semenov A, Everaert E, Baranau Y, Moreno V, Valderrama BP et al. ( 2021 ) . LBA27 Erdafitinib (ERDA) or ERDA plus cetrelimab (CET) for patients with metastatic or locally advanced urothelial carcinoma (mUC) and Fibroblast Growth Factor Receptor alterations (FGFRa): First phase (Ph) II results from the NORSE study . Annals of Oncology vol. 32 ,

Bedke J, Merseburger AS, Loriot Y, Castellano D, Choy E, Duran I, Rosenberg JE, Petrylak DP et al. ( 2021 ) . Partial Response and Stable Disease Correlate with Positive Outcomes in Atezolizumab-treated Patients with Advanced Urinary Tract Carcinoma . European Urology Focus vol. 7 , ( 5 ) 1084 - 1091 .

Crusz SM, Hall PE, Earwicker K, Dexter S, Patel-Walker G, Powles T, Diamantis N ( 2021 ) . Providing an acute oncology service during the COVID-19 pandemic . Clinical Medicine, Journal of the Royal College of Physicians of London vol. 21 , ( 5 ) E548 - E551 .

Meade A, Oza B, Frangou E, Smith B, Bryant H, Kaplan R, Choodari-Oskooei B, Powles T et al. ( 2021 ) . RAMPART: A model for a regulatory-ready academic-led phase III trial in the adjuvant renal cell carcinoma setting . Contemporary Clinical Trials vol. 108 ,

Oza B, Frangou E, Smith B, Bryant H, Kaplan R, Choodari-Oskooei B, Powles T, Stewart GD et al. ( 2021 ) . RAMPART: A phase III multi-arm multi-stage trial of adjuvant checkpoint inhibitors in patients with resected primary renal cell carcinoma (RCC) at high or intermediate risk of relapse . Contemporary Clinical Trials vol. 108 ,

Abu-Ghanem Y, Powles T, Capitanio U, Beisland C, Järvinen P, Stewart GD, Gudmundsson E, Lam TBL et al. ( 2021 ) . Should patients with low-risk renal cell carcinoma be followed differently after nephron-sparing surgery vs radical nephrectomy? . BJU International vol. 128 , ( 3 ) 386 - 394 .

Wells JC, Dudani S, Gan CL, Stukalin I, Azad AA, Liow E, Donskov F, Yuasa T et al. ( 2021 ) . Clinical Effectiveness of Second-line Sunitinib Following Immuno-oncology Therapy in Patients with Metastatic Renal Cell Carcinoma: A Real-world Study . Clinical Genitourinary Cancer vol. 19 , ( 4 ) 354 - 361 .

Merseburger AS, Castellano D, Powles T, Loriot Y, Retz M, Voortman J, Huddart RA, Gedye C et al. ( 2021 ) . Safety and Efficacy of Atezolizumab in Understudied Populations with Pretreated Urinary Tract Carcinoma: Subgroup Analyses of the SAUL Study in Real-World Practice . The Journal of urology vol. 206 , ( 2 ) 240 - 251 .

Lam JM, Liu WK, Powles T, Tang YZ, Szabados B ( 2021 ) . Single-centre Experience of Patients with Metastatic Urothelial Cancer Treated with Chemotherapy Following Immune Checkpoint Inhibition . European urology oncology vol. 4 , ( 4 ) 659 - 662 .

Butters T, Liu WK, Grant M, Jackson-Spence F, Zaynub G, So A, Lam J, Ashfar M et al. ( 2021 ) . What do emergency physicians know about immune checkpoint inhibitor-related toxicities: A brief report . International Journal of Cancer Management vol. 14 , ( 8 )

Powles T, Assaf ZJ, Davarpanah N, Banchereau R, Szabados BE, Yuen KC, Grivas P, Hussain M et al. ( 2021 ) . ctDNA guiding adjuvant immunotherapy in urothelial carcinoma . Nature vol. 595 , ( 7867 ) 432 - 437 .

van der Heijden MS, Loriot Y, Durán I, Ravaud A, Retz M, Vogelzang NJ, Nelson B, Wang J et al. ( 2021 ) . Atezolizumab Versus Chemotherapy in Patients with Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: A Long-term Overall Survival and Safety Update from the Phase 3 IMvigor211 Clinical Trial . European Urology . vol. 80 , 7 - 11 .

Petrylak DP, Powles T, Rosenberg JE ( 2021 ) . Enfortumab Vedotin in Advanced Urothelial Carcinoma. Reply . The New England journal of medicine vol. 385 , ( 1 ) 93 - 94 .

Mori K, Pradere B, Moschini M, Mostafaei H, Laukhtina E, Schuettfort VM, Sari Motlagh R, Soria F et al. ( 2021 ) . First-line immune-checkpoint inhibitor combination therapy for chemotherapy-eligible patients with metastatic urothelial carcinoma: A systematic review and meta-analysis . European Journal of Cancer vol. 151 , 35 - 48 .

Powles T, Csőszi T, Özgüroğlu M, Matsubara N, Géczi L, Cheng SYS, Fradet Y, Oudard S et al. ( 2021 ) . Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial . The Lancet Oncology vol. 22 , ( 7 ) 931 - 945 .

Rallis KS, Kleeman SO, Grant M, Ordidge KL, Sahdev A, Powles T ( 2021 ) . Radiomics for Renal Cell Carcinoma: Predicting Outcomes from Immunotherapy and Targeted Therapies—A Narrative Review . European Urology Focus vol. 7 , ( 4 ) 717 - 721 .

Choueiri TK, Tomczak P, Park H, Venugopal B, Ferguson T, Chang Y-H, Hajek J, Symeonides SN et al. ( 2021 ) . Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for patients with renal cell carcinoma: Randomized, double-blind, phase III KEYNOTE-564 study . Journal of Clinical Oncology vol. 39 , ( 18_suppl ) lba5 - lba5 .

Araujo DV, Wells JC, Hansen AR, Dizman N, Pal SK, Beuselinck B, Donskov F, Gan CL et al. ( 2021 ) . Efficacy of immune-checkpoint inhibitors (ICI) in the treatment of older adults with metastatic renal cell carcinoma (mRCC) – an International mRCC Database Consortium (IMDC) analysis . Journal of Geriatric Oncology . vol. 12 , 820 - 826 .

Mori K, Pradere B, Moschini M, Mostafaei H, Laukhtina E, Schuettfort VM, Sari MR, Soria F et al. ( 2021 ) . First-line treatments for cisplatin-eligible patients with metastatic urothelial carcinoma: A meta-analysis . EUROPEAN UROLOGY . vol. 79 , S1161 - S1163 .

Parikh M, Powles T ( 2021 ) . Immune Checkpoint Inhibition in Advanced Bladder and Kidney Cancer: Responses and Further Management . Am Soc Clin Oncol Educ Book vol. 41 , e182 - e189 .

Jackson-Spence FE, Ackerman C, Khan M, Grant M, Soosaipillai G, Nally E, Choy J, Powles TB et al. ( 2021 ) . P0461 The role of angiogenic signatures in advanced urothelial carcinoma (aUC) treated with VEGF-targeted therapy . European Urology vol. 79 ,

Choy J, Szabados B, Abu-Ghanem Y, Powles T, Wimalasingham A, Bex A ( 2021 ) . P0644 Optimizing patient selection for deferred cytoreductive nephrectomy in the contemporary era of targeted therapy . European Urology vol. 79 ,

Graafland NM, Szabados B, Mumtaz F, Barod R, Nicol D, Tanabalan C, Boleti E, Powles T et al. ( 2021 ) . P0649 Surgical safety of Cytoreductive Nephrectomy (CN) following pretreatment with Immune Checkpoint Inhibition (ICI) combination therapy in primary metastatic clear-cell Renal Carcinoma (mccRCC) . European Urology vol. 79 ,

Petrylak DP, Loriot Y, Shaffer DR, Braiteh F, Powderly J, Harshman LC, Conkling P, Delord JP et al. ( 2021 ) . Safety and clinical activity of atezolizumab in patients with metastatic castration-resistant prostate cancer: A phase i study . Clinical Cancer Research vol. 27 , ( 12 ) 3360 - 3369 .

Abu-Ghanem Y, Powles T, Capitanio U, Beisland C, Järvinen P, Stewart GD, Gudmundsson EO, Lam TB et al. ( 2021 ) . The Impact of Histological Subtype on the Incidence, Timing, and Patterns of Recurrence in Patients with Renal Cell Carcinoma After Surgery-Results from RECUR Consortium . European urology oncology vol. 4 , ( 3 ) 473 - 482 .

Szabados B, Rodriguez-Vida A, Durán I, Crabb SJ, Van Der Heijden MS, Pous AF, Gravis G, Herranz UA et al. ( 2021 ) . Toxicity and Surgical Complication Rates of Neoadjuvant Atezolizumab in Patients with Muscle-invasive Bladder Cancer Undergoing Radical Cystectomy: Updated Safety Results from the ABACUS Trial . European urology oncology vol. 4 , ( 3 ) 456 - 463 .

Powles T, Petrylak DP, Park H, Sridhar SS, Caserta C, Vuillemin AT, Lee HJ, Bellmunt J et al. ( 2021 ) . Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): Analysis of clinical and genomic subgroups from the JAVELIN Bladder 100 trial . Journal of Clinical Oncology vol. 39 , ( 15_suppl ) 4520 - 4520 .

Grivas P, Park H, Voog E, Kopyltsov E, Gurney H, Muniz DQB, Rolland F, Als AB et al. ( 2021 ) . Avelumab first-line (1L) maintenance plus best supportive care (BSC) versus BSC alone for advanced urothelial carcinoma (UC): Analysis of time to end of next-line therapy in JAVELIN Bladder 100 . Journal of Clinical Oncology vol. 39 , ( 15_suppl ) 4525 - 4525 .

Tannir NM, Agarwal N, Porta C, Lawrence NJ, Motzer RJ, Lee RJ, Jain RK, Davis NB et al. ( 2021 ) . CANTATA: Primary analysis of a global, randomized, placebo (Pbo)-controlled, double-blind trial of telaglenastat (CB-839) + cabozantinib versus Pbo + cabozantinib in advanced/metastatic renal cell carcinoma (mRCC) patients (pts) who progressed on immune checkpoint inhibitor (ICI) or anti-angiogenic therapies . Journal of Clinical Oncology . vol. 39 , 4501 - 4501 .

Shah AY, Motzer RJ, Apolo AB, Powles T, Escudier B, Zhang J, Scheffold C, Karumanchi S et al. ( 2021 ) . Cabozantinib (C) exposure-response (ER) analysis for the phase 3 CheckMate 9ER (CM 9ER) trial of nivolumab plus cabozantinib (N+C) versus sunitinib (S) in first-line advanced renal cell carcinoma (1L aRCC) . Journal of Clinical Oncology vol. 39 , ( 15_suppl ) 4561 - 4561 .

Rodriguez CS, Larkin J, Patel PM, Valderrama BP, Rodriguez-Vida A, Glen H, Thistlethwaite F, Ralph C et al. ( 2021 ) . Clinical activity of durvalumab and savolitinib in MET-driven, metastatic papillary renal cancer . Journal of Clinical Oncology vol. 39 , ( 15_suppl ) 4511 - 4511 .

Bex A, Abu-Ghanem Y, Van Thienen JV, Graafland N, Lagerveld B, Zondervan P, Beerlage H, van Moorselaar J et al. ( 2021 ) . Dynamic changes of the immune infiltrate after neoadjuvant avelumab/axitinib in patients (pts) with localized renal cell carcinoma (RCC) who are at high risk of relapse after nephrectomy (NeoAvAx) . Journal of Clinical Oncology vol. 39 , ( 15_suppl ) 4573 - 4573 .

O'Donnell PH, Balar AV, Vuky J, Castellano D, Bellmunt J, Powles T, Bajorin DF, Grivas P et al. ( 2021 ) . First-line pembrolizumab (pembro) in cisplatin-ineligible patients with advanced urothelial cancer (UC): Response and survival results up to five years from the KEYNOTE-052 phase 2 study . Journal of Clinical Oncology vol. 39 , ( 15_suppl ) 4508 - 4508 .

Choueiri TK, Donahue AC, Rini BI, Powles T, Haanen JBAG, Larkin J, Mu XJ, Pu J et al. ( 2021 ) . Integrating peripheral biomarker analyses from JAVELIN Renal 101: Avelumab + axitinib (A + Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC) . Journal of Clinical Oncology vol. 39 , ( 15_suppl ) 4547 - 4547 .

Apolo AB, Powles T, Burotto M, Bourlon MT, Hsieh JJ, Basso U, Shah AY, Suarez C et al. ( 2021 ) . Nivolumab plus cabozantinib (N+C) versus sunitinib (S) for advanced renal cell carcinoma (aRCC): Outcomes by baseline disease characteristics in the phase 3 CheckMate 9ER trial . Journal of Clinical Oncology vol. 39 , ( 15_suppl ) 4553 - 4553 .

Gan CL, Wells JC, Schmidt AL, Powles T, Tran B, Meza LA, Labaki C, Lee J-L et al. ( 2021 ) . Outcomes of first-line (1L) ipilimumab and nivolumab (IPI-NIVO) and subsequent therapy in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC) . Journal of Clinical Oncology vol. 39 , ( 15_suppl ) 4554 - 4554 .

Khan MA, Szabados B, Choy J, Jackson-Spence F, Powles T, Castellano D, Valderrama BP ( 2021 ) . Patient outcomes following disease progression with enfortumab-vedotin (EV) in metastatic urothelial carcinoma (mUC) . Journal of Clinical Oncology vol. 39 , ( 15_suppl ) e16516 - e16516 .

Rini BI, Plimack ER, Stus V, Waddell T, Gafanov R, Pouliot F, Nosov D, Melichar B et al. ( 2021 ) . Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Results from 42-month follow-up of KEYNOTE-426 . Journal of Clinical Oncology vol. 39 , ( 15_suppl ) 4500 - 4500 .

Mamtani R, Rosenberg JE, Powles T, Sonpavde GP, Loriot Y, Duran I, Lee J-L, Matsubara N et al. ( 2021 ) . Quality of life, functioning, and symptoms in patients with previously treated locally advanced or metastatic urothelial carcinoma from EV-301: A randomized phase 3 trial of enfortumab vedotin versus chemotherapy . Journal of Clinical Oncology vol. 39 , ( 15_suppl ) 4539 - 4539 .

Perez-Gracia JL, Hansen AR, Eefsen RHL, Gomez-Roca CA, Negrier S, Pedrazzoli P, Lee J-L, Gordoa TA et al. ( 2021 ) . Randomized phase Ib study to evaluate safety, pharmacokinetics and therapeutic activity of simlukafusp α in combination with atezolizumab ± bevacizumab in patients with unresectable advanced/ metastatic renal cell carcinoma (RCC) (NCT03063762) . Journal of Clinical Oncology vol. 39 , ( 15_suppl ) 4556 - 4556 .

Powles T, Carroll D, Chowdhury S, Gravis G, Joly F, Carles J, Fléchon A, Maroto P et al. ( 2021 ) . An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer . Nature Medicine vol. 27 , ( 5 ) 793 - 801 .

Rini BI, Motzer RJ, Powles T, McDermott DF, Escudier B, Donskov F, Hawkins R, Bracarda S et al. ( 2021 ) . Atezolizumab plus Bevacizumab Versus Sunitinib for Patients with Untreated Metastatic Renal Cell Carcinoma and Sarcomatoid Features: A Prespecified Subgroup Analysis of the IMmotion151 Clinical Trial . European Urology vol. 79 , ( 5 ) 659 - 662 .

Powles T, Atkins MB, Escudier B, Motzer RJ, Rini BI, Fong L, Joseph RW, Pal SK et al. ( 2021 ) . Efficacy and Safety of Atezolizumab Plus Bevacizumab Following Disease Progression on Atezolizumab or Sunitinib Monotherapy in Patients with Metastatic Renal Cell Carcinoma in IMmotion150: A Randomized Phase 2 Clinical Trial . European Urology vol. 79 , ( 5 ) 665 - 673 .

Leow JJ, Chong YL, Chang SL, Valderrama BP, Powles T, Bellmunt J ( 2021 ) . Neoadjuvant and Adjuvant Chemotherapy for Upper Tract Urothelial Carcinoma: A 2020 Systematic Review and Meta-analysis, and Future Perspectives on Systemic Therapy . European Urology vol. 79 , ( 5 ) 635 - 654 .

Kuusk T, Abu-Ghanem Y, Mumtaz F, Powles T, Bex A ( 2021 ) . Perioperative therapy in renal cancer in the era of immune checkpoint inhibitor therapy . Current Opinion in Urology vol. 31 , ( 3 ) 262 - 269 .

Leow JJ, Chong YL, Chang SL, Valderrama BP, Powles T, Bellmunt J ( 2021 ) . Reply to Alexander Andreev-Drakhlin, Jianjun Gao, Arlene Siefker-Radtke. Levelling the Evidence: A Comparison of Neoadjuvant and Adjuvant Treatment for Upper Tract Urothelial Carcinoma. Eur Urol 2021;79:655–6 . European Urology vol. 79 , ( 5 ) 657 - 658 .

Motzer R, Alekseev B, Rha SY, Porta C, Eto M, Powles T, Grünwald V, Hutson TE et al. ( 2021 ) . Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma . New England Journal of Medicine vol. 384 , ( 14 ) 1289 - 1300 .

Banchereau R, Chitre AS, Scherl A, Wu TD, Patil NS, De Almeida P, Kadel, EE, Madireddi S et al. ( 2021 ) . Intratumoral CD103+ CD8+ T cells predict response to PD-L1 blockade . Journal for ImmunoTherapy of Cancer vol. 9 , ( 4 )

Bellmunt J, Hussain M, Gschwend JE, Albers P, Oudard S, Castellano D, Daneshmand S, Nishiyama H et al. ( 2021 ) . Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial . The Lancet Oncology vol. 22 , ( 4 ) 525 - 537 .

Rini B, Abel EJ, Albiges L, Bex A, Brugarolas J, Bukowski RM, Coleman JA, Drake CG et al. ( 2021 ) . Summary from the Kidney Cancer Association's Inaugural Think Thank: Coalition for a Cure . Clinical Genitourinary Cancer vol. 19 , ( 2 ) 167 - 175 .

Powles T, Rosenberg JE, Sonpavde GP, Loriot Y, Durán I, Lee JL, Matsubara N, Vulsteke C et al. ( 2021 ) . Enfortumab vedotin in previously treated advanced urothelial carcinoma . New England Journal of Medicine vol. 384 , ( 12 ) 1125 - 1135 .

Choueiri TK, Powles T, Burotto M, Escudier B, Bourlon MT, Zurawski B, Juárez VMO, Hsieh JJ et al. ( 2021 ) . Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma . New England Journal of Medicine vol. 384 , ( 9 ) 829 - 841 .

Yuen KC, Liu LF, Gupta V, Madireddi S, Keerthivasan S, Li C, Rishipathak D, Williams P et al. ( 2021 ) . Author Correction: High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade (Nature Medicine, (2020), 26, 5, (693-698), 10.1038/s41591-020-0860-1) . Nature Medicine vol. 27 , ( 3 )

Powles T, ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org ( 2021 ) . Recent eUpdate to the ESMO Clinical Practice Guidelines on renal cell carcinoma on cabozantinib and nivolumab for first-line clear cell renal cancer: Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up . Ann Oncol vol. 32 , ( 3 ) 422 - 423 .

Bedke J, Albiges L, Capitanio U, Giles RH, Hora M, Lam TB, Ljungberg B, Marconi L et al. ( 2021 ) . Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Nivolumab plus Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-naïve Metastatic Clear-Cell Renal Cell Carcinoma . European Urology vol. 79 , ( 3 ) 339 - 342 .

Powles T, Csőszi T, Ozguroglu M, Matsubara N, Geczi L, Cheng SY, Fradet Y, Oudard S et al. ( 2021 ) . 1L pembrolizumab (pembro) versus chemotherapy (chemo) for choice-of-carboplatin patients with advanced urothelial carcinoma (UC) in KEYNOTE-361 . Journal of Clinical Oncology vol. 39 , ( 6_suppl ) 450 - 450 .

Powles T, Meeks JJ, Galsky MD, Van Der Heijden MS, Nishiyama H, Al-Ahmadie HA, Goluboff ET, Hois S et al. ( 2021 ) . A phase III, randomized, open-label, multicenter, global study of efficacy and safety of durvalumab in combination with gemcitabine plus cisplatin for neoadjuvant treatment followed by durvalumab alone for adjuvant treatment in muscle-invasive bladder cancer (NIAGARA) . Journal of Clinical Oncology vol. 39 , ( 6_suppl ) tps505 - tps505 .

Sonpavde G, Marabelle A, Loriot Y, Sternberg CN, Lee J-L, Flechon A, Roubaud G, Pouessel D et al. ( 2021 ) . An open-label, multicenter, phase IIIb study of patients with urinary tract carcinoma (UTC) (STRONG): Final analysis for fixed-dose durvalumab monotherapy (module A) . Journal of Clinical Oncology vol. 39 , ( 6_suppl ) 429 - 429 .

Ozguroglu M, Alva AS, Csőszi T, Matsubara N, Geczi L, Cheng SY, Fradet Y, Oudard S et al. ( 2021 ) . Analysis of PFS2 by subsequent therapy in KEYNOTE-361: Pembrolizumab (pembro) plus chemotherapy (chemo) or pembro alone versus chemo as 1L therapy for advanced urothelial carcinoma (UC) . Journal of Clinical Oncology vol. 39 , ( 6_suppl ) 448 - 448 .

Tsuchiya N, Yamamoto Y, Uemura H, Kanayama H-O, Eto M, Miyake H, Powles T, Yoshida M et al. ( 2021 ) . Avelumab (Ave) first-line (1L) maintenance plus best supportive care (BSC) versus BSC alone for advanced urothelial carcinoma (UC): JAVELIN Bladder 100 Japanese subgroup analysis . Journal of Clinical Oncology vol. 39 , ( 6_suppl ) 425 - 425 .

Loriot Y, Powles T, Climent Durán MÁ, Sridhar SS, Bellmunt J, Petrylak DP, Wang J, Costa NM et al. ( 2021 ) . Avelumab (Ave) first-line (1L) maintenance plus best supportive care (BSC) versus BSC alone for advanced urothelial carcinoma (UC): JAVELIN Bladder 100 subgroup analysis based on duration and cycles of 1L chemotherapy . Journal of Clinical Oncology vol. 39 , ( 6_suppl ) 438 - 438 .

Alva AS, Csőszi T, Ozguroglu M, Matsubara N, Geczi L, Cheng SY, Fradet Y, Oudard S et al. ( 2021 ) . Impact of subsequent therapy on survival in KEYNOTE-361: Pembrolizumab (pembro) plus chemotherapy (chemo) or pembro alone versus chemo as first-line therapy for advanced urothelial carcinoma (UC) . Journal of Clinical Oncology vol. 39 , ( 6_suppl ) 439 - 439 .

Choueiri TK, Albiges L, Fan L, Perini RF, Vickery D, Powles T, Rini BI ( 2021 ) . MK-6482, a hypoxia-inducible factor 2α inhibitor (HIF-2α), versus everolimus in heavily pretreated, immune checkpoint–inhibitor-resistant, advanced clear cell renal cell carcinoma (ccRCC): Phase III study . Journal of Clinical Oncology vol. 39 , ( 6_suppl ) tps368 - tps368 .

Motzer RJ, Choueiri TK, Powles T, Burotto M, Bourlon MT, Hsieh JJ, Maruzzo M, Shah AY et al. ( 2021 ) . Nivolumab + cabozantinib (NIVO+CABO) versus sunitinib (SUN) for advanced renal cell carcinoma (aRCC): Outcomes by sarcomatoid histology and updated trial results with extended follow-up of CheckMate 9ER . Journal of Clinical Oncology vol. 39 , ( 6_suppl ) 308 - 308 .

Plimack ER, Powles T, Bedke J, Pouliot F, Stus V, Waddell T, Gafanov R, Nosov D et al. ( 2021 ) . Outcomes for patients in the pembrolizumab+axitinib arm with advanced renal cell carcinoma (RCC) who completed two years of treatment in the phase III KEYNOTE-426 study . Journal of Clinical Oncology vol. 39 , ( 6_suppl ) 327 - 327 .

Tannir NM, Motzer RJ, Albiges L, Plimack ER, George S, Powles T, Donskov F, Rini BI et al. ( 2021 ) . Patterns of progression in patients treated with nivolumab plus ipilimumab (NIVO+IPI) versus sunitinib (SUN) for first-line treatment of advanced renal cell carcinoma (aRCC) in CheckMate 214 . Journal of Clinical Oncology vol. 39 , ( 6_suppl ) 313 - 313 .

Loriot Y, Alva AS, Csőszi T, Ozguroglu M, Matsubara N, Geczi L, Cheng SY, Fradet Y et al. ( 2021 ) . Post-hoc analysis of long-term outcomes in patients with CR, PR, or SD to pembrolizumab (pembro) or platinum-based chemotherapy (chemo) as 1L therapy for advanced urothelial carcinoma (UC) in KEYNOTE-361 . Journal of Clinical Oncology vol. 39 , ( 6_suppl ) 435 - 435 .

Powles T, Rosenberg JE, Sonpavde G, Loriot Y, Duran I, Lee J-L, Matsubara N, Vulsteke C et al. ( 2021 ) . Primary results of EV-301: A phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial carcinoma . Journal of Clinical Oncology vol. 39 , ( 6_suppl ) 393 - 393 .

Wei XX, Werner L, Teo MY, Rosenberg JE, Koshkin VS, Grivas P, Szabados B, Morrison L et al. ( 2021 ) . Sequencing of PD-1/L1 Inhibitors and Carboplatin Based Chemotherapy for Cisplatin Ineligible Metastatic Urothelial Carcinoma . The Journal of urology vol. 205 , ( 2 ) 414 - 419 .

Guo T, Wang Y, Jia J, Mao X, Stankiewicz E, Scandura G, Burke E, Xu L et al. ( 2021 ) . The Identification of Plasma Exosomal miR-423-3p as a Potential Predictive Biomarker for Prostate Cancer Castration-Resistance Development by Plasma Exosomal miRNA Sequencing . Frontiers in Cell and Developmental Biology vol. 8 ,

Choueiri TK, Tomczak P, Park SH, Venugopal B, Ferguson T, Chang YH, Hajek J, Symeonides SN et al. ( 2021 ) . Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma . New England Journal of Medicine vol. 385 , ( 8 ) 683 - 694 .

Tannir NM, Signoretti S, Choueiri TK, McDermott DF, Motzer RJ, Flaifel A, Pignon JC, Ficial M et al. ( 2021 ) . Efficacy and safety of nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma . Clinical Cancer Research vol. 27 , ( 1 ) 78 - 86 .

Huddart RA, Siefker-Radtke AO, Balar AV, Bilen MA, Powles T, Bamias A, Castellano D, Khalil MF et al. ( 2021 ) . PIVOT-10: Phase II study of bempegaldesleukin plus nivolumab in cisplatin-ineligible advanced urothelial cancer . Future Oncology vol. 17 , ( 2 ) 137 - 149 .

van Dijk N, Gómez de Liaño Lista A, Szabados B, Powles T, van der Heijden MS ( 2021 ) . Reply to Alessia Cimadamore, Liang Cheng, Marina Scarpelli, et al's Letter to the Editor re: Alfonso Gómez de Liaño Lista, Nick van Dijk, Guillermo de Velasco Oria de Rueda, et al. Clinical Outcome After Progressing to Frontline and Second-line Anti–PD-1/PD-L1 in Advanced Urothelial Cancer. Eur Urol 2020;77:269–76. Progression and Hyperprogression Versus Pseudoprogression: Morphologic Documentation . European Urology vol. 79 , ( 1 ) e20 - e21 .

Szabados B, Powles T ( 2021 ) . Urological Anti-cancer Agents . Basic Urological Sciences ,

Powles T, Huang B, di Pietro A ( 2020 ) . Avelumab Maintenance for Urothelial Carcinoma. Reply . The New England journal of medicine vol. 383 , ( 25 )

Motzer RJ, Banchereau R, Hamidi H, Powles T, McDermott D, Atkins MB, Escudier B, Liu LF et al. ( 2020 ) . Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade . Cancer Cell vol. 38 , ( 6 ) 803 - 817.e4 .

Powles TB, van der Heijden MS, Balar AV, O'Donnell P, Massard C, Walker J, Gupta A, Angra N et al. ( 2020 ) . 13P PD-L1 prevalence in advanced urothelial carcinoma by demographic and clinical characteristics . Annals of Oncology vol. 31 , s1421 - s1422 .

Powles TB, Assaf ZJ, Davarpanah N, Hussain M, Oudard S, Gschwend JE, Albers P, Castellano D et al. ( 2020 ) . 1O Clinical outcomes in post-operative ctDNA-positive muscle-invasive urothelial carcinoma (MIUC) patients after atezolizumab adjuvant therapy . Annals of Oncology vol. 31 ,

Choy J, Rodriguez CS, Larkin J, Patel P, Valderrama BP, Rodriguez-Vida A, Glen H, Thistlethwaite F et al. ( 2020 ) . 69P Outcomes with durvalumab and savolitinib in metastatic papillary renal cancer (mPRC) according to international metastatic renal cell carcinoma database consortium (IMDC) risk groups . Annals of Oncology vol. 31 ,

Powles T, Szabados B, Castellano D, Rodriguez-Vida A, Valderrama B, Crabb S, Van Der Heijden M, Pous A et al. ( 2020 ) . CtDNA as a predictor of outcome in patients treated with neoadjuvant atezolizumab in muscle invasive urothelial cancer . Urologic Oncology Seminars and Original Investigations vol. 38 , ( 12 )

Liu WK, Lam JM, Butters T, Grant M, Jackson-Spence F, Bex A, Powles T, Szabados B ( 2020 ) . Cytoreductive nephrectomy in metastatic renal cell carcinoma: outcome of patients treated with a multidisciplinary, algorithm-driven approach . World Journal of Urology vol. 38 , ( 12 ) 3199 - 3205 .

Powles T, van der Heijden MS, Castellano D, Galsky MD, Loriot Y, Petrylak DP, Ogawa O, Park SH et al. ( 2020 ) . Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial . The Lancet Oncology vol. 21 , ( 12 ) 1574 - 1588 .

Sonpavde G, Manitz J, Gao C, Tayama D, Kaiser C, Hennessy D, Makari D, Gupta A et al. ( 2020 ) . Five-Factor Prognostic Model for Survival of Post-Platinum Patients with Metastatic Urothelial Carcinoma Receiving PD-L1 Inhibitors . The Journal of urology vol. 204 , ( 6 ) 1173 - 1179 .

Loveday C, Litchfield K, Proszek PZ, Cornish AJ, Santo F, Levy M, Macintyre G, Holryod A et al. ( 2020 ) . Genomic landscape of platinum resistant and sensitive testicular cancers . Nature Communications vol. 11 , ( 1 )

Necchi A, Nishiyama H, Matsubara N, Lee JL, Petrylak DP, de Wit R, Drakaki A, Liepa AM et al. ( 2020 ) . Health-related quality of life in the randomized phase 3 study of ramucirumab plus docetaxel versus placebo plus docetaxel in platinum-refractory advanced urothelial carcinoma (RANGE) . BMC Urology vol. 20 , ( 1 )

Grunewald CM, Henn A, Galsky MD, Plimack ER, Harshman LC, Yu EY, Crabb SJ, Pal SK et al. ( 2020 ) . Impact of timing of adjuvant chemotherapy following radical cystectomy for bladder cancer on patient survival . Urologic Oncology: Seminars and Original Investigations vol. 38 , ( 12 ) 934.e1 - 934.e9 .

Powles T, Plimack ER, Soulières D, Waddell T, Stus V, Gafanov R, Nosov D, Pouliot F et al. ( 2020 ) . Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial . The Lancet Oncology vol. 21 , ( 12 ) 1563 - 1573 .

Rouanne M, Bajorin DF, Hannan R, Galsky MD, Williams SB, Necchi A, Sharma P, Powles T ( 2020 ) . Rationale and Outcomes for Neoadjuvant Immunotherapy in Urothelial Carcinoma of the Bladder . European urology oncology vol. 3 , ( 6 ) 728 - 738 .

Grünwald V, Voss MH, Rini BI, Powles T, Albiges L, Giles RH, Jonasch E ( 2020 ) . Axitinib plus Immuncheckpoint-Inhibitor: evidenz- und expertenbasierte Konsensusempfehlungen für die Behandlungsoptimierung und das Management von therapieassoziierten Nebenwirkungen . Kompass Onkologie vol. 7 , ( 4 ) 180 - 189 .

Albiges L, Tannir NM, Burotto M, McDermott D, Plimack ER, Barthélémy P, Porta C, Powles T et al. ( 2020 ) . Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: Extended 4-year follow-up of the phase III CheckMate 214 trial . ESMO Open vol. 5 , ( 6 )

Wood CG, Ferguson JE, Parker JS, Moore DT, Whisenant JG, Maygarden SJ, Wallen EM, Kim WY et al. ( 2020 ) . Neoadjuvant pazopanib and molecular analysis of tissue response in renal cell carcinoma . JCI Insight vol. 5 , ( 22 )

Choueiri T, Albiges L, Powles T, Mohamed N, Wang F, Motzer R ( 2020 ) . 342 A phase 3 study (COSMIC-313) of cabozantinib in combination with nivolumab and ipilimumab in patients with previously untreated advanced renal cell carcinoma of intermediate or poor risk . Conference: Regular and young investigator award abstractsa209.1 - a2a209 .

Szabados BE, Rodriguez-Vida A, Duran I, Crabb SJ, van der Heijden MS, Pous AF, Gravis G, Herranz UA et al. ( 2020 ) . 199O A phase II study investigating neoadjuvant atezolizumab in cisplatin-ineligible patients with muscle-invasive bladder cancer: Final analysis . Annals of Oncology vol. 31 ,

Kondoh CN, Bae WK, Tamada S, Matsubara N, Lee HJ, Mizuno R, Ani S, Kimura G et al. ( 2020 ) . 200O Pembrolizumab plus axitinib (pembro + axi) vs sunitinib in metastatic renal cell carcinoma (mRCC) outcomes of the KEYNOTE-426 study in patients from eastern Asia . Annals of Oncology vol. 31 ,

Wildsmith S, Walker J, L’Hernault A, Li W, Bye H, He P, Xiao F, Zhang Q et al. ( 2020 ) . 266 Tumour mutation burden (TMB) and efficacy outcomes in the phase III DANUBE study of advanced urothelial carcinoma (UC) . Journal for ImmunoTherapy of Cancer vol. 8 , ( Suppl 3 ) a163 - a164 .

Motzer RJ, Robbins PB, Powles T, Albiges L, Haanen JB, Larkin J, Mu XJ, Ching KA et al. ( 2020 ) . Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial . Nature Medicine vol. 26 , ( 11 ) 1733 - 1741 .

( 2020 ) . Nivolumab + ipilimumab (N+I) vs sunitinib (S) dans le traitement de première ligne du carcinome rénal avancé (aRCC) dans l’étude CheckMate 214 : suivi à 4 ans et analyse en sous-groupe des patients (pts) non néphrectomisés . Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie vol. 30 , ( 13 ) 785 - 786 .

Szabados B, Michael A, Powles T, Fife K, Klair B, Perrot V, Venugopal B ( 2020 ) . P070 CERES, a retrospective study of patients with advanced renal cell carcinoma who received cabozantinib as part of the UK Managed Access Program: Baseline characteristics and clinical outcomes . European Urology Open Science vol. 21 , s190 - s191 .

Wallis CJD, Catto JWF, Finelli A, Glaser AW, Gore JL, Loeb S, Morgan TM, Morgans AK et al. ( 2020 ) . The Impact of the COVID-19 Pandemic on Genitourinary Cancer Care: Re-envisioning the Future . European Urology vol. 78 , ( 5 ) 731 - 742 .

Bedke J, Merseburger AS, Loriot Y, Castellano D, Choy E, Duran I, Rosenberg J, Petrylak DP et al. ( 2020 ) . Analysis of clinical outcomes according to response status in prospective clinical trials of atezolizumab (atezo) in pretreated locally advanced/metastatic urothelial carcinoma (mUC) . ONCOLOGY RESEARCH AND TREATMENT . vol. 43 , 255 - 256 .

Lee LYW, Cazier JB, Starkey T, Briggs SEW, Arnold R, Bisht V, Booth S, Campton NA et al. ( 2020 ) . COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study . The Lancet Oncology vol. 21 , ( 10 ) 1309 - 1316 .

Martinez Chanza N, Werner L, Plimack E, Yu EY, Alva AS, Crabb SJ, Powles T, Rosenberg JE et al. ( 2020 ) . Incidence, Patterns, and Outcomes with Adjuvant Chemotherapy for Residual Disease After Neoadjuvant Chemotherapy in Muscle-invasive Urinary Tract Cancers . European urology oncology vol. 3 , ( 5 ) 671 - 679 .

Grimm M-O, Tannir N, McDermott D, Escudier B, Hammers H, Aren Frontera O, Plimack E, Barthelemy P et al. ( 2020 ) . Long-term follow-up on overall survival and independent review of response in CheckMate 214: first-line nivolumab plus ipilimumab (N plus I) versus sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC) . ONCOLOGY RESEARCH AND TREATMENT . vol. 43 , 208 - 208 .

Powles T, Park SH, Voog E, Caserta C, Valderrama BP, Gurney H, Kalofonos H, Radulović S et al. ( 2020 ) . Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma . New England Journal of Medicine vol. 383 , ( 13 ) 1218 - 1230 .

Grünwald V, Voss MH, Rini BI, Powles T, Albiges L, Giles RH, Jonasch E ( 2020 ) . Axitinib plus immune checkpoint inhibitor: evidence- and expert-based consensus recommendation for treatment optimisation and management of related adverse events . British Journal of Cancer vol. 123 , ( 6 ) 898 - 904 .

Hall PE, Shepherd STC, Brown J, Larkin J, Jones R, Ralph C, Hawkins R, Chowdhury S et al. ( 2020 ) . Radiological Response Heterogeneity Is of Prognostic Significance in Metastatic Renal Cell Carcinoma Treated with Vascular Endothelial Growth Factor-targeted Therapy . European Urology Focus vol. 6 , ( 5 ) 999 - 1005 .

Powles TB, Oudard S, Grünwald V, Calvo E, Michaelson MD, Burotto M, Melichar B, Tyagi R et al. ( 2020 ) . A phase II study of patients with advanced or metastatic renal cell carcinoma (mRCC) receiving pazopanib after previous checkpoint inhibitor treatment . Annals of Oncology vol. 31 ,

Powles TB, van der Heijden MS, Gauna DC, Loriot Y, Galsky MD, Petrylak DP, Ogawa O, Park SH et al. ( 2020 ) . A phase III, randomized, open-label study of first-line durvalumab (D) with or without tremelimumab (T) vs standard of care chemotherapy in patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE) . Annals of Oncology vol. 31 , s550 - s551 .

Bellmunt J, de Wit R, Fradet Y, Climent MA, Petrylak DP, Lee J-L, Fong L, Necchi A et al. ( 2020 ) . Association of TMB with efficacy of pembrolizumab (pembro) in patients (pts) with advanced urothelial cancer (UC): Results from KEYNOTE-045 and KEYNOTE-052 . Annals of Oncology vol. 31 , s580 - s581 .

Powles TB, Loriot Y, Bellmunt J, Sternberg CN, Sridhar S, Petrylak DP, Tambaro R, Dourthe LM et al. ( 2020 ) . Avelumab first-line (1L) maintenance + best supportive care (BSC) vs BSC alone for advanced urothelial carcinoma (UC): Association between clinical outcomes and exploratory biomarkers . Annals of Oncology vol. 31 , s552 - s553 .

Grivas P, Park SH, Voog E, Caserta C, Valderrama BP, Gurney H, Kalofonos H, Radulovic S et al. ( 2020 ) . Avelumab first-line (1L) maintenance + best supportive care (BSC) vs BSC alone with 1L chemotherapy (CTx) for advanced urothelial carcinoma (UC): Subgroup analyses from JAVELIN Bladder 100 . Annals of Oncology vol. 31 , s555 - s556 .

Mckean M, Bendell JC, Petrylak DP, Powles TB, Sonpavde GP, Dickson A, Dosunmu L, Hennessy MG et al. ( 2020 ) . BT8009-100 phase I/II study of the safety, pharmacokinetics, & preliminary clinical activity of BT8009 in patients with Nectin-4 expressing advanced malignancies . Annals of Oncology vol. 31 , s500 - s501 .

Choueiri TK, Powles T, Burotto M, Bourlon MT, Zurawski B, Juárez VMO, Hsieh JJ, Basso U et al. ( 2020 ) . Nivolumab + cabozantinib vs sunitinib in first-line treatment for advanced renal cell carcinoma: First results from the randomized phase III CheckMate 9ER trial . Annals of Oncology vol. 31 ,

Albiges L, Tannir N, Burotto M, McDermott DF, Plimack ER, Barthélémy P, Porta CG, Powles TB et al. ( 2020 ) . Nivolumab + ipilimumab (N+I) vs sunitinib (S) for first-line treatment of advanced renal cell carcinoma (aRCC) in CheckMate 214: 4-year follow-up and subgroup analysis of patients (pts) without nephrectomy . Annals of Oncology vol. 31 , s559 - s560 .

Powles TB, Kopyltsov E, Su P-J, Parnis FX, Park SH, Yamamoto Y, Fong PC, Tournigand C et al. ( 2020 ) . Patient-reported outcomes (PROs) from JAVELIN Bladder 100: Avelumab first-line (1L) maintenance + best supportive care (BSC) vs BSC alone for advanced urothelial carcinoma (UC) . Annals of Oncology vol. 31 , s578 - s579 .

Alva A, Csőszi T, Ozguroglu M, Matsubara N, Geczi L, Cheng SY-S, Fradet Y, Oudard S et al. ( 2020 ) . Pembrolizumab (P) combined with chemotherapy (C) vs C alone as first-line (1L) therapy for advanced urothelial carcinoma (UC): KEYNOTE-361 . Annals of Oncology vol. 31 ,

Steinberg GD, Saltstein D, Shore N, Cesari R, Vermette J, Pierce K, Blake-Haskins JA, Hariharan S et al. ( 2020 ) . Phase III study of the programmed cell death protein 1 inhibitor PF-06801591 plus bacillus Calmette-Guérin for non-muscle invasive bladder cancer . Annals of Oncology . vol. 31 ,

van der Heijden MS, Gupta S, Galsky MD, Derleth C, Steinberg J, Kataria R, Powles TB ( 2020 ) . Study EV-302: A 3-arm, open-label, randomized phase III study of enfortumab vedotin plus pembrolizumab and/or chemotherapy, versus chemotherapy alone, in untreated locally advanced or metastatic urothelial cancer . Annals of Oncology vol. 31 , s605 - s606 .

Meerveld-Eggink A, Graafland N, Wilgenhof S, van Thienen JV, Grant M, Szabados BE, Abu-Ghanem Y, Boleti E et al. ( 2020 ) . Synchronous metastatic renal cell carcinoma (mRCC) treated with nivolumab and ipilimumab (N+I) and the primary tumour (PT) in place . Annals of Oncology vol. 31 ,

Regan M, Jegede OA, Mantia C, Powles T, Werner L, Huo S, Del Tejo V, Stwalley B et al. ( 2020 ) . Treatment-free survival, with and without toxicity, after immuno-oncology vs targeted therapy for advanced renal cell carcinoma (aRCC): 42-month results of CheckMate 214 . Annals of Oncology vol. 31 ,

Sweeney CJ, Gillessen S, Rathkopf D, Matsubara N, Drake C, Fizazi K, Piulats JM, Wysocki PJ et al. ( 2020 ) . Abstract CT014: IMbassador250: A phase III trial comparing atezolizumab with enzalutamide vs enzalutamide alone in patients with metastatic castration-resistant prostate cancer (mCRPC) . Cancer Research . vol. 80 , ct014 - ct014 .

Lopez JS, Camidge R, Iafolla M, Rottey S, Schuler M, Hellmann M, Balmanoukian A, Dirix L et al. ( 2020 ) . Abstract CT301: A phase Ib study to evaluate RO7198457, an individualized Neoantigen Specific immunoTherapy (iNeST), in combination with atezolizumab in patients with locally advanced or metastatic solid tumors . Cancer Research . vol. 80 , ct301 - ct301 .

Vuky J, Balar AV, Castellano D, O’Donnell PH, Grivas P, Bellmunt J, Powles T, Bajorin D et al. ( 2020 ) . Long-term outcomes in KEYNOTE-052: Phase II study investigating first-line pembrolizumab in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer . Journal of Clinical Oncology vol. 38 , ( 23 ) 2658 - 2666 .

Szabados B, Abu-Ghanem Y, Grant M, Choy J, Bex A, Powles T ( 2020 ) . Clinical Characteristics and Outcome for Four SARS-CoV-2-infected Cancer Patients Treated with Immune Checkpoint Inhibitors . European Urology vol. 78 , ( 2 ) 276 - 280 .

Petrylak D, Rosenberg J, Duran I, Loriot Y, Sonpavde G, Wu C, Gartner E, Melhem-Bertrandt A et al. ( 2020 ) . EV-301: A phase 3 study evaluating enfortumab vedotin versus chemotherapy in patients with locally advanced or metastatic urothelial cancer (la/mUC) who have progressed on platinum-containing chemotherapy or anti-PD-(L)1 therapy . CLINICAL CANCER RESEARCH . vol. 26 , 59 - 60 .

Khan Z, Di Nucci F, Kwan A, Hammer C, Mariathasan S, Rouilly V, Carroll J, Fontes M et al. ( 2020 ) . Genetic risk for skin autoimmunity impacts the safety and efficacy of immune checkpoint blockade in urothelial carcinoma . CLINICAL CANCER RESEARCH . vol. 26 , 19 - 20 .

Abu-Ghanem Y, Fernández-Pello S, Bex A, Ljungberg B, Albiges L, Dabestani S, Giles RH, Hofmann F et al. ( 2020 ) . Limitations of Available Studies Prevent Reliable Comparison Between Tumour Ablation and Partial Nephrectomy for Patients with Localised Renal Masses: A Systematic Review from the European Association of Urology Renal Cell Cancer Guideline Panel . European urology oncology vol. 3 , ( 4 ) 433 - 452 .

Motzer RJ, Escudier B, McDermott DF, Arén Frontera O, Melichar B, Powles T, Donskov F, Plimack ER et al. ( 2020 ) . Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial . Journal for ImmunoTherapy of Cancer vol. 8 , ( 2 )

Witjes JA, Babjuk M, Bellmunt J, Bruins HM, De Reijke TM, De Santis M, Gillessen S, James N et al. ( 2020 ) . Corrigendum to ‘EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort Under the Auspices of the EAU-ESMO Guidelines Committees’ [European Urology 77 (2020) 223–250](S0302283819307638)(10.1016/j.eururo.2019.09.035) . European Urology vol. 78 , ( 1 ) e48 - e50 .

Pal SK, McDermott DF, Atkins MB, Escudier B, Rini BI, Motzer RJ, Fong L, Joseph RW et al. ( 2020 ) . Patient-reported outcomes in a phase 2 study comparing atezolizumab alone or with bevacizumab vs sunitinib in previously untreated metastatic renal cell carcinoma . BJU International vol. 126 , ( 1 ) 73 - 82 .

Wallis CJD, Novara G, Marandino L, Bex A, Kamat AM, Karnes RJ, Morgan TM, Mottet N et al. ( 2020 ) . Risks from Deferring Treatment for Genitourinary Cancers: A Collaborative Review to Aid Triage and Management During the COVID-19 Pandemic[Formula presented] . European Urology vol. 78 , ( 1 ) 29 - 42 .

Lee LYW, Cazier JB, Angelis V, Arnold R, Bisht V, Campton NA, Chackathayil J, Cheng VWT et al. ( 2020 ) . COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: A prospective cohort study . The Lancet vol. 395 , ( 10241 ) 1919 - 1926 .

Powles T, Park SH, Voog E, Caserta C, Valderrama BP, Gurney H, Kalofonos H, Radulovic S et al. ( 2020 ) . Maintenance avelumab + best supportive care (BSC) versus BSC alone after platinum-based first-line (1L) chemotherapy in advanced urothelial carcinoma (UC): JAVELIN Bladder 100 phase III interim analysis . Journal of Clinical Oncology vol. 38 , ( 18_suppl ) lba1 - lba1 .

Powles T, Park SH, Voog E, Caserta C, Valderrama BP, Gurney H, Kalofonos H, Radulovic S et al. ( 2020 ) . Maintenance avelumab plus best supportive care (BSC) versus BSC alone after platinum-based first-line (1L) chemotherapy in advanced urothelial carcinoma (UC): JAVELIN Bladder 100 phase III interim analysis . JOURNAL OF CLINICAL ONCOLOGY . vol. 38 ,

Khan Z, Di Nucci F, Kwan A, Hammer C, Mariathasan S, Rouilly V, Carroll J, Fontes M et al. ( 2020 ) . Polygenic risk for skin autoimmunity impacts immune checkpoint blockade in bladder cancer . Proceedings of the National Academy of Sciences of the United States of America vol. 117 , ( 22 ) 12288 - 12294 .

Gillessen S, Powles T ( 2020 ) . Advice Regarding Systemic Therapy in Patients with Urological Cancers During the COVID-19 Pandemic . European Urology vol. 77 , ( 6 ) 667 - 668 .

Atkins MB, Rini BI, Motzer RJ, Powles T, McDermott DF, Suarez C, Bracarda S, Stadler WM et al. ( 2020 ) . Patient-Reported Outcomes from the Phase III Randomized IMmotion151 Trial: Atezolizumab þ Bevacizumab versus Sunitinib in Treatment-Naïve Metastatic Renal Cell Carcinoma . Clinical Cancer Research vol. 26 , ( 11 ) 2506 - 2514 .

Grivas P, Plimack ER, Balar AV, Castellano D, O'Donnell PH, Bellmunt J, Powles T, Hahn NM et al. ( 2020 ) . Pembrolizumab as First-line Therapy in Cisplatin-ineligible Advanced Urothelial Cancer (KEYNOTE-052): Outcomes in Older Patients by Age and Performance Status . European urology oncology vol. 3 , ( 3 ) 351 - 359 .

Powles T, Kockx M, Rodriguez-Vida A, Duran I, Crabb SJ, Van Der Heijden MS, Szabados B, Pous AF et al. ( 2020 ) . Publisher Correction: Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial (Nature Medicine, (2019), 25, 11, (1706-1714), 10.1038/s41591-019-0628-7) . Nature Medicine vol. 26 , ( 6 )

Pillai M, Powles T, Szabados B, Savage P, Fife K, Klair B, Perrot V, Michael A et al. ( 2020 ) . A non-interventional retrospective study to describe early clinical experience with cabozantinib in patients with advanced renal cell carcinoma (aRCC) in the United Kingdom . Journal of Clinical Oncology vol. 38 , ( 15_suppl ) e17089 - e17089 .

Choueiri TK, Albiges L, Powles T, Scheffold C, Wang F, Motzer RJ ( 2020 ) . A phase III study (COSMIC-313) of cabozantinib in combination with nivolumab and ipilimumab in patients with previously untreated advanced renal cell carcinoma of intermediate or poor-risk . Journal of Clinical Oncology vol. 38 , ( 15_suppl ) tps5102 - tps5102 .

Dudani S, Gan CL, Wells C, Bakouny Z, Dizman N, Pal SK, Wood L, Kollmannsberger CK et al. ( 2020 ) . Application of IMDC criteria across first-line (1L) and second-line (2L) therapies in metastatic renal-cell carcinoma (mRCC): New and updated benchmarks of clinical outcomes . Journal of Clinical Oncology vol. 38 , ( 15_suppl ) 5063 - 5063 .

Motzer RJ, Choueiri TK, McDermott DF, Powles T, Yao J, Ammar R, Papillon-Cavanagh S, Saggi SS et al. ( 2020 ) . Biomarker analyses from the phase III CheckMate 214 trial of nivolumab plus ipilimumab (N plus I) or sunitinib (S) in advanced renal cell carcinoma (aRCC) . JOURNAL OF CLINICAL ONCOLOGY . vol. 38 ,

Kleeman SO, Grant M, Rallis KS, Wozniak A, So A, Tejpaul R, Heller N, Weight CJ et al. ( 2020 ) . CT-based radiomic classifier of primary renal tumors to distinguish between metastatic and non-metastatic disease . JOURNAL OF CLINICAL ONCOLOGY . vol. 38 ,

Bellmunt J, Powles T, Henriksson R, Steinberg GD, Batyrbekova N, Schain F, Fleming S, Shalaby W et al. ( 2020 ) . Clinical outcomes and economic burden for bladder cancer patients: An analysis from a Swedish cancer registry . Journal of Clinical Oncology vol. 38 , ( 15_suppl ) 5026 - 5026 .

Abu Ghanem Y, Choy J, Jackson-Spence F, Jovaisaite A, Grant M, Bex A, Powles T, Szabados B ( 2020 ) . Dynamic changes in full blood count (FBC) occurring in patients treated with immune checkpoint inhibitors (ICIs) to predict responses in patients with metastatic renal cell carcinoma (mRCC) . Journal of Clinical Oncology vol. 38 , ( 15_suppl ) e17110 - e17110 .

Araujo DV, Wells C, Hansen AR, Dizman N, Pal SK, Beuselinck B, Donskov F, Gan CL et al. ( 2020 ) . Efficacy of immune-checkpoint inhibitors (ICI) in the treatment of older adults with metastatic renal cell carcinoma (mRCC): An international mRCC database consortium (IMDC) analysis . Journal of Clinical Oncology vol. 38 , ( 15_suppl ) 5068 - 5068 .

Hussain MHA, Powles T, Albers P, Castellano D, Daneshmand S, Gschwend J, Nishiyama H, Oudard S et al. ( 2020 ) . IMvigor010: Primary analysis from a phase III randomized study of adjuvant atezolizumab (atezo) versus observation (obs) in high-risk muscle-invasive urothelial carcinoma (MIUC) . Journal of Clinical Oncology vol. 38 , ( 15_suppl ) 5000 - 5000 .

Retz M, Seseke F, Banna GL, De Giorgi U, Powles T, Basso U, McDermott RS, Llado A et al. ( 2020 ) . Impact of renal impairment on clinical outcomes in patients (pts) with locally advanced or metastatic (LA/M) urinary tract carcinoma (UTC) treated with atezolizumab (atezo): Analysis of the international SAUL study . Journal of Clinical Oncology vol. 38 , ( 15_suppl ) 5036 - 5036 .

Plimack ER, Rini BI, Stus V, Gafanov R, Waddell T, Nosov D, Pouliot F, Soulieres D et al. ( 2020 ) . Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced renal cell carcinoma (RCC): Updated analysis of KEYNOTE-426 . Journal of Clinical Oncology vol. 38 , ( 15_suppl ) 5001 - 5001 .

Choueiri TK, Albiges L, Fan L, Perini RF, Zojwalla NJ, Powles T, Rini BI ( 2020 ) . Phase III study of the hypoxia-inducible factor 2 alpha (HIF-2 alpha) inhibitor MK-6482 versus everolimus in previously treated patients with advanced clear cell renal cell carcinoma (ccRCC) . JOURNAL OF CLINICAL ONCOLOGY . vol. 38 ,

Choueiri TK, Albiges L, Fan L, Perini RF, Zojwalla NJ, Powles T, Rini BI ( 2020 ) . Phase III study of the hypoxia-inducible factor 2α (HIF-2α) inhibitor MK-6482 versus everolimus in previously treated patients with advanced clear cell renal cell carcinoma (ccRCC) . Journal of Clinical Oncology vol. 38 , ( 15_suppl ) tps5094 - tps5094 .

Meerveld-Eggink A, Graafland N, Wilgenhof S, Van Thienen JV, Grant M, Szabados B, Abu-Ghanem Y, Boleti E et al. ( 2020 ) . Real-world safety and efficacy data of patients with synchronous metastatic renal cell carcinoma (mRCC) treated with nivolumab and ipilimumab (N plus I) and the primary tumour (PT) in place . JOURNAL OF CLINICAL ONCOLOGY . vol. 38 ,

Meerveld-Eggink A, Graafland N, Wilgenhof S, Van Thienen JV, Grant M, Szabados B, Abu-Ghanem Y, Boleti E et al. ( 2020 ) . Real-world safety and efficacy data of patients with synchronous metastatic renal cell carcinoma (mRCC) treated with nivolumab and ipilimumab (N+I) and the primary tumour (PT) in place . Journal of Clinical Oncology vol. 38 , ( 15_suppl ) e17083 - e17083 .

Szabados B, Powles T ( 2020 ) . Immune checkpoint inhibition in urothelial carcinoma . The Lancet vol. 395 , ( 10236 ) 1522 - 1523 .

Yuen KC, Liu LF, Gupta V, Madireddi S, Keerthivasan S, Li C, Rishipathak D, Williams P et al. ( 2020 ) . High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade . Nature Medicine vol. 26 , ( 5 ) 693 - 698 .

Fulton B, Jones R, Powles T, Crabb S, Paul J, Birtle A, Chowdhury S, Hussain S et al. ( 2020 ) . ATLANTIS: A randomised multi-arm phase II biomarker-directed umbrella screening trial of maintenance targeted therapy after chemotherapy in patients with advanced or metastatic urothelial cancer . Trials vol. 21 , ( 1 )

Birtle A, Johnson M, Chester J, Jones R, Dolling D, Bryan RT, Harris C, Winterbottom A et al. ( 2020 ) . Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial . The Lancet vol. 395 , ( 10232 ) 1268 - 1277 .

Kamoun A, de Reyniès A, Allory Y, Sjödahl G, Robertson AG, Seiler R, Hoadley KA, Groeneveld CS et al. ( 2020 ) . A Consensus Molecular Classification of Muscle-invasive Bladder Cancer[Formula presented] . European Urology vol. 77 , ( 4 ) 420 - 433 .

de Bruijn R, Wimalasingham A, Szabados B, Stewart GD, Welsh SJ, Kuusk T, Blank C, Haanen J et al. ( 2020 ) . Deferred Cytoreductive Nephrectomy Following Presurgical Vascular Endothelial Growth Factor Receptor-targeted Therapy in Patients with Primary Metastatic Clear Cell Renal Cell Carcinoma: A Pooled Analysis of Prospective Trial Data . European urology oncology vol. 3 , ( 2 ) 168 - 173 .

Chalabi M, Cardona A, Nagarkar DR, Dhawahir Scala A, Gandara DR, Rittmeyer A, Albert ML, Powles T et al. ( 2020 ) . Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR trials . Annals of Oncology vol. 31 , ( 4 ) 525 - 531 .

Kamoun A, de Reyniès A, Allory Y, Sjödahl G, Robertson AG, Seiler R, Hoadley KA, Groeneveld CS et al. ( 2020 ) . Reply To Kenneth B. Yatai, Mark J. Dunning, Dennis Wang. Consensus Genomic Subtypes of Muscle-invasive Bladder Cancer: A Step in the Right Direction but Still a Long Way To Go. Eur Urol 2020;77:434–5 . European Urology vol. 77 , ( 4 ) 436 - 438 .

Al-Lamki RS, Hudson NJ, Bradley JR, Warren AY, Eisen T, Welsh SJ, Riddick ACP, O‘Mahony FC et al. ( 2020 ) . The efficacy of sunitinib treatment of renal cancer cells is associated with the Protein PHAX in vitro . Biology vol. 9 , ( 4 )

Powles T ( 2020 ) . Treatment Choices for Front-line Metastatic Clear Cell Renal Cancer . European Urology vol. 77 , ( 4 ) 454 - 456 .

Tannir NM, Powles T, Escudier B, Donskov F, Grünwald V, Sternberg CN, Schmidinger M, Schöffski P et al. ( 2020 ) . Clinical Outcomes by Nephrectomy Status In METEOR, A Randomized Phase 3 Trial of Cabozantinib Versus Everolimus in Patients with Advanced Renal Cell Carcinoma . Kidney Cancer vol. 4 , ( 1 ) 29 - 39 .

Choueiri TK, Albiges L, Powles T, Scheffold C, Wang F, Motzer RJ ( 2020 ) . A phase III study (COSMIC-313) of cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in patients (pts) with previously untreated advanced renal cell carcinoma (aRCC) of intermediate or poor risk . JOURNAL OF CLINICAL ONCOLOGY . vol. 38 ,

Choueiri TK, Albiges L, Powles T, Scheffold C, Wang F, Motzer RJ ( 2020 ) . A phase III study (COSMIC-313) of cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in patients (pts) with previously untreated advanced renal cell carcinoma (aRCC) of intermediate or poor risk . Journal of Clinical Oncology vol. 38 , ( 6_suppl ) tps767 - tps767 .

Bedke J, Merseburger AS, Loriot Y, Castellano D, Choy E, Duran I, Rosenberg JE, Petrylak DP et al. ( 2020 ) . Analysis of clinical outcomes according to response status in prospective clinical trials of atezolizumab (atezo) in pretreated locally advanced/metastatic urothelial carcinoma (mUC) . JOURNAL OF CLINICAL ONCOLOGY . vol. 38 ,

Bedke J, Merseburger AS, Loriot Y, Castellano D, Choy E, Duran I, Rosenberg JE, Petrylak DP et al. ( 2020 ) . Analysis of clinical outcomes according to response status in prospective clinical trials of atezolizumab (atezo) in pretreated locally advanced/metastatic urothelial carcinoma (mUC) . Journal of Clinical Oncology vol. 38 , ( 6_suppl ) 492 - 492 .

Abu-Ghanem Y, Van Thienen JV, Blank CU, Powles T, Tombal BF, Collette L, Haanen JBAG, Bex A ( 2020 ) . Differences in the exposure to sunitinib in the immediate and deferred cytoreductive nephrectomy (CN) arms of the randomized controlled trial SURTIME . JOURNAL OF CLINICAL ONCOLOGY . vol. 38 ,

Abu-Ghanem Y, Van Thienen JV, Blank CU, Powles T, TOMBAL BF, Collette L, Haanen JBAG, Bex A ( 2020 ) . Differences in the exposure to sunitinib in the immediate and deferred cytoreductive nephrectomy (CN) arms of the randomized controlled trial SURTIME . Journal of Clinical Oncology vol. 38 , ( 6_suppl ) 703 - 703 .

Chaudhry A, Sternberg CN, De Santis M, Bellmunt J, Necchi A, Powles T, Cantero F, Marszewska M et al. ( 2020 ) . FIDES-02, a phase Ib/II study of derazantinib (DZB) as monotherapy and combination therapy with atezolizumab (A) in patients with surgically unresectable or metastaticurothelial cancer (UC) and FGFR genetic aberrations . JOURNAL OF CLINICAL ONCOLOGY . vol. 38 ,

Chaudhry A, Sternberg CN, De Santis M, Bellmunt J, Necchi A, Powles T, Cantero F, Marszewska M et al. ( 2020 ) . FIDES-02, a phase Ib/II study of derazantinib (DZB) as monotherapy and combination therapy with atezolizumab (A) in patients with surgically unresectable or metastaticurothelial cancer (UC) and FGFR genetic aberrations . Journal of Clinical Oncology vol. 38 , ( 6_suppl ) tps590 - tps590 .

Galsky MD, Powles T, Dreicer R, Kitamura H, Asatiani E, Howe J, Zhen H, Oliveira N et al. ( 2020 ) . FIGHT-205: Phase II study of first-line pemigatinib (PEMI) plus pembrolizumab (PEMBRO) versus PEMI alone versus standard of care (SOC) for cisplatin (CIS)-Ineligible urothelial carcinoma (UC) with FGFR3 mutation or rearrangement . JOURNAL OF CLINICAL ONCOLOGY . vol. 38 ,

Galsky MD, Powles T, Dreicer R, Kitamura H, Asatiani E, Howe J, Zhen H, Oliveira N et al. ( 2020 ) . FIGHT-205: Phase II study of first-line pemigatinib (PEMI) plus pembrolizumab (PEMBRO) versus PEMI alone versus standard of care (SOC) for cisplatin (CIS)—Ineligible urothelial carcinoma (UC) with FGFR3 mutation or rearrangement . Journal of Clinical Oncology vol. 38 , ( 6_suppl ) tps592 - tps592 .

Jiang DM, Wong B, Morgans AK, Sweeney C, Fizazi K, Chi KN, Powles T, Perlis N et al. ( 2020 ) . Improving quality of health-related quality of life (HRQOL) reporting in phase III randomized controlled trials (RCTs) of metastatic prostate cancer (mPC) . JOURNAL OF CLINICAL ONCOLOGY . vol. 38 ,

Jiang DM, Wong B, Morgans AK, Sweeney C, Fizazi K, Chi KN, Powles T, Perlis N et al. ( 2020 ) . Improving quality of health-related quality of life (HRQOL) reporting in phase III randomized controlled trials (RCTs) of metastatic prostate cancer (mPC) . Journal of Clinical Oncology vol. 38 , ( 6_suppl ) 58 - 58 .

Jiang DM, Wong B, Bellmunt J, Powles T, Morgans AK, Vaughn DJ, Sridhar SS ( 2020 ) . Improving quality of health-related quality of life (HRQOL) reporting in phase III randomized controlled trials (RCTs) of metastatic urothelial carcinoma (mUC) . JOURNAL OF CLINICAL ONCOLOGY . vol. 38 ,

Jiang DM, Wong B, Bellmunt J, Powles T, Morgans AK, Vaughn DJ, Sridhar SS ( 2020 ) . Improving quality of health-related quality of life (HRQOL) reporting in phase III randomized controlled trials (RCTs) of metastatic urothelial carcinoma (mUC) . Journal of Clinical Oncology vol. 38 , ( 6_suppl ) 467 - 467 .

Szabados B, Kockx M, Van Dam P-J, Rodriguez-Vida A, Duran I, Crabb SJ, Van Der Heijden MS, Font A et al. ( 2020 ) . MHCI and FOXP3 predicting outcome to neoadjuvant atezolizumab in sequential urothelial cancer tissue . JOURNAL OF CLINICAL ONCOLOGY . vol. 38 ,

Szabados B, Kockx M, Van Dam P-J, Rodriguez-Vida A, Duran I, Crabb SJ, Van Der Heijden MS, Font A et al. ( 2020 ) . MHCI and FOXP3 predicting outcome to neoadjuvant atezolizumab in sequential urothelial cancer tissue . Journal of Clinical Oncology vol. 38 , ( 6_suppl ) 541 - 541 .

Jackson-Spence F, Jovaisaite A, Grant M, Liu W-K, Butters T, Powles T, Szabados B ( 2020 ) . Outcomes after first-line therapy for immune/immune or immune/VEGF combinations . JOURNAL OF CLINICAL ONCOLOGY . vol. 38 ,

Jackson-Spence F, Jovaisaite A, Grant M, Liu W-K, Butters T, Powles T, Szabados B ( 2020 ) . Outcomes after first-line therapy for immune/immune or immune/VEGF combinations . Journal of Clinical Oncology vol. 38 , ( 6_suppl ) 706 - 706 .

Tannir NM, McDermott DF, Escudier B, Hammers HJ, Aren OR, Plimack ER, Barthelemy P, Neiman V et al. ( 2020 ) . Overall survival and independent review of response in CheckMate 214 with 42-month follow-up: First-line nivolumab + ipilimumab (N+I) versus sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC) . Journal of Clinical Oncology vol. 38 , ( 6_suppl ) 609 - 609 .

Tannir NM, McDermott DF, Escudier B, Hammers HJ, Aren OR, Plimack ER, Barthelemy P, Neiman V et al. ( 2020 ) . Overall survival and independent review of response in CheckMate 214 with 42-month follow-up: First-line nivolumab plus ipilimumab (N plus I) versus sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC) . JOURNAL OF CLINICAL ONCOLOGY . vol. 38 ,

Suarez Rodriguez C, Larkin JMG, Patel P, Perez Valderrama B, Rodriguez-Vida A, Glen H, Thistlethwaite F, Ralph C et al. ( 2020 ) . Overall survival results for durvalumab and savolitinib in metastatic papillary renal cancer . JOURNAL OF CLINICAL ONCOLOGY . vol. 38 ,

Suarez Rodriguez C, Larkin JMG, Patel P, Valderrama BP, Rodriguez-Vida A, Glen H, Thistlethwaite F, Ralph C et al. ( 2020 ) . Overall survival results for durvalumab and savolitinib in metastatic papillary renal cancer . Journal of Clinical Oncology vol. 38 , ( 6_suppl ) 619 - 619 .

Huddart RA, Siefker-Radtke AO, Balar AV, Bilen MA, Powles T, Bamias A, Castellano D, Khalil MF et al. ( 2020 ) . PIVOT-10: A phase II study of bempegaldesleukin (NKTR-214) in combination with nivolumab (NIVO) in cisplatin (cis) ineligible patients with previously untreated locally advanced or metastatic urothelial cancer (mUC) . JOURNAL OF CLINICAL ONCOLOGY . vol. 38 ,

Huddart RA, Siefker-Radtke AO, Balar AV, Bilen MA, Powles T, Bamias A, Castellano D, Khalil MF et al. ( 2020 ) . PIVOT-10: A phase II study of bempegaldesleukin (NKTR-214) in combination with nivolumab (NIVO) in cisplatin (cis) ineligible patients with previously untreated locally advanced or metastatic urothelial cancer (mUC) . Journal of Clinical Oncology vol. 38 , ( 6_suppl ) tps589 - tps589 .

Hussain SA, Lester JF, Jackson R, Gornall M, Elliott A, Crabb SJ, Huddart RA, Vasudev N et al. ( 2020 ) . Phase II randomized placebo-controlled neoadjuvant trial of nintedanib or placebo with gemcitabine and cisplatin in locally advanced muscle invasive bladder cancer (NEO-BLADE) . JOURNAL OF CLINICAL ONCOLOGY . vol. 38 ,

Hussain SA, Lester JF, Jackson R, Gornall M, Elliott A, Crabb SJ, Huddart RA, Vasudev N et al. ( 2020 ) . Phase II randomized placebo-controlled neoadjuvant trial of nintedanib or placebo with gemcitabine and cisplatin in locally advanced muscle invasive bladder cancer (NEO-BLADE) . Journal of Clinical Oncology vol. 38 , ( 6_suppl ) 438 - 438 .

Drakaki A, Kalebasty AR, Lee J-L, Martin-Liberal J, Kim M, Shin SJ, Shi J, Mariathasan S et al. ( 2020 ) . Phase Ib/II umbrella trial to evaluate the safety and efficacy of multiple 2L cancer immunotherapy (CIT) combinations in advanced/metastatic urothelial carcinoma (mUC): MORPHEUS-mUC . JOURNAL OF CLINICAL ONCOLOGY . vol. 38 ,

Drakaki A, Rezazadeh Kalebasty A, Lee J-L, Martin-Liberal J, Kim M, Shin SJ, Shi J, Mariathasan S et al. ( 2020 ) . Phase Ib/II umbrella trial to evaluate the safety and efficacy of multiple 2L cancer immunotherapy (CIT) combinations in advanced/metastatic urothelial carcinoma (mUC): MORPHEUS-mUC . Journal of Clinical Oncology vol. 38 , ( 6_suppl ) tps591 - tps591 .

Stukalin I, Dudani S, Wells C, Gan CL, Pal SK, Dizman N, Powles T, Donskov F et al. ( 2020 ) . Second-line VEGF TKI after IO combination therapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) . JOURNAL OF CLINICAL ONCOLOGY . vol. 38 ,

Stukalin I, Dudani S, Wells C, Gan CL, Pal SK, Dizman N, Powles T, Donskov F et al. ( 2020 ) . Second-line VEGF TKI after IO combination therapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) . Journal of Clinical Oncology vol. 38 , ( 6_suppl ) 684 - 684 .

Kuebler HR, Powles T, Meeks JJ, Galsky M, van der Heijdens MS, Nishiyama H, Al-Ahmadie H, Gupta A et al. ( 2020 ) . A Phase 3, Randomized, Open-Label, Multicenter, Global Study of Efficacy and Safety of Durvalumab in Combination with Gemcitabine plus CiSPLATiN (G plus C) for Neoadjuvant Treatment Followed By Durvalumab Alone for Adjuvant Treatment in Muscle-Invasive Bladder Cancer (MiBC) (NiAGARA) . ONCOLOGY RESEARCH AND TREATMENT . vol. 43 , 82 - 82 .

Gruenwald V, Choueiri TK, Rini BI, Powles T, George S, Grimm M-O, Mchenry MB, Maurer M et al. ( 2020 ) . Association Between Depth of Response (DepOR) and Overall Survival (OS): Exploratory Analysis of Nivolumab plus Ipilimumab (N plus I) vs Sunitinib (S) in Patients with Previously Untreated Advanced Renal Cell Carcinoma (ARCC) in Checkmate 214 . ONCOLOGY RESEARCH AND TREATMENT . vol. 43 , 74 - 75 .

Grimm M-O, Mcdermott DF, Choueiri TK, Motzer RJ, Frontera OA, George S, Powles T, Donskov F et al. ( 2020 ) . Checkmate 214 Post Hoc Analyses of Nivolumab Plus Ipilimumab or Sunitinib in IMDC Intermediate/Poor-Risk Patients with Previously Untreated Advanced Renal Cell Carcinoma (ARCC) with Sarcomatoid Features (SRCC) . ONCOLOGY RESEARCH AND TREATMENT . vol. 43 , 70 - 71 .

Zengerling F, Sternberg CN, Merseburger AS, Choy E, Castellano D, Lopez-Rios F, James N, Banna GL et al. ( 2020 ) . Clinical Outcomes According to PD-L1 Status and Age in the Prospective International Saul Study of atezolizumab (ATEZO) for Locally Advanced or Metastatic Urothelial Carcinoma (UC) or Non-UC of the Urinary Tract . ONCOLOGY RESEARCH AND TREATMENT . vol. 43 , 73 - 74 .

Gómez de Liaño Lista A, van Dijk N, de Velasco Oria de Rueda G, Necchi A, Lavaud P, Morales-Barrera R, Alonso Gordoa T, Maroto P et al. ( 2020 ) . Clinical outcome after progressing to frontline and second-line Anti–PD-1/PD-L1 in advanced urothelial cancer[Formula presented] . European Urology vol. 77 , ( 2 ) 269 - 276 .

Witjes JA, Babjuk M, Bellmunt J, Maxim Bruins H, De Reijke TM, De Santis M, Gillessen S, James N et al. ( 2020 ) . EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort^†[Formula presented]: Under the Auspices of the EAU-ESMO Guidelines Committees . European Urology vol. 77 , ( 2 ) 223 - 250 .

Fernández-Pello S, Hora M, Kuusk T, Tahbaz R, Dabestani S, Abu-Ghanem Y, Albiges L, Giles RH et al. ( 2020 ) . Management of Sporadic Renal Angiomyolipomas: A Systematic Review of Available Evidence to Guide Recommendations from the European Association of Urology Renal Cell Carcinoma Guidelines Panel . European urology oncology vol. 3 , ( 1 ) 57 - 72 .

Donskov F, Motzer RJ, Voog E, Hovey E, Grüllich C, Nott LM, Cuff K, Gil T et al. ( 2020 ) . Outcomes based on age in the phase III METEOR trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma . European Journal of Cancer vol. 126 , 1 - 10 .

Grant M, Szabados B, Kuusk T, Powles T, Bex A ( 2020 ) . Cytoreductive nephrectomy: Does CARMENA (Cancer du Rein Metastatique Nephrectomie et Antiangiogéniques) change everything? . Current Opinion in Urology vol. 30 , ( 1 ) 36 - 40 .

Grant M, Szabados B, Kuusk T, Powles T, Bex A ( 2020 ) . Cytoreductive nephrectomy: does CARMENA (Cancer du Rein Metastatique Nephrectomie et Antiangiogéniques) change everything? . Curr Opin Urol vol. 30 , ( 1 ) 36 - 40 .

Drakaki A, Kirby CJ, Van Der Heijden MS, Petrylak DP, Powles T, Chi KN, Fléchon A, Necchi A et al. ( 2020 ) . Docetaxel with or without Ramucirumab after Platinum-Based Chemotherapy and Checkpoint Inhibitors in Advanced Urothelial Carcinoma: A Pre-Specified Subgroup Analysis from the Phase 3 RANGE Trial . Bladder Cancer vol. 6 , ( 1 ) 43 - 52 .

Petrylak DP, de Wit R, Chi KN, Drakaki A, Sternberg CN, Nishiyama H, Castellano D, Hussain SA et al. ( 2020 ) . Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial . The Lancet Oncology vol. 21 , ( 1 ) 105 - 120 .

Powles T, Walker J, Andrew Williams J, Bellmunt J ( 2020 ) . The evolving role of PD-L1 testing in patients with metastatic urothelial carcinoma . Cancer Treatment Reviews vol. 82 ,

Buckley HL, Collinson FJ, Ainsworth G, Poad H, Flanagan L, Katona E, Howard HC, Murden G et al. ( 2019 ) . PRISM protocol: a randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinoma . BMC Cancer . vol. 19 ,

Petrylak DP, Rosenberg JE, Lee J, Yonese J, Duran I, Loriot Y, Sonpavde G, Wu C et al. ( 2019 ) . 223TiP EV-301: A phase III trial in progress evaluating enfortumab vedotin versus chemotherapy in patients with locally advanced or metastatic urothelial carcinoma . Annals of Oncology vol. 30 , ix75 - ix76 .

Powles T, Kockx M, Rodriguez-Vida A, Duran I, Crabb SJ, Van Der Heijden MS, Szabados B, Pous AF et al. ( 2019 ) . Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial . Nature Medicine vol. 25 , ( 11 ) 1706 - 1714 .

Horwich A, Babjuk M, Bellmunt J, Bruins HM, De Reijke TM, De Santis M, Gillessen S, James N et al. ( 2019 ) . EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees . Ann Oncol vol. 30 , ( 11 ) 1697 - 1727 .

Horwich A, Babjuk M, Bellmunt J, Bruins HM, De Reijke TM, De Santis M, Gillessen S, James N et al. ( 2019 ) . EAU–ESMO consensus statements on the management of advanced and variant bladder cancer—an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees . Annals of Oncology vol. 30 , ( 11 ) 1697 - 1727 .

Petrylak DP, Rosenberg JE, Lee J, Yonese J, Duran I, Loriot Y, Sonpavde G, Wu C et al. ( 2019 ) . EV-301: A phase III trial in progress evaluating enfortumab vedotin versus chemotherapy in patients with locally advanced or metastatic urothelial carcinoma . ANNALS OF ONCOLOGY . vol. 30 ,

Bamias A, Tzannis K, Harshman LC, Crabb SJ, Wong YN, Kumar Pal S, De Giorgi U, Ladoire S et al. ( 2019 ) . Erratum: Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC) (Annals of Oncology (2018) 29(2) (361–369), (S0923753419350392), (10.1093/annonc/mdx692)) . Annals of Oncology vol. 30 , ( 11 )

Szabados B, Ruiz MD, Grant M, Liu W-K, Butters T, Pouliot F, Nosov D, Rini B et al. ( 2019 ) . P096 Clinical outcomes of patients with metastatic renal cell carcinoma receiving subsequent therapy after progression on front-line immune-VEGF TKI combination therapy . European Urology Open Science vol. 18 , ( 11 )

Grant M, Liu W, Butters T, Powles T, Szabados B ( 2019 ) . P130 Outcome of patients with metastatic urothelial cancer treated with chemotherapy following immune checkpoint inhibition . European Urology Open Science vol. 18 , ( 11 )

Butters T, Szabados B, Grant M, Liu W-K, Lam J, Powles T ( 2019 ) . P133 Do emergency department physicians understand immunotherapy?: Survey in the largest London University Hospital Trust . European Urology Open Science vol. 18 , ( 11 )

Flaifel A, Xie W, Braun DA, Ficial M, Bakouny Z, Nassar AH, Jennings RB, Escudier B et al. ( 2019 ) . PD-L1 expression and clinical outcomes to cabozantinib, everolimus, and sunitinib in patients with metastatic renal cell carcinoma: Analysis of the randomized clinical trials Meteor and Cabosun . Clinical Cancer Research vol. 25 , ( 20 ) 6080 - 6088 .

Powles T, Balar A, Gravis G, Jones R, Ravaud A, Florence J, Grivas P, Petrylak DP et al. ( 2019 ) . 902O An adaptive, biomarker directed platform study in metastatic urothelial cancer (BISCAY) with durvalumab in combination with targeted therapies . Annals of Oncology vol. 30 , v356 - v357 .

Van der Heijden MS, Loriot Y, Duran I, Ravaud A, Retz MM, Vogelzang NJ, Nelson B, Wang J et al. ( 2019 ) . 918P Atezolizumab (atezo) vs chemotherapy (chemo) in patients (pts) with platinum-treated locally advanced or metastatic urothelial carcinoma (mUC): A long-term overall survival (OS) and safety update from the phase III IMvigor211 study . Annals of Oncology vol. 30 , v365 - v366 .

van der Heijden M, Powles T, Petrylak D, de Wit R, Chi K, Necchi A, Sternberg CN, Matsubara N et al. ( 2019 ) . 929P Biomarker analyses of ramucirumab in patients with platinum refractory urothelial cancer from RANGE, a global, randomized, double-blind, phase III study . Annals of Oncology vol. 30 , v373 - v374 .

Grünwald V, Choueiri TK, Rini BI, Powles T, George S, Grimm M-O, McHenry MB, Maurer M et al. ( 2019 ) . 950P Association between depth of response and overall survival: Exploratory analysis in patients with previously untreated advanced renal cell carcinoma (aRCC) in CheckMate 214 . Annals of Oncology vol. 30 , v382 - v383 .

Regan MM, Atkins MB, Powles T, Werner L, Mantia C, Yang S, Johansen JL, Rao S et al. ( 2019 ) . 971P Treatment-free survival, with and without toxicity, as a novel outcome applied to immuno-oncology agents in advanced renal cell carcinoma . Annals of Oncology vol. 30 , v393 - v394 .

Powles T, Balar A, Gravis G, Jones R, Ravaud A, Florence J, Grivas P, Petrylak DP et al. ( 2019 ) . An adaptive, biomarker directed platform study in metastatic urothelial cancer (BISCAY) with durvalumab in combination with targeted therapies . ANNALS OF ONCOLOGY . vol. 30 ,

Gruenwald V, Choueiri TK, Rini BI, Powles T, George S, Grimm M-O, McHenry MB, Maurer M et al. ( 2019 ) . Association between depth of response and overall survival: Exploratory analysis in patients with previously untreated advanced renal cell carcinoma (aRCC) in CheckMate 214 . ANNALS OF ONCOLOGY . vol. 30 , 382 - + .

Van der Heijden M, Powles T, Petrylak D, de Wit R, Chi K, Necchi A, Sternberg CN, Matsubara N et al. ( 2019 ) . Biomarker analyses of ramucirumab in patients with platinum refractory urothelial cancer from RANGE, a global, randomized, double-blind, phase III study . ANNALS OF ONCOLOGY . vol. 30 ,

Song D, Powles T, Shi L, Zhang L, Ingersoll MA, Lu YJ ( 2019 ) . Bladder cancer, a unique model to understand cancer immunity and develop immunotherapy approaches . Journal of Pathology vol. 249 , ( 2 ) 151 - 165 .

Motzer RJ, Rini BI, McDermott DF, Arén Frontera O, Hammers HJ, Carducci MA, Salman P, Escudier B et al. ( 2019 ) . Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial . The Lancet Oncology vol. 20 , ( 10 ) 1370 - 1385 .

Szabados B, van Dijk N, Tang YZ, van der Heijden MS, Wimalasingham A, Gomez de Liano A, Chowdhury S, Hughes S et al. ( 2019 ) . Re: Response rate to chemotherapy after immune checkpoint inhibition in metastatic urothelial cancer . Journal of Urology vol. 202 , ( 4 ) 658 - 659 .

De Bruijn RE, Mulders P, Jewett MA, Wagstaff J, Van Thienen JV, Blank CU, Van Velthoven R, Wood L et al. ( 2019 ) . Surgical Safety of Cytoreductive Nephrectomy Following Sunitinib: Results from the Multicentre, Randomised Controlled Trial of Immediate Versus Deferred Nephrectomy (SURTIME)(Figure presented.) . European Urology vol. 76 , ( 4 ) 437 - 440 .

Bamias A, Tzannis K, Bamia C, Harshman LC, Crabb S, Plimack ER, Pal S, De Giorgi U et al. ( 2019 ) . The Impact of Cisplatin- or Non-Cisplatin-Containing Chemotherapy on Long-Term and Conditional Survival of Patients with Advanced Urinary Tract Cancer . Oncologist vol. 24 , ( 10 ) 1348 - 1355 .

Regan MM, Atkins MB, Powles T, Werner L, Mantia C, Yang S, Johansen JL, Rao S et al. ( 2019 ) . Treatment-free survival, with and without toxicity, as a novel outcome applied to immuno-oncology agents in advanced renal cell carcinoma . ANNALS OF ONCOLOGY . vol. 30 , 393 - + .

Martini A, Jia R, Ferket BS, Waingankar N, Plimack ER, Crabb SJ, Harshman LC, Yu EY et al. ( 2019 ) . Tumor downstaging as an intermediate endpoint to assess the activity of neoadjuvant systemic therapy in patients with muscle-invasive bladder cancer . Cancer vol. 125 , ( 18 ) 3155 - 3163 .

Michaelson MD, Gupta S, Agarwal N, Szmulewitz R, Powles T, Pili R, Bruce JY, Vaishampayan U et al. ( 2019 ) . A Phase Ib Study of Axitinib in Combination with Crizotinib in Patients with Metastatic Renal Cell Cancer or Other Advanced Solid Tumors . Oncologist vol. 24 , ( 9 ) 1151 - e817 .

Auvray M, Auclin E, Barthelemy P, Bono P, Kellokumpu-Lehtinen P, Gross-Goupil M, De Velasco G, Powles T et al. ( 2019 ) . Erratum to ‘Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma’ (European Journal of Cancer (2019) 108 (33–40), (S0959804918315399), (10.1016/j.ejca.2018.11.031)) . European Journal of Cancer vol. 119 , 200 - 201 .

Dabestani S, Beisland C, Stewart GD, Bensalah K, Gudmundsson E, Lam TB, Gietzmann W, Zakikhani P et al. ( 2019 ) . Intensive Imaging-Based Follow-up of Surgically Treated Localised Renal Cell Carcinoma Does Not Improve Post-Recurrence Survival: Results from a European Multicentre Database (RECUR) . Journal of Urology vol. 202 , ( 3 ) 455 - 456 .

Dabestani S, Beisland C, Stewart GD, Bensalah K, Gudmundsson E, Lam TB, Gietzmann W, Zakikhani P et al. ( 2019 ) . Long-term Outcomes of Follow-up for Initially Localised Clear Cell Renal Cell Carcinoma: RECUR Database Analysis . European Urology Focus vol. 5 , ( 5 ) 857 - 866 .

Grimm MO, Bex A, De Santis M, Ljungberg B, Catto JWF, Rouprêt M, Hussain SA, Bellmunt J et al. ( 2019 ) . Safe Use of Immune Checkpoint Inhibitors in the Multidisciplinary Management of Urological Cancer: The European Association of Urology Position in 2019 . European Urology vol. 76 , ( 3 ) 368 - 380 .

de Velasco G, Bex A, Albiges L, Powles T, Rini BI, Motzer RJ, Heng DYC, Escudier B ( 2019 ) . Sequencing and Combination of Systemic Therapy in Metastatic Renal Cell Carcinoma . European Urology Oncology vol. 2 , ( 5 ) 505 - 514 .

Alifrangis C, McGovern U, Freeman A, Powles T, Linch M ( 2019 ) . Molecular and histopathology directed therapy for advanced bladder cancer . Nature Reviews Urology vol. 16 , ( 8 ) 465 - 483 .

Albiges L, Powles T, Staehler M, Bensalah K, Giles RH, Hora M, Kuczyk MA, Lam TB et al. ( 2019 ) . Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibition Is the New Backbone in First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma . European Urology vol. 76 , ( 2 ) 151 - 156 .

Woolston A, Khan K, Spain G, Barber LJ, Griffiths B, Gonzalez-Exposito R, Hornsteiner L, Punta M et al. ( 2019 ) . Genomic and Transcriptomic Determinants of Therapy Resistance and Immune Landscape Evolution during Anti-EGFR Treatment in Colorectal Cancer . Cancer Cell vol. 36 , ( 1 ) 35 - 50.e9 .

Plimack ER, Rini BI, Stus V, Gafanov R, Hawkins R, Nosov D, Pouliot F, Soulieres D et al. ( 2019 ) . AUTHOR INDEX . ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY . vol. 15 , 33 - 34 .

Choueiri TK, Quinn DI, Zhang T, Gurney H, Doshi GK, Cobb PW, Parnis F, Lee J-L et al. ( 2019 ) . Abstract CT162: Pembrolizumab monotherapy for the adjuvant treatment of renal cell carcinoma post-nephrectomy: Randomized, double-blind, Phase III KEYNOTE-564 study . Cancer Research . vol. 79 , ct162 - ct162 .

Neves JB, Shepherd S, Cullen D, Powles T, Aitchison M, Tran MGB ( 2019 ) . Performance and cost of a renal cancer specialist multidisciplinary team meeting: Results from 1500 discussions . Journal of Clinical Urology vol. 12 , ( 4 ) 314 - 319 .

Sternberg CN, Loriot Y, James N, Choy E, Castellano D, Lopez-Rios F, Banna GL, De Giorgi U et al. ( 2019 ) . Primary Results from SAUL, a Multinational Single-arm Safety Study of Atezolizumab Therapy for Locally Advanced or Metastatic Urothelial or Nonurothelial Carcinoma of the Urinary Tract . European Urology vol. 76 , ( 1 ) 73 - 81 .

Porta C, Cosmai L, Leibovich BC, Powles T, Gallieni M, Bex A ( 2019 ) . The adjuvant treatment of kidney cancer: a multidisciplinary outlook . Nature Reviews Nephrology vol. 15 , ( 7 ) 423 - 433 .

Rini BI, Powles T ( 2019 ) . Immune Checkpoint Blockade plus Axitinib for Renal-Cell Carcinoma. Reply . The New England journal of medicine vol. 380 , ( 26 )

Cathomas R, Merseburger AS, Loriot Y, James N, Choy E, Castellano D, Lopez-Rios F, Banna GL et al. ( 2019 ) . Primary results from the SAUL study: atezolizumab for locally advanced or metastatic urothelial carcinoma (UC) or non-UC . SWISS MEDICAL WEEKLY . vol. 149 , 12S - 13S .

Rini BI, Powles T, Atkins MB, Escudier B, McDermott DF, Suarez C, Bracarda S, Stadler WM et al. ( 2019 ) . Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial . The Lancet vol. 393 , ( 10189 ) 2404 - 2415 .

Powles T, Meeks JJ, Galsky MD, Van Der Heijden MS, Nishiyama H, Al-Ahmadie H, Gupta AK, Ye J et al. ( 2019 ) . A phase III, randomized, open label, multicenter, global study of efficacy and safety of durvalumab in combination with gemcitabine+cisplatin (G+C) for neoadjuvant treatment followed by durvalumab alone for adjuvant treatment in muscle-invasive bladder cancer (MIBC) (NIAGARA) . Journal of Clinical Oncology . vol. 37 , tps4592 - tps4592 .

Rudd P, Hines J, Watkins E, Powles T, Tipples K ( 2019 ) . Assessment of 2,000 patients presenting to a multidisciplinary prostate cancer clinic in the United Kingdom . Journal of Clinical Oncology . vol. 37 , 5077 - 5077 .

Rini BI, Motzer RJ, Powles T, McDermott DF, Escudier B, Donskov F, Hawkins RE, Bracarda S et al. ( 2019 ) . Atezolizumab (atezo) + bevacizumab (bev) versus sunitinib (sun) in pts with untreated metastatic renal cell carcinoma (mRCC) and sarcomatoid (sarc) histology: IMmotion151 subgroup analysis . Journal of Clinical Oncology . vol. 37 , 4512 - 4512 .

McDermott DF, Choueiri TK, Motzer RJ, Aren OR, George S, Powles T, Donskov F, Harrison MR et al. ( 2019 ) . CheckMate 214 post-hoc analyses of nivolumab plus ipilimumab or sunitinib in IMDC intermediate/poor-risk patients with previously untreated advanced renal cell carcinoma with sarcomatoid features . Journal of Clinical Oncology . vol. 37 , 4513 - 4513 .

Sternberg CN, Merseburger AS, Choy E, Castellano DE, Lopez-Rios F, James N, Banna GL, De Giorgi U et al. ( 2019 ) . Clinical outcomes according to PD-L1 status and age in the prospective international SAUL study of atezolizumab (atezo) for locally advanced or metastatic urothelial carcinoma (UC) or non-UC of the urinary tract . Journal of Clinical Oncology . vol. 37 , 4519 - 4519 .

Carroll D, McEwen R, Kozarewa I, Harrington E, L'Hernault A, Ratnayake J, Mather R, Hodgson D et al. ( 2019 ) . Correlation of circulating tumor DNA (ctDNA), tissue-based genomic profiling and clinical efficacy in the biomarker directed Ph1b trial in metastatic bladder cancer (BISCAY) . Journal of Clinical Oncology . vol. 37 , 4553 - 4553 .

Grunewald CM, Henn A, Galsky MD, Plimack ER, Harshman LC, Yu EY, Crabb SJ, Pal SK et al. ( 2019 ) . Impact of timing of adjuvant chemotherapy following radical cystectomy for bladder cancer on patient survival . Journal of Clinical Oncology . vol. 37 , e16017 - e16017 .

O'Donnell PH, Balar AV, Vuky J, Castellano DE, Bellmunt J, Powles T, Bajorin DF, Grivas P et al. ( 2019 ) . KEYNOTE-052: Phase 2 study evaluating first-line pembrolizumab (pembro) in cisplatin-ineligible advanced urothelial cancer (UC)— Updated response and survival results . Journal of Clinical Oncology . vol. 37 , 4546 - 4546 .

Szabados B, Rebelatto M, Barker C, Milner A, Lewis A, Stokes M, Zajac M, Powles T et al. ( 2019 ) . Molecular biomarker analysis and survival in patients (pts) with advanced urothelial cancer (UC) previously treated with chemotherapy . Journal of Clinical Oncology . vol. 37 , 4529 - 4529 .

Pal SK, McDermott DF, Atkins MB, Escudier B, Rini BI, Motzer RJ, Fong L, Joseph RW et al. ( 2019 ) . Patient-reported outcomes (PROs) in IMmotion150: Atezolizumab (atezo) alone or with bevacizumab (bev) versus sunitinib (sun) in first-line metastatic renal cell carcinoma (mRCC) . Journal of Clinical Oncology . vol. 37 , 4515 - 4515 .

Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, Pouliot F, Soulieres D et al. ( 2019 ) . Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for metastatic renal cell carcinoma (mRCC): Outcomes in the combined IMDC intermediate/poor risk and sarcomatoid subgroups of the phase 3 KEYNOTE-426 study . Journal of Clinical Oncology . vol. 37 , 4500 - 4500 .

Ljungberg B, Albiges L, Abu-Ghanem Y, Bensalah K, Dabestani S, Montes SFP, Giles RH, Hofmann F et al. ( 2019 ) . European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update . European Urology vol. 75 , ( 5 ) 799 - 810 .

Gonzalez-Exposito R, Semiannikova M, Griffiths B, Khan K, Barber LJ, Woolston A, Spain G, Von Loga K et al. ( 2019 ) . CEA expression heterogeneity and plasticity confer resistance to the CEA-targeting bispecific immunotherapy antibody cibisatamab (CEA-TCB) in patient-derived colorectal cancer organoids . Journal for ImmunoTherapy of Cancer vol. 7 , ( 1 )

Vogel C, Ziegelmüller B, Ljungberg B, Bensalah K, Bex A, Canfield S, Giles RH, Hora M et al. ( 2019 ) . Imaging in Suspected Renal-Cell Carcinoma: Systematic Review . Clinical Genitourinary Cancer vol. 17 , ( 2 ) e345 - e355 .

Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, Pouliot F, Alekseev B et al. ( 2019 ) . Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma . New England Journal of Medicine vol. 380 , ( 12 ) 1116 - 1127 .

Szabados B, Duran I, Crabb SJ, Van Der Heijden MS, Pous AF, Gravis G, Herranz UA, Protheroe A et al. ( 2019 ) . 1121 Surgical outcome of pre-operative atezolizumab before radical cystectomy for muscle-invasive urothelial carcinoma of the bladder . European Urology Open Science vol. 18 , ( 1 )

Powles T, Larkin JMG, Patel P, Pérez-Valderrama B, Rodriguez-Vida A, Glen H, Thistlethwaite F, Ralph C et al. ( 2019 ) . A phase II study investigating the safety and efficacy of savolitinib and durvalumab in metastatic papillary renal cancer (CALYPSO) . Journal of Clinical Oncology . vol. 37 , 545 - 545 .

Perez-Gracia JL, Loriot Y, Rosenberg JE, Powles T, Necchi A, Hussain SA, Morales-Barrera R, Retz MM et al. ( 2019 ) . Corrigendum re: “Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens” (European Urology (2018) 73(3) (462–468), (S0302283817310151) (10.1016/j.eururo.2017.11.023)) . European Urology vol. 75 , ( 3 ) e82 - e83 .

Petrylak DP, Rosenberg JE, Duran I, Loriot Y, Sonpavde G, Wu C, Gartner EM, Melhem-Bertrandt A et al. ( 2019 ) . EV-301: Phase III study to evaluate enfortumab vedotin (EV) versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial cancer (la/mUC) . Journal of Clinical Oncology . vol. 37 , tps497 - tps497 .

Jiang DM, Brundage MD, Sweeney C, Fizazi K, Bellmunt J, Vaughn DJ, Powles T, Perlis N et al. ( 2019 ) . Health-Related Quality of Life (HRQOL) reporting in phase III randomized controlled trials (RCTs) of metastatic prostate adenocarcinoma (mPCa) and urothelial carcinoma (mUC) . Journal of Clinical Oncology . vol. 37 , 478 - 478 .

Necchi A, Mariani L, Lo Vullo S, Yu EY, Woods ME, Wong YN, Harshman LC, Alva A et al. ( 2019 ) . Lack of Effectiveness of Postchemotherapy Lymphadenectomy in Bladder Cancer Patients with Clinical Evidence of Metastatic Pelvic or Retroperitoneal Lymph Nodes Only: A Propensity Score-based Analysis . European Urology Focus vol. 5 , ( 2 ) 242 - 249 .

Grünwald V, Powles T, Choueiri TK, Hutson TE, Porta C, Eto M, Sternberg CN, Rha SY et al. ( 2019 ) . Lenvatinib plus everolimus or pembrolizumab versus sunitinib in advanced renal cell carcinoma: Study design and rationale . Future Oncology vol. 15 , ( 9 ) 929 - 941 .

Tannir NM, Motzer RJ, Plimack ER, McDermott DF, Barthelemy P, Porta C, George S, Powles T et al. ( 2019 ) . Outcomes in patients (pts) with advanced renal cell carcinoma (aRCC) who discontinued (DC) first-line nivolumab + ipilimumab (N+I) or sunitinib (S) due to treatment-related adverse events (TRAEs) in CheckMate 214 . Journal of Clinical Oncology . vol. 37 , 581 - 581 .

Powles T, Plimack ER, Stus V, Gafanov RA, Hawkins RE, Nosov D, Pouliot F, Alekseev BY et al. ( 2019 ) . Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for locally advanced or metastatic renal cell carcinoma (mRCC): phase III KEYNOTE-426 study . Journal of Clinical Oncology . vol. 37 , 543 - 543 .

Dabestani S, Beisland C, Stewart G, Capitanio U, Jarvinen P, Nisen H, Bensalah K, Guðmundsson E et al. ( 2019 ) . Prevalence, disease-free (DFS) and overall (OS) survival of contemporary high-risk renal cell carcinoma (RCC) patients eligible for adjuvant checkpoint inhibitor trials: A RECUR database analysis . Journal of Clinical Oncology . vol. 37 , 636 - 636 .

De Wit R, Powles T, Castellano DE, Necchi A, Lee J-L, Van Der Heijden MS, Matsubara N, Bamias A et al. ( 2019 ) . Ramucirumab (RAM) exposure-response (ER) relationship in RANGE: A randomized phase III trial of RAM plus docetaxel (DOC) versus placebo (P) plus DOC in advanced platinum-refractory urothelial carcinoma (UC) patients (pts) . Journal of Clinical Oncology . vol. 37 , 353 - 353 .

van Dijk N, Funt SA, Blank CU, Powles T, Rosenberg JE, van der Heijden MS ( 2019 ) . The Cancer Immunogram as a Framework for Personalized Immunotherapy in Urothelial Cancer . European Urology vol. 75 , ( 3 ) 435 - 444 .

Tannir NM, Frontera OA, Hammers HJ, Carducci MA, McDermott DF, Salman P, Escudier B, Beuselinck B et al. ( 2019 ) . Thirty-month follow-up of the phase III CheckMate 214 trial of first-line nivolumab + ipilimumab (N+I) or sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC) . Journal of Clinical Oncology . vol. 37 , 547 - 547 .

McDermott DF, Rini BI, Motzer RJ, Tannir NM, Escudier B, Kollmannsberger CK, Hammers HJ, Porta C et al. ( 2019 ) . Treatment-free survival (TFS) after discontinuation of first-line nivolumab (NIVO) plus ipilimumab (IPI) or sunitinib (SUN) in intention-to-treat (ITT) and IMDC favorable-risk patients (pts) with advanced renal cell carcinoma (aRCC) from CheckMate 214 . Journal of Clinical Oncology . vol. 37 , 564 - 564 .

Sonpavde G, Hennessy D, Manitz J, Niegisch G, Powles T, Rosenberg JE, Bajorin DF, Apolo AB et al. ( 2019 ) . Validated five-factor prognostic model for survival of patients (pts) with metastatic urothelial carcinoma (mUC) receiving different post-platinum PD-L1 inhibitors . Journal of Clinical Oncology . vol. 37 , 476 - 476 .

Bex A, Mulders P, Jewett M, Wagstaff J, Van Thienen JV, Blank CU, Van Velthoven R, Del Pilar Laguna M et al. ( 2019 ) . Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients with Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial . JAMA Oncology vol. 5 , ( 2 ) 164 - 170 .

Auvray M, Auclin E, Barthelemy P, Bono P, Kellokumpu-Lehtinen P, Gross-Goupil M, De Velasco G, Powles T et al. ( 2019 ) . Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma . European Journal of Cancer vol. 108 , 33 - 40 .

Merseburger AS, Apolo AB, Chowdhury S, Hahn NM, Galsky MD, Milowsky MI, Petrylak D, Powles T et al. ( 2019 ) . SIU-ICUD recommendations on bladder cancer: systemic therapy for metastatic bladder cancer . World Journal of Urology vol. 37 , ( 1 ) 95 - 105 .

Gruenwald V, Tannir NM, Motzer RJ, Plimack ER, McDermott DF, Barthelemy P, Porta C, George S et al. ( 2019 ) . CheckMate 214 patients who discontinued first-line Nivolumab plus Ipilimumab or sunitinib due to treatment-related adverse events . ONCOLOGY RESEARCH AND TREATMENT . vol. 42 , 150 - 150 .

Kuusk T, Szabados B, Liu WK, Powles T, Bex A ( 2019 ) . Cytoreductive nephrectomy in the current treatment algorithm . Therapeutic Advances in Medical Oncology vol. 11 ,

Dabestani S, Beisland C, Stewart GD, Bensalah K, Gudmundsson E, Lam TB, Gietzmann W, Zakikhani P et al. ( 2019 ) . Increased use of cross-sectional imaging for follow-up does not improve post-recurrence survival of surgically treated initially localized R.C.C.: results from a European multicenter database (R.E.C.U.R.) . Scandinavian Journal of Urology vol. 53 , ( 1 ) 14 - 20 .

Gruellich C, Rini BI, Huseni M, Atkins M, McDermott D, Powles T, Escudier B, Banchereau R et al. ( 2019 ) . Molecular correlates differentiate response to atezolizumab (atezo) plus bevacizumab (bev) vs sunitinib (sun): results from a Phase III study (IMmotion151) in untreated metastatic renal cell carcinoma (mRCC) . ONCOLOGY RESEARCH AND TREATMENT . vol. 42 , 148 - 148 .

Retz M, Merseburger AS, Loriot Y, James N, Choy E, Castellano D, Lopez-Rios F, Banna GL et al. ( 2019 ) . Primary results from SAUL, a prospective multinational single-arm study of Atezolizumab (atezo) for locally advanced or metastatic urothelial carcinoma (UC) or non-UC of the urinary tract . ONCOLOGY RESEARCH AND TREATMENT . vol. 42 , 104 - 105 .

Bhindi B, Abel EJ, Albiges L, Bensalah K, Boorjian SA, Daneshmand S, Karam JA, Mason RJ et al. ( 2019 ) . Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma . European Urology vol. 75 , ( 1 ) 111 - 128 .

Lalani AKA, McGregor BA, Albiges L, Choueiri TK, Motzer R, Powles T, Wood C, Bex A ( 2019 ) . Systemic Treatment of Metastatic Clear Cell Renal Cell Carcinoma in 2018: Current Paradigms, Use of Immunotherapy, and Future Directions . European Urology vol. 75 , ( 1 ) 100 - 110 .

SMITH KJ ( 2018 ) . Identifying and targeting LIM-domain loss in clear cell renal cell carcinoma . Supervisors: SHARP, T, POWLES, T ,

Powles T, Rini B ( 2018 ) . Novel agents and drug development needs in advanced clear cell renal cancer . Journal of Clinical Oncology vol. 36 , ( 36 ) 3639 - 3644 .

Bex A, Albiges L, Staehler M, Bensalah K, Giles RH, Dabestani S, Hofmann F, Hora M et al. ( 2018 ) . A Joint Statement from the European Association of Urology Renal Cell Cancer Guidelines Panel and the International Kidney Cancer Coalition: The Rejection of Ipilimumab and Nivolumab for Renal Cancer by the Committee for Medicinal Products for Human Use Does not Change Evidence-based Guideline Recommendations . European Urology vol. 74 , ( 6 ) 849 - 851 .

Chalabi M, Cardona A, Nagarkar D, Scala AMD, Albert M, Kok M, Powles TB, Herrera F ( 2018 ) . Effects of antibiotics and proton pump inhibitors in NSCLC patients treated with atezolizumab and docetaxel: Pooled analysis of the OAK and POPLAR trials . ANNALS OF ONCOLOGY . vol. 29 ,

McDermott DF, Huseni MA, Atkins MB, Motzer RJ, Rini BI, Escudier B, Fong L, Joseph RW et al. ( 2018 ) . Erratum to: Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma (Nature Medicine, (2018), 24, 6, (749-757), 10.1038/s41591-018-0053-3) . Nature Medicine vol. 24 , ( 12 )

Sonpavde GP, Mariani L, Lo Vullo S, Raggi D, Giannatempo P, Bamias A, Crabb SJ, Bellmunt J et al. ( 2018 ) . Impact of the Number of Cycles of Platinum Based First Line Chemotherapy for Advanced Urothelial Carcinoma . Journal of Urology vol. 200 , ( 6 ) 1207 - 1214 .

Necchi A, Pond GR, Smaldone MC, Pal SK, Chan K, Wong YN, Viterbo R, Sonpavde G et al. ( 2018 ) . Robot-assisted Versus Open Radical Cystectomy in Patients Receiving Perioperative Chemotherapy for Muscle-invasive Bladder Cancer: The Oncologist's Perspective from a Multicentre Study . European Urology Focus vol. 4 , ( 6 ) 937 - 945 .

Bex A, Albiges L, Ljungberg B, Bensalah K, Dabestani S, Giles RH, Hofmann F, Hora M et al. ( 2018 ) . Updated European Association of Urology Guidelines for Cytoreductive Nephrectomy in Patients with Synchronous Metastatic Clear-cell Renal Cell Carcinoma . European Urology vol. 74 , ( 6 ) 805 - 809 .

Birtle A, Johnson M, Kockelbergh R, Jr KF, Catto J, Bryan R, Jones R, Chester J et al. ( 2018 ) . Results of POUT - A phase III randomised trial of perioperative chemotherapy versus surveillance in upper tract urothelial cancer (UTUC) . BRITISH JOURNAL OF CANCER . vol. 119 , 44 - 45 .

Bex A, Powles T, Haanen J ( 2018 ) . To the editor . New England Journal of Medicine vol. 379 , ( 19 ) 1877 - 1878 .

Sun M, Marconi L, Eisen T, Escudier B, Giles RH, Haas NB, Harshman LC, Quinn DI et al. ( 2018 ) . Adjuvant Vascular Endothelial Growth Factor–targeted Therapy in Renal Cell Carcinoma: A Systematic Review and Pooled Analysis [Figure presented] . European Urology vol. 74 , ( 5 ) 611 - 620 .

Rini BI, Tannir NM, Escudier B, McDermott DF, Grimm M-O, Porta C, Powles T, Kollmannsberger C et al. ( 2018 ) . Caractérisation de la réponse au traitement par nivolumab plus ipilimumab (N+I) ou sunitinib (S) chez des patients (pts) atteints d’un carcinome à cellules rénales avancé (CCRa) non préalablement traité : CheckMate 214 . Progrès en Urologie vol. 28 , ( 13 ) 624 - 625 .

Tshuma N, Glynn N, Evanson J, Powles T, Drake WM ( 2018 ) . Hypothalamitis and severe hypothalamic dysfunction associated with anti–programmed cell death ligand 1 antibody treatment . European Journal of Cancer vol. 104 , 247 - 249 .

Szabados B, Kelly JD, Lam JJM, Liu W-K, Powles T ( 2018 ) . LP212 Surgical outcome of pre-operative atezolizumab before radical cystectomy for muscle-invasive urothelial carcinoma of the bladder . European Urology Open Science vol. 17 , ( 14 )

Liu WK, Szabados B, Morrison L, Powles T ( 2018 ) . LP219 The efficacy of targeted therapy after progression on Bevacizumab and Atezolizumab combination therapy in metastatic renal cell carcinoma . European Urology Open Science vol. 17 , ( 14 )

Powles T ( 2018 ) . Re: Nivolumab plus Ipilimumab Versus Sunitinib in Advanced Renal-cell Carcinoma . European Urology vol. 74 , ( 5 ) 679 - 680 .

Mansukhani S, Barber LJ, Kleftogiannis D, Moorcraft SY, Davidson M, Woolston A, Proszek PZ, Griffiths B et al. ( 2018 ) . Ultra-Sensitive mutation detection and genome-wide DNA copy number reconstruction by error- corrected circulating tumor DNA sequencing . Clinical Chemistry vol. 64 , ( 11 ) 1626 - 1635 .

Wong YNS, Joshi K, Khetrapal P, Ismail M, Reading JL, Sunderland MW, Georgiou A, Furness AJS et al. ( 2018 ) . Urine-derived lymphocytes as a non-invasive measure of the bladder tumor immune microenvironment . Journal of Experimental Medicine vol. 215 , ( 11 ) 2748 - 2759 .

Castellano D, Duran I, Rodríguez-Vida A, Crabb SJ, van der Heijden MS, Font Pous A, Gravis G, Anido Herranz U et al. ( 2018 ) . A phase II study investigating the safety and efficacy of neoadjuvent atezolizumab in muscle invasive bladder cancer (ABACUS) . Annals of oncology : official journal of the European Society for Medical Oncology vol. 29 ,

Galsky MD, Banchereau R, Kadel EE, Ramirez-Montagut T, Mariathasan S, Thåström A, Rosenberg J, Powles T et al. ( 2018 ) . Biological features and clinical outcomes in atezolizumab (atezo)-treated patients (pts) with metastatic urothelial cancer (mUC) of the upper vs lower urinary tract (UTUC vs LTUC) . Annals of oncology : official journal of the European Society for Medical Oncology vol. 29 ,

Powles T, Morrison L ( 2018 ) . Biomarker challenges for immune checkpoint inhibitors in urothelial carcinoma . Nature Reviews Urology vol. 15 , ( 10 ) 585 - 587 .

Gomez de Liano Lista A, Venugopal B, Fife K, Symeonides S, Vasudev NS, Rudman SM, Vohra S, Khasati L et al. ( 2018 ) . Cabozantinib in metastatic renal cell carcinoma (mRCC): Data from UK expanded access program (EAP) . Annals of oncology : official journal of the European Society for Medical Oncology . vol. 29 ,

Rini BI, Tannir NM, Escudier B, McDermott DF, Grimm MO, Porta C, Powles T, Kollmannsberger CK et al. ( 2018 ) . Characterization of response to nivolumab plus ipilimumab (N+I) or sunitinib (S) in patients (Pts) with previously untreated advanced renal cell carcinoma (arcc): Checkmate 214 . Annals of oncology : official journal of the European Society for Medical Oncology vol. 29 , viii309 - viii310 .

Petrylak DP, Rosenberg J, Duran I, Loriot Y, Sonpavde G, Wu C, Gartner E, Melhem-Bertrandt A et al. ( 2018 ) . EV-301: An open-label, randomized phase III study to evaluate enfortumab vedotin versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial cancer (la/mUC) . Annals of oncology : official journal of the European Society for Medical Oncology vol. 29 ,

Walker J, Zajac M, Ye J, Scott M, Ratcliffe M, Scorer P, Barker C, Al-Masri H et al. ( 2018 ) . Impact of different programmed cell death ligand-1 (PD-L1) expression algorithms on patient selection and durvalumab efficacy in urothelial carcinoma (UC) . Annals of oncology : official journal of the European Society for Medical Oncology . vol. 29 ,

Rini BI, Huseni M, Atkins MB, McDermott DF, Powles TB, Escudier B, Banchereau R, Liu LF et al. ( 2018 ) . Molecular correlates differentiate response to atezolizumab (atezo) + bevacizumab (bev) vs sunitinib (sun): Results from a phase III study (IMmotion151) in untreated metastatic renal cell carcinoma (mRCC) . Annals of oncology : official journal of the European Society for Medical Oncology . vol. 29 , viii724 - viii725 .

Choueiri TK, Flaifel A, Xie W, Braun D, Ficial M, Jennings R, Nassar A, Escudier B et al. ( 2018 ) . PD-L1 status and clinical outcomes to cabozantinib, sunitinib and everolimus in patients with metastatic clear-cell RCC treated on CABOSUN and METEOR clinical trials . Annals of oncology : official journal of the European Society for Medical Oncology . vol. 29 ,

Collinson F, Brown S, Buckley H, Ainsworth G, Howard H, Poad H, Carr G, Banks RE et al. ( 2018 ) . PRISM: A randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinoma . Annals of oncology : official journal of the European Society for Medical Oncology vol. 29 ,

Petrylak DP, Sternberg CN, Drakaki A, de Wit R, Nishiyama H, Necchi A, Castellano D, Bamias A et al. ( 2018 ) . RANGE, a phase III, randomized, placebo-controlled, double-blind trial of ramucirumab (RAM) and docetaxel (DOC) in platinum-refractory urothelial carcinoma (UC): Overall survival results . ANNALS OF ONCOLOGY . vol. 29 ,

Crusz SM, Radunovic A, Shepherd S, Shah S, Newey V, Phillips M, Lim L, Powles T et al. ( 2018 ) . Rituximab in the treatment of pembrolizumab-induced myasthenia gravis . European Journal of Cancer vol. 102 , 49 - 51 .

Suarez C, Choueiri TK, McDermott DF, Escudier B, Atkins MB, Powles TB, Rini BI, Motzer RJ et al. ( 2018 ) . Safety and tolerability of atezolizumab (atezo) plus bevacizumab (bev) vs sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC): Pooled analysis of IMmotion150 and IMmotion151 . Annals of oncology : official journal of the European Society for Medical Oncology . vol. 29 ,

McDermott DF, Rini BI, Motzer RJ, Tannir NM, Escudier B, Kollmannsberger CK, Hammers HJ, Porta C et al. ( 2018 ) . Treatment-free interval (TFI) following discontinuation of first-line nivolumab plus ipilimumab (N+I) or sunitinib (S) in patients (Pts) with advanced renal cell carcinoma (aRCC): CheckMate 214 analysis . Annals of oncology : official journal of the European Society for Medical Oncology . vol. 29 ,

Powles T, Motzer RJ, Escudier B, Pal S, Kollmannsberger C, Pikiel J, Gurney H, Rha SY et al. ( 2018 ) . Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma . British Journal of Cancer vol. 119 , ( 6 ) 663 - 669 .

Powles T ( 2018 ) . Choosing Front-line Treatment for Metastatic Renal Cancer: Which Data Are Meaningful? . European Urology vol. 74 , ( 3 ) 322 - 323 .

Honecker F, Aparicio J, Berney D, Beyer J, Bokemeyer C, Cathomas R, Clarke N, Cohn-Cedermark G et al. ( 2018 ) . ESMO consensus conference on testicular germ cell cancer: Diagnosis, treatment and follow-up . Annals of Oncology vol. 29 , ( 8 ) 1658 - 1686 .

Hahn NM, Necchi A, Loriot Y, Powles T, Plimack ER, Sonpavde G, Roupret M, Kamat AM ( 2018 ) . Role of Checkpoint Inhibition in Localized Bladder Cancer . European Urology Oncology vol. 1 , ( 3 ) 190 - 198 .

Barata PC, De Liano AG, Mendiratta P, Crolley V, Szabados B, Morrison L, Wood L, Allman K et al. ( 2018 ) . The efficacy of VEGFR TKI therapy after progression on immune combination therapy in metastatic renal cell carcinoma . British Journal of Cancer vol. 119 , ( 2 ) 160 - 163 .

Mariathasan S, Turley SJ, Nickles D, Castiglioni A, Yuen K, Wang Y, Kadel EE, Koeppen H et al. ( 2018 ) . Abstract 2979: A balance of genomic instability, tumor-immune contexture and TGF-β signaling contributing to exclusion of T cells governs response to PD-L1 checkpoint blockade . Cancer Research . vol. 78 , 2979 - 2979 .

O'Donnell P, Massard C, Keam B, Kim S-W, Friedlander T, Ahn M-J, Ong M, Gordon M et al. ( 2018 ) . Abstract CT031: Updated efficacy and safety profile of durvalumab monotherapy in urothelial carcinoma . Cancer Research . vol. 78 , ct031 - ct031 .

Balar AV, Mahipal A, Grande E, Villalobos VM, Salas S, Kang TW, Kim SH, Powles T et al. ( 2018 ) . Abstract CT112: Durvalumab + tremelimumab in patients with metastatic urothelial cancer . Cancer Research . vol. 78 , ct112 - ct112 .

Jepson M, Elliott D, Conefrey C, Wade J, Rooshenas L, Wilson C, Beard D, Blazeby JM et al. ( 2018 ) . An observational study showed that explaining randomization using gambling-related metaphors and computer-agency descriptions impeded randomized clinical trial recruitment . Journal of Clinical Epidemiology vol. 99 , 75 - 83 .

McDermott DF, Huseni MA, Atkins MB, Motzer RJ, Rini BI, Escudier B, Fong L, Joseph RW et al. ( 2018 ) . Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma . Nature Medicine vol. 24 , ( 6 ) 749 - 757 .

Galsky MD, Powles T, Li S, Hennicken D, Sonpavde G ( 2018 ) . A phase 3, open-label, randomized study of nivolumab plus ipilimumab or standard of care (SoC) vs SoC alone in patients (pts) with previously untreated unresectable or metastatic urothelial carcinoma (mUC; CheckMate 901) . Journal of Clinical Oncology . vol. 36 , tps4588 - tps4588 .

Choueiri TK, Apolo AB, Powles T, Escudier B, Aren OR, Shah A, Kessler ER, Hsieh JJ et al. ( 2018 ) . A phase 3, randomized, open-label study of nivolumab combined with cabozantinib vs sunitinib in patients with previously untreated advanced or metastatic renal cell carcinoma (RCC; CheckMate 9ER) . Journal of Clinical Oncology vol. 36 , ( 15_suppl ) tps4598 - tps4598 .

Powles T, Rodriguez-Vida A, Duran I, Crabb SJ, Van Der Heijden MS, Font Pous A, Gravis G, Anido Herranz U et al. ( 2018 ) . A phase II study investigating the safety and efficacy of neoadjuvant atezolizumab in muscle invasive bladder cancer (ABACUS) . Journal of Clinical Oncology vol. 36 , ( 15_suppl ) 4506 - 4506 .

Matsubara N, Petrylak DP, Nishiyama H, Su W-P, Lee J-L, Li J-R, Walgren RA, Hamid O et al. ( 2018 ) . A subgroup analysis of the East Asia population in RANGE: A randomized phase 3 study of docetaxel (DOC) with or without ramucirumab (RAM) in platinum-refractory advanced or metastatic urothelial carcinoma (UC) . Journal of Clinical Oncology . vol. 36 , 4542 - 4542 .

Legrand FA, Gandara DR, Mariathasan S, Powles T, He X, Zhang W, Jhunjhunwala S, Nickles D et al. ( 2018 ) . Association of high tissue TMB and atezolizumab efficacy across multiple tumor types . Journal of Clinical Oncology . vol. 36 , 12000 - 12000 .

de Liano AG, Venugopal B, Fife K, Khasti L, Symeonides SN, Pettinger C, Powles T, Rudman SM et al. ( 2018 ) . Cabozantinib in metastatic renal cell carcinoma (mRCC): Real world experience from the UK . JOURNAL OF CLINICAL ONCOLOGY . vol. 36 ,

Gomez de Liano A, Venugopal B, Fife K, Khasti L, Symeonides SN, Pettinger C, Powles T, Rudman SM et al. ( 2018 ) . Cabozantinib in metastatic renal cell carcinoma (mRCC): Real world experience from the UK . Journal of Clinical Oncology vol. 36 , ( 15_suppl ) e16578 - e16578 .

Wei XX, Lundgren K, Teo MY, Rosenberg JE, Koshkin VS, Grivas P, Carril L, Castellano DE et al. ( 2018 ) . First-line PD-1/PD-L1 inhibitor followed by carboplatin (carbo)-based chemotherapy (chemo) or the reverse sequence in cisplatin-ineligible metastatic urothelial cancer (mUC) patients (pts) . Journal of Clinical Oncology . vol. 36 , e16517 - e16517 .

Choueiri TK, Quinn DI, Zhang T, Gurney H, Doshi GK, Cobb PW, Parnis F, Lee J-L et al. ( 2018 ) . KEYNOTE-564: A phase 3, randomized, double blind, trial of pembrolizumab in the adjuvant treatment of renal cell carcinoma . Journal of Clinical Oncology vol. 36 , ( 15_suppl ) tps4599 - tps4599 .

Escudier B, Motzer RJ, Rini BI, Powles T, McDermott DF, Suarez C, Bracarda S, Stadler WM et al. ( 2018 ) . Patient-reported outcomes (PROs) in IMmotion151: Atezolizumab (atezo) + bevacizumab (bev) vs sunitinib (sun) in treatment (tx) naive metastatic renal cell carcinoma (mRCC) . Journal of Clinical Oncology vol. 36 , ( 15_suppl ) 4511 - 4511 .

Powles T, Bellmunt J, Petrylak DP, Fong L, Nishiyama H, Sternberg CN, Chen M, Pang L et al. ( 2018 ) . Pembrolizumab (pembro) plus epacadostat or placebo for locally advanced or metastatic urothelial carcinoma (UC) after failure of first-line platinum-containing chemotherapy: KEYNOTE-698/ECHO-303 . Journal of Clinical Oncology . vol. 36 , tps4586 - tps4586 .

De Wit R, Powles T, Castellano DE, Necchi A, Lee J-L, Van Der Heijden MS, Matsubara N, Bamias A et al. ( 2018 ) . Ramucirumab (RAM) exposure-response (ER) relationship in RANGE, a randomized phase III trial of docetaxel (DOC) with or without RAM in advanced urothelial carcinoma (UC) patients (pts) who progressed on or after platinum therapy . Journal of Clinical Oncology vol. 36 , ( 15_suppl ) 4526 - 4526 .

Vuky J, Balar AV, Castellano DE, O'Donnell PH, Grivas P, Bellmunt J, Powles T, Bajorin DF et al. ( 2018 ) . Updated efficacy and safety of KEYNOTE-052: A single-arm phase 2 study investigating first-line pembrolizumab (pembro) in cisplatin-ineligible advanced urothelial cancer (UC) . Journal of Clinical Oncology . vol. 36 , 4524 - 4524 .

Motzer RJ, Escudier B, Powles T, Scheffold C, Choueiri TK ( 2018 ) . Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma . British Journal of Cancer vol. 118 , ( 9 ) 1176 - 1178 .

Motzer RJ, Tannir NM, McDermott DF, Arén Frontera O, Melichar B, Choueiri TK, Plimack ER, Barthélémy P et al. ( 2018 ) . Nivolumab plus Ipilimumab versus Sunitinib in advanced renal-cell carcinoma . New England Journal of Medicine vol. 378 , ( 14 ) 1277 - 1290 .

Boustani J, Bertaut A, Galsky MD, Rosenberg JE, Bellmunt J, Powles T, Recine F, Harshman LC et al. ( 2018 ) . Radical cystectomy or bladder preservation with radiochemotherapy in elderly patients with muscle-invasive bladder cancer: Retrospective International Study of Cancers of the Urothelial Tract (RISC) Investigators . Acta Oncologica vol. 57 , ( 4 ) 491 - 497 .

Powles T, Necchi A, Rosen G, Hariharan S, Apolo AB ( 2018 ) . Anti–Programmed Cell Death 1/Ligand 1 (PD-1/PD-L1) Antibodies for the Treatment of Urothelial Carcinoma: State of the Art and Future Development . Clinical Genitourinary Cancer vol. 16 , ( 2 ) 117 - 129 .

Petrylak DP, Powles T, Bellmunt J, Braiteh F, Loriot Y, Morales-Barrera R, Burris HA, Kim JW et al. ( 2018 ) . Atezolizumab (MPDL3280A) monotherapy for patients with metastatic urothelial cancer long-term outcomes from a phase 1 study . JAMA Oncology vol. 4 , ( 4 ) 537 - 544 .

Necchi A, Pond GR, Pal SK, Agarwal N, Bowles DW, Plimack ER, Yu EY, Ladoire S et al. ( 2018 ) . Bone Metastases as the Only Metastatic Site in Patients With Urothelial Carcinoma: Focus on a Special Patient Population . Clinical Genitourinary Cancer vol. 16 , ( 2 ) e483 - e490 .

Choueiri TK, Larkin J, Oya M, Thistlethwaite F, Martignoni M, Nathan P, Powles T, McDermott D et al. ( 2018 ) . Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial . The Lancet Oncology vol. 19 , ( 4 ) 451 - 460 .

Powles T, Morrison L ( 2018 ) . Clinical Trials Corner . Kidney Cancer vol. 2 , ( 1 ) 69 - 71 .

Escudier B, Powles T, Motzer RJ, Olencki T, Frontera OA, Oudard S, Rolland F, Tomczak P et al. ( 2018 ) . Cabozantinib, a new standard of care for patients with advanced renal cell carcinoma and bone metastases? Subgroup analysis of the METEOR trial . Journal of Clinical Oncology vol. 36 , ( 8 ) 765 - 772 .

Cella D, Escudier B, Tannir NM, Powles T, Donskov F, Peltola K, Schmidinger M, Heng DYC et al. ( 2018 ) . Quality of life outcomes for cabozantinib versus everolimus in patients with metastatic renal cell carcinoma: METEOR phase III randomized trial . Journal of Clinical Oncology vol. 36 , ( 8 ) 757 - 764 .

Perez-Gracia JL, Loriot Y, Rosenberg JE, Powles T, Necchi A, Hussain SA, Morales-Barrera R, Retz MM et al. ( 2018 ) . Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens . European Urology vol. 73 , ( 3 ) 462 - 468 .

Shaw G, Oliver T, Kealy R, Powles T, Hillman P, Cuzick J ( 2018 ) . The PROVENT study, a multicentre double blind placebo controlled randomised trial to evaluate the effects of Vitamin D and aspirin on progression of low risk prostate cancer during active surveillance . European Journal of Surgical Oncology vol. 44 ,

Powles T, Albiges L, Staehler M, Bensalah K, Dabestani S, Giles RH, Hofmann F, Hora M et al. ( 2018 ) . Updated European Association of Urology Guidelines: Recommendations for the Treatment of First-line Metastatic Clear Cell Renal Cancer . European Urology vol. 73 , ( 3 ) 311 - 315 .

Powles T, Durán I, van der Heijden MS, Loriot Y, Vogelzang NJ, De Giorgi U, Oudard S, Retz MM et al. ( 2018 ) . Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial . The Lancet vol. 391 , ( 10122 ) 748 - 757 .

Mariathasan S, Turley SJ, Nickles D, Castiglioni A, Yuen K, Wang Y, Kadel EE, Koeppen H et al. ( 2018 ) . TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells . Nature vol. 554 , ( 7693 ) 544 - 548 .

Motzer RJ, Grünwald V, Hutson TE, Porta C, Powles T, Eto M, Dutcus CE, Baig MA et al. ( 2018 ) . A phase 3 trial to compare efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of patients with metastatic renal cell carcinoma . Journal of Clinical Oncology . vol. 36 , tps706 - tps706 .

Galsky MD, Powles T, Li S, Hennicken D, Sonpavde G ( 2018 ) . A phase 3, open-label, randomized study of nivolumab plus ipilimumab or standard of care (SOC) versus SOC alone in patients (pts) with previously untreated unresectable or metastatic urothelial carcinoma (mUC; CheckMate 901) . Journal of Clinical Oncology . vol. 36 , tps539 - tps539 .

Kim JW, Shaffer DR, Massard C, Powles T, Harshman LC, Braiteh FS, Conkling PR, Sarkar I et al. ( 2018 ) . A phase Ia study of safety and clinical activity of atezolizumab (atezo) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) . Journal of Clinical Oncology . vol. 36 , 187 - 187 .

Powles T, Loriot Y, Ravaud A, Vogelzang NJ, Duran I, Retz M, De Giorgi U, Oudard S et al. ( 2018 ) . Atezolizumab (atezo) vs. chemotherapy (chemo) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC): Immune biomarkers, tumor mutational burden (TMB), and clinical outcomes from the phase III IMvigor211 study . Journal of Clinical Oncology . vol. 36 , 409 - 409 .

Jonasch E, Motzer RJ, Escudier B, Powles T, Markby DW, Nielsen J, Lacy S, Choueiri TK ( 2018 ) . Cabozantinib (C) exposure-response (ER) modeling of efficacy and safety endpoints as a function of clearance in patients (pts) with renal cell carcinoma (RCC) . Journal of Clinical Oncology . vol. 36 , 645 - 645 .

Barata PC, Gomez de Liano A, Mendiratta P, Crolley V, Szabados B, Wood LS, Zanick B, Allman KD et al. ( 2018 ) . Clinical outcome of patients (Pts) with metastatic renal cell carcinoma (mRCC) progressing on front-line immune-oncology based combination (IO-COMBO) regimens . Journal of Clinical Oncology . vol. 36 , 613 - 613 .

Drakaki A, Kirby CJ, Van Der Heijden MS, Petrylak DP, Powles T, Chi KN, Flechon A, Necchi A et al. ( 2018 ) . Docetaxel with or without ramucirumab after immune checkpoint inhibition in platinum-refractory metastatic urothelial carcinoma (mUC): Prespecified subgroup analysis from the phase 3 RANGE trial . Journal of Clinical Oncology . vol. 36 , 434 - 434 .

Motzer RJ, Powles T, Atkins MB, Escudier B, McDermott DF, Suarez C, Bracarda S, Stadler WM et al. ( 2018 ) . IMmotion151: A Randomized Phase III Study of Atezolizumab Plus Bevacizumab vs Sunitinib in Untreated Metastatic Renal Cell Carcinoma (mRCC) . Journal of Clinical Oncology . vol. 36 , 578 - 578 .

Beisland C, Dabestani S, Stewart G, Bensalah K, Guðmundsson E, Lam TB, Gietzmann W, Zakikhani P et al. ( 2018 ) . Imaging modalities used for follow-up of localized renal cell carcinoma (RCC) and subsequent effect on overall survival after recurrence: RECUR-database analysis . Journal of Clinical Oncology . vol. 36 , 637 - 637 .

Necchi A, Mariani L, Lo Vullo S, Raggi D, Giannatempo P, Bamias A, Crabb SJ, Bellmunt J et al. ( 2018 ) . Impact of number of cycles of platinum-based first-line chemotherapy for advanced urothelial carcinoma . Journal of Clinical Oncology . vol. 36 , 426 - 426 .

Pond GR, Niegisch G, Rosenberg JE, Dreicer R, Powles T, Necchi A, Wei XX, Grivas P et al. ( 2018 ) . New 6-factor prognostic model for patients (pts) with advanced urothelial carcinoma (UC) receiving post-platinum atezolizumab . Journal of Clinical Oncology . vol. 36 , 413 - 413 .

Necchi A, Pond GR, Plimack ER, Niegisch G, Yu EY, Pal SK, Bamias A, Agarwal N et al. ( 2018 ) . Nomogram-based risk prediction of local and distant relapse after radical cystectomy, and role of perioperative chemotherapy, in patients with muscle-invasive bladder cancer (MIBC): A multicenter study . Journal of Clinical Oncology . vol. 36 , 448 - 448 .

Agarwal N, Vaishampayan UN, McGregor BA, Green MC, Mohamed N, Chang P-Y, Powles T, Pal SK ( 2018 ) . Phase 1b trial of cabozantinib in combination with atezolizumab in patients with locally advanced or metastatic urothelial carcinoma (UC) or renal cell carcinoma (RCC) . JOURNAL OF CLINICAL ONCOLOGY . vol. 36 ,

Quinn DI, Zhang T, Gurney H, Doshi GK, Cobb PW, Parnis F, Lee J-L, Park SH et al. ( 2018 ) . Phase 3, randomized, double-blind trial of pembrolizumab in the adjuvant treatment of renal cell carcinoma (RCC): KEYNOTE-564 . Journal of Clinical Oncology . vol. 36 , tps712 - tps712 .

Necchi A, Nishiyama H, Matsubara N, Lee J-L, Petrylak DP, De Wit R, Drakaki A, Liepa AM et al. ( 2018 ) . Quality-of-life (QoL) in RANGE: A phase 3 study of ramucirumab (RAM) plus docetaxel (DOC) versus placebo (P) plus DOC in platinum-refractory locally advanced or metastatic urothelial carcinoma (UC) . Journal of Clinical Oncology . vol. 36 , 419 - 419 .

Birtle AJ, Chester JD, Jones RJ, Johnson M, Hill M, Bryan RT, Catto J, Donovan J et al. ( 2018 ) . Results of POUT: A phase III randomised trial of perioperative chemotherapy versus surveillance in upper tract urothelial cancer (UTUC) . Journal of Clinical Oncology . vol. 36 , 407 - 407 .

Bruno R, Claret L, Wu B, Jin JY, Winter H, Cui N, Derleth CL, Shen X et al. ( 2018 ) . A tumor growth rate/overall survival model for atezolizumab as an early predictor of OS in patients with first or second line metastatic urothelial carcinoma . Journal of Clinical Oncology . vol. 36 , 62 - 62 .

Maia MC, Agarwal N, McGregor BA, Vaishampayan UN, Choueiri TK, Green MC, Hessel C, Scheffold C et al. ( 2018 ) . Phase 1b trial of cabozantinib in combination with atezolizumab in patients with locally advanced or metastatic urothelial carcinoma (UC) or renal cell carcinoma (RCC) . Journal of Clinical Oncology . vol. 36 , tps42 - tps42 .

Bamias A, Tzannis K, Harshman LC, Crabb SJ, Wong YN, Kumar Pal S, De Giorgi U, Ladoire S et al. ( 2018 ) . Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: A Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC) . Annals of Oncology vol. 29 , ( 2 ) 361 - 369 .

Ramos JD, Wingate JT, Gulati R, Plimack ER, Harshman LC, Powles T, Crabb SJ, Niegisch G et al. ( 2018 ) . Venous Thromboembolism Risk in Patients With Locoregional Urothelial Tract Tumors . Clinical Genitourinary Cancer vol. 16 , ( 1 ) e161 - e167 .

Waller CF, Galsky MD, Powles T, van der Heijden MS, Li S, Hennicken D, Sonpavde G ( 2018 ) . A phase 3, open-label, randomized study of nivolumab plus ipilimumab or standard of care (SoC) vs SoC alone in patients with previously untreated unresectable or metastatic urothelial carcinoma (CheckMate 901) . ONCOLOGY RESEARCH AND TREATMENT . vol. 41 , 324 - 325 .

von Amsberg G, Powles T, Loriot Y, Ravaud A, Vogelzang NJ, Duran I, Retz M, De Giorgi U et al. ( 2018 ) . Atezolizumab (atezo) vs chemotherapy (chemo) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC): immune biomarkers, tumor mutational burden (TMB) and clinical outcomes from the Phase III IMvigor211 study . ONCOLOGY RESEARCH AND TREATMENT . vol. 41 , 325 - 326 .

Schmidinger M, Tannir NM, Powles T, Escudier BJ, Donskov F, Gruenwald V, Sternberg CN, Schoffski P et al. ( 2018 ) . Clinical outcomes by nephrectomy status in METEOR, a randomized phase 3 trial of cabozantinib (cabo) vs everolimus (eve) in patients (pts) with advanced renal cell carcinoma (RCC) . ONCOLOGY RESEARCH AND TREATMENT . vol. 41 , 200 - 200 .

Gruellich C, Motzer RJ, Powles T, Atkins M, Escudier BJ, McDermott D, Suarez C, Bracarda S et al. ( 2018 ) . IMmotion151: A randomized phase III study of atezolizumab plus bevacizumab vs sunitinib in untreated metastatic Renal Cell Carcinoma (mRCC) . ONCOLOGY RESEARCH AND TREATMENT . vol. 41 , 41 - 42 .

Stephen Hodi F, Ballinger M, Lyons B, Soria JC, Nishino M, Tabernero J, Powles T, Smith D et al. ( 2018 ) . Immune-modified response evaluation criteria in solid tumors (imrecist): Refining guidelines to assess the clinical benefit of cancer immunotherapy . Journal of Clinical Oncology vol. 36 , ( 9 ) 850 - 858 .

Bene GD, Calabrò F, Giannarelli D, Plimack ER, Harshman LC, Yu EY, Crabb SJ, Pal SK et al. ( 2018 ) . Neoadjuvant vs. Adjuvant chemotherapy in muscle invasive bladder cancer (MIBC): Analysis from the RISC database . Frontiers in Oncology vol. 8 , ( NOV )

Bergmann L, Donskov F, Motzer RJ, Voog E, Hovey EJ, Gruellich C, Nott LM, Cuff KE et al. ( 2018 ) . Outcomes based on age in the phase 3 Meteor trial of cabozantinib (cabo) vs everolimus (eve) in patients with advanced renal cell carcinoma (RCC) . ONCOLOGY RESEARCH AND TREATMENT . vol. 41 , 200 - 201 .

Gruellich C, Powles T, Motzer RJ, George DJ, Jonasch E, Pal SK, Tannir NM, Signoretti S et al. ( 2018 ) . Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib (c) vs everolimus (e) in advanced renal cell carcinoma (RCC) . ONCOLOGY RESEARCH AND TREATMENT . vol. 41 , 201 - 201 .

Mariathasan S, Turley SJ, Nickles D, Castiglioni A, Yuen K, Wang Y, III EKE, Koeppen H et al. ( 2017 ) . TGF-beta signalling attenuates tumour response to PD-L1 checkpoint blockade by contributing to retention of T cells in the peritumoural stroma . ANNALS OF ONCOLOGY . vol. 28 , 30 - 30 .

Mariathasan S, Turley SJ, Nickles D, Castiglioni A, Yuen K, Wang Y, Edward E K, Koeppen H et al. ( 2017 ) . TGF-β signalling attenuates tumour response to PD-L1 checkpoint blockade by contributing to retention of T cells in the peritumoural stroma . Annals of Oncology vol. 28 ,

Petrylak DP, de Wit R, Chi KN, Drakaki A, Sternberg CN, Nishiyama H, Castellano D, Hussain S et al. ( 2017 ) . Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial . The Lancet vol. 390 , ( 10109 ) 2266 - 2277 .

Mariathasan S, Turley SJ, Nickles D, Wang Y, III KEE, Koeppen H, Yuen K, Castiglioni A et al. ( 2017 ) . Pre-existing T cell immunity, mutational burden and stromal TGF-beta signaling drives clinical responses to atezolizumab in locally advanced or metastatic urothelial carcinoma (mUC) . JOURNAL FOR IMMUNOTHERAPY OF CANCER . vol. 5 ,

Motzer RJ, Grunwald V, Hutson TE, Porta C, Powles T, Eto M, Dutcus C, Baig MA et al. ( 2017 ) . A Phase III Trial to Compare Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab vs Sunitinib Alone in First-Line Treatment of Patients With Metastatic Renal Cell Carcinoma (RCC) . ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY . vol. 13 , 169 - 169 .

Balar AV, Castellano D, O'Donnell PH, Grivas P, Vuky J, Powles T, Plimack ER, Hahn NM et al. ( 2017 ) . First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study . The Lancet Oncology vol. 18 , ( 11 ) 1483 - 1492 .

Mainwaring P, Powles T, Escudier BJ, Tannir NM, Rini BI, Hammers HJ, Donskov F, Roth BJ et al. ( 2017 ) . Overall Survival (OS) in Meteor, A Randomised Phase III Trial of Cabozantinib Versus Everolimus in Patients with Advanced Renal Cell Carcinoma (RCC) . ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY . vol. 13 , 109 - 109 .

Tandstad T, Kollmannsberger CK, Roth BJ, Jeldres C, Gillessen S, Fizazi K, Daneshmand S, Lowrance WT et al. ( 2017 ) . Practice makes perfect: The rest of the story in testicular cancer as a model curable neoplasm . Journal of Clinical Oncology vol. 35 , ( 31 ) 3525 - 3528 .

Powles T, Gómez de Liaño A, Ackerman C ( 2017 ) . Reply to Pontus Eriksson, Gottfrid Sjödahl, and Fredrik Liedberg's Letter to the Editor re: Thomas Powles, Robert A. Huddart, Tony Elliott, et al. Phase III, Double-blind, Randomized Trial that Compared Maintenance Lapatinib versus Placebo after First-line Chemotherapy in Patients with Human Epidermal Growth Factor Receptor 1/2-positive Metastatic Bladder Cancer. J Clin Oncol 2017;35:48–55. Knowing HER2 Status is Not Enough: A Molecular Subtype Approach to Bladder Cancer is Also Needed: Protein Expression to Predict Outcome to Targeted Therapy in Bladder Cancer: Too Little, Too Late? . European Urology vol. 72 , ( 5 ) e137 - e138 .

Shaw G, Oliver T, Kealy R, Powles T, Hillman P, Cuzick J ( 2017 ) . The PROVENT study, a multicentre double blind placebo controlled randomised trial to evaluate the effects of vitamin D and aspirin on progression of low risk prostate cancer during active surveillance . European Journal of Surgical Oncology vol. 43 , ( 11 ) 2212 - 2213 .

Paul J, Kelly C, Stobo J, Powles T ( 2017 ) . Reply to M. Horiguchi et al . Journal of Clinical Oncology vol. 35 , ( 29 )

Powles T, Smith K, Stenzl A, Bedke J ( 2017 ) . Immune Checkpoint Inhibition in Metastatic Urothelial Cancer . European Urology vol. 72 , ( 4 ) 477 - 481 .

Choueiri TK, Plimack E, Arkenau HT, Jonasch E, Heng DYC, Powles T, Frigault MM, Clark EA et al. ( 2017 ) . Biomarker-based phase II trial of savolitinib in patients with advanced papillary renal cell cancer . Journal of Clinical Oncology vol. 35 , ( 26 ) 2993 - 3001 .

Badreldin W, Powles T, Menard L, Ho-Yen C, Kermorgant S ( 2017 ) . 60P Understanding and targeting Met signalling in bladder cancer . Annals of Oncology vol. 28 ,

Grivas P, Plimack E, Balar AV, Castellano D, O'Donnell PH, Bellmunt J, Powles T, Hahn N et al. ( 2017 ) . 857P Pembrolizumab (pembro) as first-line therapy in cisplatin-ineligible advanced urothelial cancer (UC): Outcomes from KEYNOTE-052 in senior patients (pts) with poor performance status . Annals of Oncology vol. 28 ,

Bamias A, Tzannis K, Bamia C, Harshman LC, Crabb S, Wong Y-N, Pal SK, De Giorgi U et al. ( 2017 ) . 866P Impact of cisplatin-based therapy on long-term survival in advanced urinary tract cancer (aUTC). A retrospective international study of invasive/advanced cancer of the urothelium (RISC) . Annals of Oncology vol. 28 ,

Powles T, Motzer RJ, George DJ, Jonasch E, Pal S, Tannir NM, Signoretti S, Mai TH et al. ( 2017 ) . 872P Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib (c) vs everolimus (e) in advanced renal cell carcinoma (rcc) . Annals of Oncology vol. 28 , v307 - v308 .

Wong YNS, Joshi K, Khetrapal P, Ismail M, Linares J, Akarca AU, Reading JL, Furness A et al. ( 2017 ) . 879P Urine-derived lymphocytes (UDLs) as a non-invasive surrogate marker of tumour infiltrating lymphocytes (TILs) in patients with muscle invasive bladder cancer (MIBC) . Annals of Oncology vol. 28 , v309 - v310 .

Powles T, Gschwend JE, Loriot Y, Bellmunt J, Geczi L, Vulsteke C, Abdelsalam M, Gafanov R et al. ( 2017 ) . 919TiP Pembrolizumab ± chemotherapy versus chemotherapy in advanced urothelial cancer: Phase 3 KEYNOTE-361 trial . Annals of Oncology vol. 28 ,

Choueiri TK, Powles T, Zhang T, Quinn DI, Gschwend JE, Wan SS, Poehlein C ( 2017 ) . 922TiP KEYNOTE-564: Phase 3 trial of pembrolizumab in the adjuvant treatment of renal cell carcinoma (RCC) . Annals of Oncology vol. 28 ,

Choueiri TK, Porta C, Rodriguez CS, Alter R, Czaykowski P, Duran I, Gross-Goupil M, Kalinka-Warzocha E et al. ( 2017 ) . A phase 2 study of investigational TORC1/2 inhibitor TAK-228 and TAK-228 plus investigational PI3K alpha-selective inhibitor TAK-117 vs everolimus in adults with advanced or metastatic clear-cell renal cell carcinoma (ccRCC) that has progressed on VEGF-targeted therapy . ANNALS OF ONCOLOGY . vol. 28 ,

Gruenwald V, McDermott DF, Atkins M, Motzer R, Rini B, Escudier B, Fong L, Joseph R et al. ( 2017 ) . A phase II study of atezolizumab (atezo) with or without bevacizumab (bev) vs sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC) patients (pts) . ONCOLOGY RESEARCH AND TREATMENT . vol. 40 , 113 - + .

Schulz C, Schmid P, Hedge P, Zou W, Kowanetz M, Mariathasan S, Gadgeel S, Powles T et al. ( 2017 ) . Association of PD-L2 expression in human tumors with atezolizumab activity . ONCOLOGY RESEARCH AND TREATMENT . vol. 40 , 134 - 134 .

von Amsberg G, Perez-Garcia JL, Loriot Y, Rosenberg JE, Powles T, Necchi A, Hussain SA, Morales-Barrera R et al. ( 2017 ) . Atezolizumab (atezo) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC): outcomes by prior therapy . ONCOLOGY RESEARCH AND TREATMENT . vol. 40 , 115 - 115 .

Escudier B, Tannir NM, McDermott DF, Frontera OA, Melichar B, Plimack ER, Barthelemy P, George S et al. ( 2017 ) . CheckMate 214: Efficacy and safety of nivolumab plus ipilimumab (N plus I) v sunitinib (S) for treatment-naive advanced or metastatic renal cell carcinoma (mRCC), including IMDC risk and PD-L1 expression subgroups . ANNALS OF ONCOLOGY . vol. 28 ,

Powles T, McDermott DF, Rini B, Motzer RJ, Atkins MB, Fong L, Joseph RW, Pal SK et al. ( 2017 ) . IMmotion150: Novel radiological endpoints and updated data from a randomized phase II trial investigating atezolizumab (atezo) with or without bevacizumab (bev) vs sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC) . ANNALS OF ONCOLOGY . vol. 28 ,

Bex A, Mulders P, Jewett MAS, Wagstaff J, van Velthoven R, Pes PML, Wood L, van Melick HHE et al. ( 2017 ) . Immediate versus deferred cytoreductive nephrectomy (CN) in patients with synchronous metastatic renal cell carcinoma (mRCC) receiving sunitinib (EORTC 30073 SURTIME) . ANNALS OF ONCOLOGY . vol. 28 ,

Bamias A, Tzannis K, Bamia C, Harshman LC, Crabb S, Wong Y-N, Pal SK, De Giorgi U et al. ( 2017 ) . Impact of cisplatin-based therapy on long-term survival in advanced urinary tract cancer (aUTC). A retrospective international study of invasive/advanced cancer of the urothelium (RISC) . ANNALS OF ONCOLOGY . vol. 28 ,

Choueiri TK, Powles T, Zhang T, Quinn DI, Gschwend JE, Wan SS, Poehlein C ( 2017 ) . KEYNOTE-564: Phase 3 trial of pembrolizumab in the adjuvant treatment of renal cell carcinoma (RCC) . ANNALS OF ONCOLOGY . vol. 28 ,

Petrylak DP, Chi KN, Drakaki A, Sternberg CN, de Wit R, Nishiyama H, Yu EY, Castellano D et al. ( 2017 ) . LBA4_PR RANGE: A randomized, double-blind, placebo-controlled phase 3 study of docetaxel (DOC) with or without ramucirumab (RAM) in platinum-refractory advanced or metastatic urothelial carcinoma . Annals of Oncology vol. 28 ,

Escudier B, Tannir NM, McDermott DF, Frontera OA, Melichar B, Plimack ER, Barthelemy P, George S et al. ( 2017 ) . LBA5 CheckMate 214: Efficacy and safety of nivolumab + ipilimumab (N+I) v sunitinib (S) for treatment-naïve advanced or metastatic renal cell carcinoma (mRCC), including IMDC risk and PD-L1 expression subgroups . Annals of Oncology vol. 28 , v621 - v622 .

Necchi A, Pond GR, Pal SK, Agarwal N, Bowles D, Plimack E, Yu EY, Ladoire S et al. ( 2017 ) . Outcomes of patients with metastatic urothelial carcinoma (mUC) with exclusive bone metastases: Focus on a special patient population . ANNALS OF ONCOLOGY . vol. 28 ,

Grivas P, Plimack E, Balar AV, Castellano D, O'Donnell PH, Bellmunt J, Powles T, Hahn N et al. ( 2017 ) . Pembrolizumab (pembro) as first-line therapy in cisplatin-ineligible advanced urothelial cancer (UC): Outcomes from KEYNOTE-052 in senior patients (pts) with poor performance status . ANNALS OF ONCOLOGY . vol. 28 ,

Powles T, Gschwend JE, Loriot Y, Bellmunt J, Geczi L, Vulsteke C, Abdelsalam M, Gafanov R et al. ( 2017 ) . Pembrolizumab +/- chemotherapy versus chemotherapy in advanced urothelial cancer: Phase 3 KEYNOTE-361 trial . ANNALS OF ONCOLOGY . vol. 28 ,

Petrylak DP, Chi KN, Drakaki A, Sternberg CN, de Wit R, Nishiyama H, Yu EY, Castellano D et al. ( 2017 ) . RANGE: A randomized, double-blind, placebo-controlled phase 3 study of docetaxel (DOC) with or without ramucirumab (RAM) in platinum-refractory advanced or metastatic urothelial carcinoma . ANNALS OF ONCOLOGY . vol. 28 ,

Lista AGDL, Necchi A, Lavaud P, Carles Galceran J, Castellano D, Ravaud A, Duran I, van Dijk N et al. ( 2017 ) . Treatment and outcome after Immune checkpoint inhibitors (ICI) in metastatic Urothelial Carcinoma (mUC): A European perspective . ANNALS OF ONCOLOGY . vol. 28 ,

Badreldin W, Powles T, Menard L, Ho-Yen C, Kermorgant S ( 2017 ) . Understanding and targeting Met signalling in bladder cancer . ANNALS OF ONCOLOGY . vol. 28 ,

Wong YNS, Joshi K, Khetrapal P, Ismail M, Linares J, Akarca AU, Reading JL, Furness A et al. ( 2017 ) . Urine-derived lymphocytes (UDLs) as a non-invasive surrogate marker of tumour infiltrating lymphocytes (TILs) in patients with muscle invasive bladder cancer (MIBC) . ANNALS OF ONCOLOGY . vol. 28 ,

Powles T, O'Donnell PH, Massard C, Arkenau H-T, Friedlander TW, Hoimes CJ, Lee JL, Ong M et al. ( 2017 ) . Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study . JAMA Oncol vol. 3 , ( 9 ) e172411 - e172411 .

Powles T ( 2017 ) . Interview with Thomas Powles: The use of durvalumab in urothelial cancer - The latest strides in immuno-oncology . Future Oncology vol. 13 , ( 18 ) 1581 - 1583 .

Powles T ( 2017 ) . Clinical Trials Corner . Kidney Cancer vol. 1 , ( 1 ) 89 - 91 .

Lubbock ALR, Stewart GD, O'Mahony FC, Laird A, Mullen P, O'Donnell M, Powles T, Harrison DJ et al. ( 2017 ) . Overcoming intratumoural heterogeneity for reproducible molecular risk stratification: A case study in advanced kidney cancer . BMC Medicine vol. 15 , ( 1 )

Van Neste C, Laird A, O’Mahony F, Van Criekinge W, Deforce D, Van Nieuwerburgh F, Powles T, Harrison DJ et al. ( 2017 ) . Epigenetic sampling effects: nephrectomy modifies the clear cell renal cell cancer methylome . Cellular Oncology vol. 40 , ( 3 ) 293 - 297 .

Jones RJ, Hussain SA, Protheroe AS, Birtle A, Chakraborti P, Huddart RA, Jagdev S, Bahl A et al. ( 2017 ) . Randomized phase II study investigating pazopanib versus weekly paclitaxel in relapsed or progressive urothelial cancer . Journal of Clinical Oncology vol. 35 , ( 16 ) 1770 - 1777 .

Powles T, Fizazi K, Gillessen S, Drake CG, Rathkopf DE, Narayanan S, Green MC, Mecke A et al. ( 2017 ) . A phase III trial comparing atezolizumab with enzalutamide vs enzalutamide alone in patients with metastatic castration-resistant prostate cancer (mCRPC) . Journal of Clinical Oncology . vol. 35 , tps5090 - tps5090 .

Motzer RJ, Grünwald V, Hutson TE, Porta C, Powles T, Eto M, Dutcus CE, Baig MA et al. ( 2017 ) . A phase III trial to compare efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab vs sunitinib alone in first-line treatment of patients (Pts) with metastatic renal cell carcinoma (RCC) . Journal of Clinical Oncology . vol. 35 , tps4595 - tps4595 .

Michaelson MD, Gupta S, Agarwal N, Szmulewitz RZ, Powles T, Pili R, Bruce JY, Vaishampayan UN et al. ( 2017 ) . Axitinib plus crizotinib in patients with advanced solid tumors and metastatic renal cell carcinoma (mRCC): Preliminary phase 1b results . Journal of Clinical Oncology . vol. 35 , 2551 - 2551 .

O'Donnell PH, Grivas P, Balar AV, Bellmunt J, Vuky J, Powles T, Plimack ER, Hahn NM et al. ( 2017 ) . Biomarker findings and mature clinical results from KEYNOTE-052: First-line pembrolizumab (pembro) in cisplatin-ineligible advanced urothelial cancer (UC) . Journal of Clinical Oncology vol. 35 , ( 15_suppl ) 4502 - 4502 .

Shepherd STC, Hall P, Brown JE, Larkin JMG, Jones RJ, Ralph C, Hawkins RE, Chowdhury S et al. ( 2017 ) . Can dynamic changes in prognostic markers predict survival in patients receiving VEGF-targeted therapy in clear cell renal cell carcinoma? . Journal of Clinical Oncology . vol. 35 , e16061 - e16061 .

Tannir NM, Powles T, Escudier BJ, Donskov F, Grünwald V, Sternberg CN, Schmidinger M, Schoffski P et al. ( 2017 ) . Clinical outcomes by nephrectomy status in METEOR, a randomized phase 3 trial of cabozantinib (cabo) vs everolimus (eve) in patients (pts) with advanced renal cell carcinoma (RCC) . Journal of Clinical Oncology . vol. 35 , 4570 - 4570 .

Atkins MB, McDermott DF, Powles T, Motzer RJ, Rini BI, Fong L, Joseph RW, Pal SK et al. ( 2017 ) . IMmotion150: A phase II trial in untreated metastatic renal cell carcinoma (mRCC) patients (pts) of atezolizumab (atezo) and bevacizumab (bev) vs and following atezo or sunitinib (sun) . Journal of Clinical Oncology vol. 35 , ( 15_suppl ) 4505 - 4505 .

Donskov F, Motzer RJ, Voog E, Hovey EJ, Grüllich C, Nott LM, Cuff KE, Gil T et al. ( 2017 ) . Outcomes based on age in the phase 3 METEOR trial of cabozantinib (cabo) vs everolimus (eve) in patients with advanced renal cell carcinoma (RCC) . Journal of Clinical Oncology . vol. 35 , 4578 - 4578 .

Powles T, Gschwend JE, Loriot Y, Bellmunt J, Geczi L, Vulsteke C, Abdelsalam M, Gafanov R et al. ( 2017 ) . Phase 3 KEYNOTE-361 trial: Pembrolizumab (pembro) with or without chemotherapy versus chemotherapy alone in advanced urothelial cancer . Journal of Clinical Oncology . vol. 35 , tps4590 - tps4590 .

Rini BI, Powles T, Chen M, Puhlmann M, Atkins MB ( 2017 ) . Phase 3 KEYNOTE-426 trial: Pembrolizumab (pembro) plus axitinib versus sunitinib alone in treatment-naive advanced/metastatic renal cell carcinoma (mRCC) . Journal of Clinical Oncology . vol. 35 , tps4597 - tps4597 .

Szabados B, Van Der Heijden MS, Gomez De Liano Lista A, Tang YZ, Powles T ( 2017 ) . Responses to chemotherapy in patients with metastatic urothelial cancer (MUC) after frontline immunotherapy . Journal of Clinical Oncology . vol. 35 , e16004 - e16004 .

Powles T, Jin C, Zheng Y, Baverel P, Narwal R, Mukhopadhyay P, Jin X, Dennis PA et al. ( 2017 ) . Tumor shrinkage and increased overall survival are associated with improved albumin, neutrophil lymphocyte ratio (NLR) and decreased durvalumab clearance in NSCLC and UC patients receiving durvalumab . Journal of Clinical Oncology . vol. 35 , 3035 - 3035 .

Hahn NM, Powles T, Massard C, Arkenau H-T, Friedlander TW, Hoimes CJ, Lee J-L, Ong M et al. ( 2017 ) . Updated efficacy and tolerability of durvalumab in locally advanced or metastatic urothelial carcinoma (UC) . Journal of Clinical Oncology . vol. 35 , 4525 - 4525 .

Kuusk T, Albiges L, Escudier B, Grivas N, Haanen J, Powles T, Bex A ( 2017 ) . Antiangiogenic therapy combined with immune checkpoint blockade in renal cancer . Angiogenesis vol. 20 , ( 2 ) 205 - 215 .

Bex A, Albiges L, Ljungberg B, Bensalah K, Dabestani S, Giles RH, Hofmann F, Hora M et al. ( 2017 ) . Updated European Association of Urology Guidelines Regarding Adjuvant Therapy for Renal Cell Carcinoma . European Urology vol. 71 , ( 5 ) 719 - 722 .

González-Billalabeitia E, Sepúlveda JM, Maroto P, Aparicio J, Arranz JA, Esteban E, Gironés R, López-Brea M et al. ( 2017 ) . Consensus Recommendations from the Spanish Germ Cell Cancer Group on the Use of High-dose Chemotherapy in Germ Cell Cancer . European Urology Focus vol. 3 , ( 2-3 ) 280 - 286 .

Sonpavde G, Pond GR, Mullane S, Ramirez AA, Vogelzang NJ, Necchi A, Powles T, Bellmunt J ( 2017 ) . Outcomes in patients with advanced urothelial carcinoma after discontinuation of programmed death (PD)-1 or PD ligand 1 inhibitor therapy . BJU International . vol. 119 , 579 - 584 .

Szabados B, De Liano Lista AG, Wimalasingham A, De Bruijn R, Haanen J, Blank C, Hall P, Staehler M et al. ( 2017 ) . 921 Meta-analysis of upfront VEGF targeted therapy prior to nephrectomy in metastatic clear cell renal cancer . European Urology Open Science vol. 16 , ( 3 )

Fernández-Pello S, Hofmann F, Tahbaz R, Marconi L, Lam TB, Albiges L, Bensalah K, Canfield SE et al. ( 2017 ) . A Systematic Review and Meta-analysis Comparing the Effectiveness and Adverse Effects of Different Systemic Treatments for Non-clear Cell Renal Cell Carcinoma . European Urology vol. 71 , ( 3 ) 426 - 436 .

Bellmunt J, Powles T, Vogelzang NJ ( 2017 ) . A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: The future is now . Cancer Treatment Reviews vol. 54 , 58 - 67 .

Rudd P, Maroun P, Patrikidou A, Blanchard P, Powles T, Tipples K ( 2017 ) . Patient Satisfaction with Multidisciplinary Clinics for Early Prostate Cancer: a Comparison of the French and UK Patient Experience . Clinical Oncology . vol. 29 , e86 - e87 .

McDermott DF, Atkins MB, Motzer RJ, Rini BI, Escudier BJ, Fong L, Joseph RW, Pal SK et al. ( 2017 ) . A phase II study of atezolizumab (atezo) with or without bevacizumab (bev) versus sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC) patients (pts) . Journal of Clinical Oncology vol. 35 , ( 6_suppl ) 431 - 431 .

Choueiri TK, Plimack ER, Arkenau H-T, Jonasch E, Heng DYC, Powles T, Frigault MM, Clark E et al. ( 2017 ) . A single-arm biomarker-based phase II trial of savolitinib in patients with advanced papillary renal cell cancer (PRCC) . Journal of Clinical Oncology vol. 35 , ( 6_suppl ) 436 - 436 .

Pal SK, Motzer RJ, Fishman MN, McDermott RS, Passos-Coelho J, Kopyltsov E, Garcia del Muro X, Donas JG et al. ( 2017 ) . Analysis of overall survival (OS) based on tumor target lesion change in the phase 3 METEOR trial of cabozantinib (cabo) versus everolimus (eve) in advanced renal cell carcinoma (RCC) . Journal of Clinical Oncology vol. 35 , ( 6_suppl ) 522 - 522 .

Petrylak DP, Powles T, Bellmunt J, Braiteh FS, Loriot Y, Morales R, Burris HA, Kim JW et al. ( 2017 ) . Atezolizumab (atezo) in patients with metastatic urothelial carcinoma (mUC): A 2-year clinical update from a phase Ia study . Journal of Clinical Oncology vol. 35 , ( 6_suppl ) 290 - 290 .

Perez-Gracia JL, Loriot Y, Rosenberg JE, Powles T, Necchi A, Hussain SA, Morales R, Retz M et al. ( 2017 ) . Atezolizumab (atezo) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC): Outcomes by prior therapy . Journal of Clinical Oncology vol. 35 , ( 6_suppl ) 323 - 323 .

Lacy S, Hutmacher MM, Yang B, Motzer RJ, Escudier BJ, Powles T, Choueiri TK, Nielsen J ( 2017 ) . Cabozantinib (C) exposure-response (ER) modeling of safety endpoints in patients (pts) with renal cell carcinoma (RCC) in the phase III METEOR study . Journal of Clinical Oncology vol. 35 , ( 6_suppl ) 447 - 447 .

Kattan MW, Van Der Graaf WTA, Powles T, Lam S, Ahmad Q, Dezzani L, Han J, Sternberg CN ( 2017 ) . Development of a prognostic nomogram for liver toxicity in patients treated with pazopanib . Journal of Clinical Oncology vol. 35 , ( 6_suppl ) 455 - 455 .

Szabados B, Wimalasingham AG, Tang YZ, Sahdev A, Gomez De Liano Lista A, Lim L, Hopkins T, Berner A et al. ( 2017 ) . High responses to chemotherapy in patients with metastatic urothelial cancer (MUC) after frontline immunotherapy . Journal of Clinical Oncology . vol. 35 , 377 - 377 .

Wimalasingham AG, Gomez De Liano Lista A, de Bruijn R, Haanen JBAG, Szabados B, Hall P, Blank CU, Chowdhury S et al. ( 2017 ) . Meta-analysis of upfront VEGF targeted therapy prior to nephrectomy in metastatic clear cell renal cancer . Journal of Clinical Oncology . vol. 35 , 514 - 514 .

Ackerman C, Mariathasan S, Nickles D, Gomez De Liano Lista A, Wimalasingham AG, Szabados B, Powles T ( 2017 ) . Molecular subtyping of metastatic urothelial bladder cancer . Journal of Clinical Oncology . vol. 35 , 326 - 326 .

Donskov F, Motzer RJ, Voog E, Hovey EJ, Grüllich C, Nott LM, Cuff K, Gil T et al. ( 2017 ) . Outcomes based on age in the phase 3 METEOR trial of cabozantinib (cabo) versus everolimus (eve) in patients with advanced renal cell carcinoma (RCC) . Journal of Clinical Oncology vol. 35 , ( 6_suppl ) 517 - 517 .

Balar AV, Castellano DE, O'Donnell PH, Grivas P, Vuky J, Powles T, Plimack ER, Hahn NM et al. ( 2017 ) . Pembrolizumab as first-line therapy in cisplatin-ineligible advanced urothelial cancer: Results from the total KEYNOTE-052 study population . Journal of Clinical Oncology vol. 35 , ( 6_suppl ) 284 - 284 .

Powles T, O'Donnell PH, Massard C, Arkenau H-T, Friedlander TW, Hoimes C, Lee J-L, Ong M et al. ( 2017 ) . Updated efficacy and tolerability of durvalumab in locally advanced or metastatic urothelial carcinoma . Journal of Clinical Oncology . vol. 35 , 286 - 286 .

Schmidinger M, Motzer RJ, Powles T, Escudier B, Tannir NM, Mainwaring PN, Rini BI, Hammers HJ et al. ( 2017 ) . 2117 Overall survival results from the phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma (METEOR) . European Journal of Cancer . vol. 72 , s187 - s188 .

Bracarda S, Choueiri TK, Powles T, Motzer RJ, Olencki T, Frontera OA, Oudard S, Rolland F et al. ( 2017 ) . 2196 Efficacy of cabozantinib vs everolimus in advanced renal cell carcinoma with bone metastases: results from the phase 3 METEOR study . European Journal of Cancer . vol. 72 ,

Grande E, Choueiri TK, Motzer RJ, Escudier B, Pal S, Kollmannsberger C, Pikiel J, Gurney H et al. ( 2017 ) . 2199 Effect of prior systemic therapy on clinical outcomes with cabozantinib vs everolimus in advanced renal cell carcinoma: Results from the phase 3 METEOR study . European Journal of Cancer . vol. 72 , s197 - s198 .

Necchi A, Sonpavde G, Lo Vullo S, Giardiello D, Bamias A, Crabb SJ, Harshman LC, Bellmunt J et al. ( 2017 ) . Nomogram-based Prediction of Overall Survival in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC) . European Urology vol. 71 , ( 2 ) 281 - 289 .

BALKWILL F, Berlato C, Khan MN, Schioppa T, Thompson R, Maniati E, Montfort A, Jangani M et al. ( 2017 ) . A CCR4 antagonist reverses the tumor-promoting microenvironment of renal cancer . Journal of Clinical Investigation

Balar AV, Galsky MD, Rosenberg JE, Powles T, Petrylak DP, Bellmunt J, Loriot Y, Necchi A et al. ( 2017 ) . Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial . The Lancet vol. 389 , ( 10064 ) 67 - 76 .

Powles T, Huddart RA, Elliott T, Sarker S-J, Ackerman C, Jones R, Hussain S, Crabb S et al. ( 2017 ) . Phase III, Double-Blind, Randomized Trial That Compared Maintenance Lapatinib Versus Placebo After First-Line Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 1/2-Positive Metastatic Bladder Cancer . J Clin Oncol vol. 35 , ( 1 ) 48 - 55 .

Ramos JD, Casey MF, Crabb SJ, Bamias A, Harshman LC, Wong YN, Bellmunt J, De Giorgi U et al. ( 2017 ) . Venous thromboembolism in metastatic urothelial carcinoma or variant histologies: incidence, associative factors, and effect on survival . Cancer Medicine vol. 6 , ( 1 ) 186 - 194 .

Stewart GD, De Santis M, Escudier B, Powles T, Sonpavde G ( 2016 ) . Immunotherapy for Renal Cancer: Sequencing and Combinations . European Urology Focus vol. 2 , ( 6 ) 582 - 588 .

Park SH, Castellano D, Petrylak DP, Galsky MD, van der Heijden MS, Loriot Y, Ogawa O, Su W-P et al. ( 2016 ) . 285TiP DANUBE: A Phase 3 randomised study of first-line durvalumab (MEDI4736) 6 tremelimumab vs standard of care (SoC) chemotherapy (CT) in patients (pts) with Stage IV urothelial carcinoma (UC) . Annals of Oncology vol. 27 , ix88 - ix89 .

Powles T, Escudier B, Motzer RJ, Tannir NM, Scheffold C, Aftab DT, Chouieri TK ( 2016 ) . Clinical outcomes based on MET expression level in METEOR, a randomized phase 3 trial of cabozantinib versus everolimus in advanced renal cell carcinoma (RCC) . BJU INTERNATIONAL . vol. 118 , 4 - 4 .

Park SH, Castellano D, Petrylak DP, Galsky MD, van der Heijden MS, Loriot Y, Ogawa O, Su W-P et al. ( 2016 ) . DANUBE: A Phase 3 randomised study of first-line durvalumab (MEDI4736) +/- tremelimumab vs standard of care (SoC) chemotherapy (CT) in patients (pts) with Stage IV urothelial carcinoma (UC) . ANNALS OF ONCOLOGY . vol. 27 ,

Choueiri TK, Gross-Goupil M, Porta C, Suarez Rodriguez C, Patel C, Neuwirth R, Enke A, Zohren F et al. ( 2016 ) . Phase 2 study of investigational TORC1/2 inhibitor TAK-228 and TAK-228 plus investigational PI3Ka-selective inhibitor TAK-117 versus everolimus in adults with advanced or metastatic clear-cell renal cell carcinoma (ccRCC) that has progressed on VEGF-targeted therapy . BJU INTERNATIONAL . vol. 118 , 13 - 14 .

Bex A, Ljungberg B, van Poppel H, Powles T ( 2016 ) . The Role of Cytoreductive Nephrectomy: European Association of Urology Recommendations in 2016 . European Urology vol. 70 , ( 6 ) 901 - 905 .

Lundqvist A, van Hoef V, Zhang X, Wennerberg E, Lorent J, Witt K, Sanz LM, Liang S et al. ( 2016 ) . 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one . Journal for ImmunoTherapy of Cancer vol. 4 , ( Suppl 1 )

Crusz SM, Tang YZ, Sarker SJ, Prevoo W, Kiyani I, Beltran L, Peters J, Sahdev A et al. ( 2016 ) . Heterogeneous response and progression patterns reveal phenotypic heterogeneity of tyrosine kinase inhibitor response in metastatic renal cell carcinoma . BMC Medicine vol. 14 , ( 1 ) 185 - 185 .

Powles THOMAS, Huddart RA, Elliott T, SARKER S-J, Ackerman CHARLOTTE, Jones R, Hussaine S, Crabb S et al. ( 2016 ) . A phase II/III, double-blind, randomized trial comparing maintenance lapatinib versus placebo after first line chemotherapy in HER1/2 positive metastatic bladder cancer patients . Journal of Clinical Oncology

Powles T, Grivas P, Aragon-Ching JB, Faroun Y, Kessler ER, Tomita Y, Chakrabarti D, Laliberte RJ et al. ( 2016 ) . A multicentre, international, randomised, open-label phase 3 trial of avelumab + best supportive care (BSC) vs BSC alone as maintenance therapy after first-line platinum-based chemotherapy in patients with advanced urothelial cancer (JAVELIN bladder 100) . Annals of Oncology vol. 27 ,

Bamias A, Tzannis K, Liontos M, Crabb SJ, Harshman L, De Giorgi U, Bellmunt J, Wong YN et al. ( 2016 ) . Adherence to cisplatin-based regimens prescription in “fit” patients fulfilling platinum eligibility criteria. Impact on outcomes: a retrospective international study of invasive/advanced cancer of the urothelium (RISC) analysis . Annals of Oncology . vol. 27 ,

Tannir N, Powles T, Motzer RJ, Rolland F, Gravis G, Staehler M, Rink M, Retz M et al. ( 2016 ) . Analysis of regional differences in the phase 3 METEOR study of cabozantinib (cabo) versus everolimus (eve) in advanced renal cell carcinoma (RCC) . Annals of Oncology . vol. 27 ,

Loriot Y, Rosenberg JE, Powles TB, Necchi A, Hussain S, Morales R, Retz M, Niegisch G et al. ( 2016 ) . Atezolizumab (atezo) in platinum (plat)-treated locally advanced/metastatic urothelial carcinoma (mUC): Updated OS, safety and biomarkers from the Ph II IMvigor210 study . Annals of Oncology . vol. 27 ,

Heng D, Park J, Signorovitch JE, Yang H, Song J, Weiss J, Dezzani L, Powles TB ( 2016 ) . Clinical outcomes and dosing patterns of 2nd targeted therapy in metastatic renal carcinoma: a retrospective chart review in the EU . Annals of Oncology vol. 27 ,

Powles TB, Escudier B, de Souza P, Chowdhury S, Pook D, Harmenberg U, Basappa N, Geynisman D et al. ( 2016 ) . Efficacy of cabozantinib (cabo) vs everolimus (eve) by metastatic site and tumor burden in patients (pts) with advanced renal cell carcinoma (RCC) in the phase 3 METEOR trial . Annals of Oncology . vol. 27 ,

Hessel C, Mangeshkar M, Motzer RJ, Escudier B, Powles TB, Schwab G, Choueiri TK ( 2016 ) . Evaluation of the novel “trial within a trial” design of METEOR, a randomized phase 3 trial of cabozantinib versus everolimus in patients (pts) with advanced renal cell carcinoma (RCC) . Annals of Oncology . vol. 27 ,

Bamias A, Tzannis K, Liontos M, Harshman L, Crabb SJ, Wong YN, Pal SK, Powles TB et al. ( 2016 ) . Patterns of chemotherapy utilization in metastatic urothelial cancer (mUC): analysis from the retrospective international study of invasive/advanced cancer of the urothelium (RISC) database . Annals of Oncology . vol. 27 ,

Balar A, Bellmunt J, O'Donnell PH, Castellano D, Grivas P, Vuky J, Powles T, Plimack ER et al. ( 2016 ) . Pembrolizumab (pembro) as first-line therapy for advanced/unresectable or metastatic urothelial cancer: Preliminary results from the phase 2 KEYNOTE-052 study . Annals of Oncology . vol. 27 ,

Cella D, Escudier B, Tannir N, Powles T, Donskov F, Peltola K, Schmidinger M, Heng D et al. ( 2016 ) . Quality of life (QoL) in the phase 3 METEOR trial of cabozantinib vs everolimus for advanced renal cell carcinoma (RCC) . Annals of Oncology . vol. 27 ,

Lardas M, Stewart F, Scrimgeour D, Hofmann F, Marconi L, Dabestani S, Bex A, Volpe A et al. ( 2016 ) . Systematic Review of Surgical Management of Nonmetastatic Renal Cell Carcinoma with Vena Caval Thrombus . European Urology vol. 70 , ( 2 ) 265 - 280 .

Powles T ( 2016 ) . Where next in kidney cancer? . Annals of Oncology vol. 27 , ( 8 ) 1376 - 1377 .

Smith K, Sheaff M, Elia G, Clear A, Trevisan G, Foxler D, Bridge K, Shepherd S et al. ( 2016 ) . 888 Loss of LIM-domain proteins LIMD1, Ajuba and WTIP as a novel molecular mechanism for disease aetiology in clear cell renal cell carcinoma (ccRCC) . European Journal of Cancer vol. 61 ,

Choueiri TK, Escudier B, Powles T, Tannir NM, Mainwaring PN, Rini BI, Hammers HJ, Donskov F et al. ( 2016 ) . Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial . The Lancet Oncology vol. 17 , ( 7 ) 917 - 927 .

Smith K, Sheaff M, Elia G, Clear A, Trevisan G, Foxler D, Bridge K, Shepherd S et al. ( 2016 ) . Loss of LIM-domain proteins LIMD1, Ajuba and WTIP as a novel molecular mechanism for disease aetiology in clear cell renal cell carcinoma (ccRCC) . EUROPEAN JOURNAL OF CANCER . vol. 61 , S206 - S206 .

Balar AV, Galsky MD, Loriot Y, Dawson NA, Necchi A, Srinivas S, Joseph RW, Vaishampayan UN et al. ( 2016 ) . Atezolizumab (atezo) as first-line (1L) therapy in cisplatin-ineligible locally advanced/metastatic urothelial carcinoma (mUC): Primary analysis of IMvigor210 cohort 1 . Journal of Clinical Oncology . vol. 34 , lba4500 - lba4500 .

Feber A, Worth DC, Chakravarthy A, de Winter P, Shah K, Arya M, Saqib M, Nigam R et al. ( 2016 ) . CSN1 Somatic Mutations in Penile Squamous Cell Carcinoma . Cancer Research vol. 76 , ( 16 ) 4720 - 4727 .

Powles T, Sarwar N, Stockdale A, Sarker S-J, Boleti E, Protheroe A, Jones R, Chowdhury S et al. ( 2016 ) . Safety and Efficacy of Pazopanib Therapy Prior to Planned Nephrectomy in Metastatic Clear Cell Renal Cancer . JAMA Oncology vol. 2 , ( 10 ) 1303 - 1309 .

Powles T, Galsky MD, Castellano D, Van Der Heijden MS, Petrylak DP, Armstrong J, Belli R, Ferro S et al. ( 2016 ) . A phase 3 study of first-line durvalumab (MEDI4736) ± tremelimumab versus standard of care (SoC) chemotherapy (CT) in patients (pts) with unresectable Stage IV urothelial bladder cancer (UBC): DANUBE . Journal of Clinical Oncology . vol. 34 , tps4574 - tps4574 .

Schmid P, Hegde PS, Zou W, Kowanetz M, Mariathasan S, Molinero L, Gadgeel SM, Powles T et al. ( 2016 ) . Association of PD-L2 expression in human tumors with atezolizumab activity . Journal of Clinical Oncology . vol. 34 , 11506 - 11506 .

Balar AV, Galsky MD, Loriot Y, Dawson NA, Necchi A, Srinivas S, Joseph RW, Vaishampayan UN et al. ( 2016 ) . Atezolizumab (atezo) as first-line (1L) therapy in cisplatin-ineligible locally advanced/metastatic urothelial carcinoma (mUC): Primary analysis of IMvigor210 cohort 1 . Journal of Clinical Oncology vol. 34 , ( 15_suppl ) lba4500 - lba4500 .

Powles T, Kilgour E, Mather R, Galer A, Arkenau H-T, Farnsworth A, Wilde J, Ratnayake J et al. ( 2016 ) . BISCAY, a phase Ib, biomarker-directed multidrug umbrella study in patients with metastatic bladder cancer . Journal of Clinical Oncology . vol. 34 , tps4577 - tps4577 .

Escudier BJ, Powles T, Motzer RJ, Olencki T, Aren OR, Oudard S, Bracarda S, Tomczak P et al. ( 2016 ) . Efficacy of cabozantinib (C) vs everolimus (E) in patients (pts) with advanced renal cell carcinoma (RCC) and bone metastases (mets) from the phase III METEOR study . Journal of Clinical Oncology . vol. 34 , 4558 - 4558 .

Powles T, Motzer RJ, Escudier BJ, Pal SK, Kollmannsberger CK, Pikiel J, Gurney H, Rha SY et al. ( 2016 ) . Outcomes based on prior VEGFR TKI and PD-1 checkpoint inhibitor therapy in METEOR, a randomized phase 3 trial of cabozantinib (C) vs everolimus (E) in advanced renal cell carcinoma (RCC) . Journal of Clinical Oncology . vol. 34 , 4557 - 4557 .

Choueiri TK, Powles T, Escudier BJ, Tannir NM, Mainwaring P, Rini BI, Hammers HJ, Donskov F et al. ( 2016 ) . Overall survival (OS) in METEOR, a randomized phase 3 trial of cabozantinib (Cabo) versus everolimus (Eve) in patients (pts) with advanced renal cell carcinoma (RCC) . Journal of Clinical Oncology . vol. 34 , 4506 - 4506 .

Rosenberg JE, Petrylak DP, Van Der Heijden MS, Necchi A, O'Donnell PH, Loriot Y, Retz M, Perez-Gracia JL et al. ( 2016 ) . PD-L1 expression, Cancer Genome Atlas (TCGA) subtype, and mutational load as independent predictors of response to atezolizumab (atezo) in metastatic urothelial carcinoma (mUC; IMvigor210) . Journal of Clinical Oncology . vol. 34 , 104 - 104 .

Rose TL, Ladoire S, Crehange G, Galsky MD, Rosenberg JE, Bellmunt J, Powles T, Wong Y-N et al. ( 2016 ) . Patterns of chemotherapy administration in bladder preservation therapy (BPT) for muscle-invasive bladder cancer (MIBC) . Journal of Clinical Oncology . vol. 34 , 4536 - 4536 .

Lacy S, Hutmacher MM, Yang B, Motzer RJ, Escudier BJ, Powles T, Choueiri TK, Miles D et al. ( 2016 ) . Population pharmacokinetic (PopPK) and exposure-response (ER) modeling of cabozantinib (C) in patients (pts) with renal cell carcinoma (RCC) in the phase 3 METEOR study . Journal of Clinical Oncology . vol. 34 , 2565 - 2565 .

Rudd P, Hines J, Cathcart P, Wilkinson K, Shaw G, Wilson P, Shamash J, Richards TM et al. ( 2016 ) . Results of the first thousand patients from a multidisciplinary prostate cancer clinic . Journal of Clinical Oncology . vol. 34 , e16602 - e16602 .

Powles T, Lackner MR, Oudard S, Escudier B, Ralph C, Brown JE, Hawkins RE, Castellano D et al. ( 2016 ) . Randomized open-label phase II trial of apitolisib (GDC-0980), a novel inhibitor of the PI3K/mammalian target of rapamycin pathway, versus everolimus in patients with metastatic renal cell carcinoma . Journal of Clinical Oncology vol. 34 , ( 14 ) 1660 - 1668 .

Rosenberg JE, Hoffman-Censits J, Powles T, Van Der Heijden MS, Balar AV, Necchi A, Dawson N, O'Donnell PH et al. ( 2016 ) . Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial . The Lancet vol. 387 , ( 10031 ) 1909 - 1920 .

Powles T, Brown J, Larkin J, Jones R, Ralph C, Hawkins R, Chowdhury S, Boleti E et al. ( 2016 ) . A randomized, double-blind phase II study evaluating cediranib versus cediranib and saracatinib in patients with relapsed metastatic clear-cell renal cancer (COSAK) . Annals of Oncology vol. 27 , ( 5 ) 880 - 886 .

Stewart GD, Powles T, Van Neste C, Meynert A, O'Mahony F, Laird A, Deforce D, Van Nieuwerburgh F et al. ( 2016 ) . Dynamic epigenetic changes to VHL occur with sunitinib in metastatic clear cell renal cancer . Oncotarget vol. 7 , ( 18 ) 25241 - 25250 .

Gulley JL, Mulders P, Albers P, Banchereau J, Bolla M, Pantel K, Powles T ( 2016 ) . Perspectives on sipuleucel-T: Its role in the prostate cancer treatment paradigm . OncoImmunology vol. 5 , ( 4 )

Beaumont JL, Salsman JM, Diaz J, Deen KC, McCann L, Powles T, Hackshaw MD, Motzer RJ et al. ( 2016 ) . Quality-adjusted time without symptoms or toxicity analysis of pazopanib versus sunitinib in patients with renal cell carcinoma . Cancer vol. 122 , ( 7 ) 1108 - 1115 .

Xu CF, Johnson T, Wang X, Carpenter C, Graves AP, Warren L, Xue Z, King KS et al. ( 2016 ) . HLA-B∗57:01 confers susceptibility to pazopanib-associated liver injury in patients with cancer . Clinical Cancer Research vol. 22 , ( 6 ) 1371 - 1377 .

McDermott DF, Sosman JA, Sznol M, Massard C, Gordon MS, Hamid O, Powderly JD, Infante JR et al. ( 2016 ) . Atezolizumab, an anti-programmed death-ligand 1 antibody, in metastatic renal cell carcinoma: Long-term safety, clinical activity, and immune correlates from a phase Ia study . Journal of Clinical Oncology vol. 34 , ( 8 ) 833 - 842 .

Powles T, Wheater M, Din O, Geldart T, Boleti E, Stockdale A, Sundar S, Robinson A et al. ( 2016 ) . A Randomised Phase 2 Study of AZD2014 Versus Everolimus in Patients with VEGF-Refractory Metastatic Clear Cell Renal Cancer . European Urology . vol. 69 , 450 - 456 .

Feldman DR, Lorch A, Kramar A, Albany C, Einhorn LH, Giannatempo P, Necchi A, Flechon A et al. ( 2016 ) . Brain metastases in patients with germ cell tumors: Prognostic factors and treatment options - An analysis from the Global Germ Cell Cancer Group . Journal of Clinical Oncology vol. 34 , ( 4 ) 345 - 351 .

Heng DYC, Park J, Signorovitch JE, Yang H, Song J, Patel D, Lin C, Powles T ( 2016 ) . Outcomes of second targeted therapy in metastatic renal carcinoma: A retrospective chart review in the EU . Journal of Clinical Oncology . vol. 34 , 558 - 558 .

Powles T, Hussain SA, Protheroe A, Birtle A, Chakraborti PR, Huddart R, Jagdev S, Bahl A et al. ( 2016 ) . PLUTO: A randomised phase II study of pazopanib versus paclitaxel in relapsed urothelial tumours . Journal of Clinical Oncology . vol. 34 , 430 - 430 .

Escudier BJ, Motzer RJ, Powles T, Tannir NM, Davis ID, Donskov F, Grünwald V, Heng DYC et al. ( 2016 ) . Subgroup analyses of METEOR, a randomized phase 3 trial of cabozantinib versus everolimus in patients (pts) with advanced renal cell carcinoma (RCC) . Journal of Clinical Oncology . vol. 34 , 499 - 499 .

Ramos J, Wong Y-N, Crabb SJ, Niegisch G, Bellmunt J, Ladoire S, Hussain SA, Baniel J et al. ( 2016 ) . Venous thromboembolism (VTE) risk in patients with localized urinary tract tumors (UTT) . Journal of Clinical Oncology . vol. 34 , 422 - 422 .

Powles T, Staehler M, Ljungberg B, Bensalah K, Canfield SE, Dabestani S, Giles RH, Hofmann F et al. ( 2016 ) . European Association of Urology Guidelines for Clear Cell Renal Cancers That Are Resistant to Vascular Endothelial Growth Factor Receptor–Targeted Therapy . European Urology vol. 70 , ( 5 ) 705 - 706 .

Bridgeman VL, Wan E, Foo S, Nathan MR, Welti JC, Frentzas S, Vermeulen PB, Preece N et al. ( 2016 ) . Preclinical evidence that trametinib enhances the response to antiangiogenic tyrosine kinase inhibitors in renal cell carcinoma . Molecular Cancer Therapeutics vol. 15 , ( 1 ) 172 - 183 .

Bex A, Powles T, Karam JA ( 2016 ) . Role of targeted therapy in combination with surgery in renal cell carcinoma . International Journal of Urology vol. 23 , ( 1 ) 5 - 12 .

Powles T, Staehler M, Ljungberg B, Bensalah K, Canfield SE, Dabestani S, Giles R, Hofmann F et al. ( 2016 ) . Updated EAU Guidelines for Clear Cell Renal Cancer Patients Who Fail VEGF Targeted Therapy . European Urology vol. 69 , ( 1 ) 4 - 6 .

Kramar A, Negrier S, Sylvester R, Joniau S, Mulders P, Powles T, Bex A, Bonnetain F et al. ( 2015 ) . Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: Results of the DATECAN project . Annals of Oncology vol. 26 , ( 12 ) 2392 - 2398 .

Kanu N, Grönroos E, Martinez P, Burrell RA, Yi Goh X, Bartkova J, Maya-Mendoza A, Mistrík M et al. ( 2015 ) . SETD2 loss-of-function promotes renal cancer branched evolution through replication stress and impaired DNA repair . Oncogene vol. 34 , ( 46 ) 5699 - 5708 .

Choueiri TK, Escudier B, Powles T, Mainwaring PN, Rini BI, Donskov F, Hammers H, Hutson TE et al. ( 2015 ) . Cabozantinib versus everolimus in advanced renal-cell carcinoma . New England Journal of Medicine vol. 373 , ( 19 ) 1814 - 1823 .

Powles T, Nickles D, Van Allen E, Chappey C, Zou W, Kowanetz M, Kadel E, Denker M et al. ( 2015 ) . Immune biomarkers associated with clinical benefit from atezolizumab (MPDL3280a; anti-PD-L1) in advanced urothelial bladder cancer (UBC) . Journal for ImmunoTherapy of Cancer vol. 3 , ( Suppl 2 )

Coleman R, Gray R, Powles T, Paterson A, Gnant M, Bergh J, Pritchard KI, Bliss J et al. ( 2015 ) . Adjuvant bisphosphonate treatment in early breast cancer: Meta-analyses of individual patient data from randomised trials . The Lancet vol. 386 , ( 10001 ) 1353 - 1361 .

Kurtoglu M, Davarpanah NN, Qin R, Powles T, Rosenberg JE, Apolo AB ( 2015 ) . Elevating the Horizon: Emerging Molecular and Genomic Targets in the Treatment of Advanced Urothelial Carcinoma . Clinical Genitourinary Cancer vol. 13 , ( 5 ) 410 - 420 .

Olson TA, Murray MJ, Rodriguez-Galindo C, Nicholson JC, Billmire DF, Krailo MD, Dang HM, Amatruda JF et al. ( 2015 ) . Pediatric and adolescent extracranial germ cell tumors: The road to collaboration . Journal of Clinical Oncology vol. 33 , ( 27 ) 3018 - 3028 .

Stewart GD, O'Mahony FC, Laird A, Eory L, Lubbock ALR, Mackay A, Nanda J, O'Donnell M et al. ( 2015 ) . Sunitinib treatment exacerbates intratumoral heterogeneity in metastatic renal cancer . Clinical Cancer Research vol. 21 , ( 18 ) 4212 - 4223 .

Rosenberg J, Petrylak D, Abidoye O, Van der Heijden MS, Hofman-Censits J, Necchi A, O'Donnell PH, Balmanoukian A et al. ( 2015 ) . 21LBA Atezolizumab in patients (pts) with locally-advanced or metastatic urothelial carcinoma (mUC): Results from a pivotal multicenter phase II study (IMvigor 210) . European Journal of Cancer . vol. 51 ,

Harshman L, Werner L, Wong YN, Yu E, Alva A, Crabb S, Powles T, Rosenberg J et al. ( 2015 ) . 2619 Patterns and potential benefit of adjuvant chemotherapy for residual muscle invasive disease after neoadjuvant chemotherapy for muscle invasive urothelial cancer (MIUC) . European Journal of Cancer . vol. 51 ,

Choueiri T, Escudier B, Powles T, Mainwaring P, Rini B, Donskov F, Hammers H, Hutson T et al. ( 2015 ) . 4LBA Cabozantinib versus everolimus in patients with advanced renal cell carcinoma: Results of the randomized phase 3 METEOR trial . European Journal of Cancer . vol. 51 , s708 - s709 .

Marconi L, Dabestani S, Lam TB, Hofmann F, Stewart F, Norrie J, Bex A, Bensalah K et al. ( 2015 ) . Systematic Review and Meta-analysis of Diagnostic Accuracy of Percutaneous Renal Tumour Biopsy . EUROPEAN UROLOGY vol. 69 , ( 4 ) 660 - 673 .

Galsky MD, Pal SK, Chowdhury S, Harshman LC, Crabb SJ, Wong YN, Yu EY, Powles T et al. ( 2015 ) . Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer . Cancer vol. 121 , ( 15 ) 2586 - 2593 .

Powles T ( 2015 ) . Immune Checkpoint Inhibitors for Urologic Cancer: The Tip of the Iceberg? . European Urology vol. 68 , ( 2 ) 280 - 282 .

Feldman DR, Powles T ( 2015 ) . Salvage high-dose chemotherapy for germ cell tumors . Urologic Oncology: Seminars and Original Investigations vol. 33 , ( 8 ) 355 - 362 .

Mulders PF, De Santis M, Powles T, Fizazi K ( 2015 ) . Targeted treatment of metastatic castration-resistant prostate cancer with sipuleucel-T immunotherapy . Cancer Immunology, Immunotherapy vol. 64 , ( 6 ) 655 - 663 .

Powles T, Bracarda S, Chen M, Norry E, Compton N, Heise M, Hutson T, Harter P et al. ( 2015 ) . Characterisation of liver chemistry abnormalities associated with pazopanib monotherapy: A systematic review and meta-analysis of clinical trials in advanced cancer patients . European Journal of Cancer vol. 51 , ( 10 ) 1293 - 1302 .

Petrylak DP, Powles T, Bellmunt J, Braiteh FS, Loriot Y, Cruz Zambrano C, Burris HA, Kim JW et al. ( 2015 ) . A phase Ia study of MPDL3280A (anti-PDL1): Updated response and survival data in urothelial bladder cancer (UBC) . Journal of Clinical Oncology . vol. 33 , 4501 - 4501 .

Harshman LC, Werner L, Wong Y-N, Yu EY, Alva AS, Crabb SJ, Powles T, Rosenberg JE et al. ( 2015 ) . Adjuvant chemotherapy for residual disease after neoadjuvant chemotherapy for muscle invasive urothelial cancer (MIUC) . Journal of Clinical Oncology . vol. 33 , 4524 - 4524 .

De Santis M, Mulders P, Fizazi K, Gray TE, McCoy C, Stubbs A, Powles T ( 2015 ) . First prospective, open-label, phase 2 study of sipuleucel-T (sip-T) in European men with metastatic, castration-resistant prostate cancer (mCRPC) . Journal of Clinical Oncology . vol. 33 , e16015 - e16015 .

Hussain SA, Jackson R, Shields A, Dickinson L, Cornford P, Jones RJ, Lester JF, Chester JD et al. ( 2015 ) . Phase II randomised placebo controlled neoadjuvant chemotherapy study of nintedanib with gemcitabine and cisplatin in locally advanced muscle invasive bladder cancer . Journal of Clinical Oncology . vol. 33 , tps4574 - tps4574 .

Ljungberg B, Bensalah K, Canfield S, Dabestani S, Hofmann F, Hora M, Kuczyk MA, Lam T et al. ( 2015 ) . EAU guidelines on renal cell carcinoma: 2014 update . European Urology vol. 67 , ( 5 ) 913 - 924 .

Powles T ( 2015 ) . Immunotherapy: The development of immunotherapy in urothelial bladder cancer . Nature Reviews Clinical Oncology vol. 12 , ( 4 ) 193 - 194 .

Kim JW, Bellmunt J, Powles T, Loriot Y, Vogelzang NJ, Cruz Zambrano C, Burris HA, Teng S-LM et al. ( 2015 ) . Clinical activity, safety, and biomarkers of MPDL3280A in metastatic urothelial bladder cancer: Additional analysis from phase IA study . Journal of Clinical Oncology . vol. 33 , 297 - 297 .

Choueiri TK, Figueroa DJ, Fay AP, Signoretti S, Liu Y, Gagnon R, Deen K, Carpenter C et al. ( 2015 ) . Correlation of PD-L1 tumor expression and treatment outcomes in patients with renal cell carcinoma receiving sunitinib or pazopanib: Results from COMPARZ, a randomized controlled trial . Clinical Cancer Research vol. 21 , ( 5 ) 1071 - 1077 .

Stewart G, Van Neste C, Meynert A, Semple C, O'Mahony F, Laird A, Mackay A, Trooskens G et al. ( 2015 ) . Effect of sunitinib treatment on mutations and methylation in metastatic renal cancer . Journal of Clinical Oncology . vol. 33 , 492 - 492 .

Ferguson J, McKibben M, Parker JS, Wallen E, Wood CG, Powles T, Rathmell K ( 2015 ) . Evaluation of the effects of neoadjuvant pazopanib for renal cell carcinoma on intratumor genetic heterogeneity . Journal of Clinical Oncology . vol. 33 , 425 - 425 .

Fitzpatrick A, Soosaipillai G, Wilson P, Powles T, Shamash J ( 2015 ) . High Dose Interleukin-2 Therapy for Metastatic Renal Cell Carcinoma in the VEGF Targeted Era . Clinical Oncology vol. 27 , ( 3 ) e7 - e8 .

Ramos J, Casey MF, Crabb SJ, Bamias A, Harshman LC, Wong Y-N, Bellmunt J, De Giorgi U et al. ( 2015 ) . Impact of chemotherapy (CTX) on venous thromboembolism (VTE) and prognostic implications in patients with metastatic urinary tract tumors (UTT) . Journal of Clinical Oncology . vol. 33 , 318 - 318 .

Rodriguez-Vida A, Bianchini D, Van Hemelrijck M, Hughes S, Malik Z, Powles T, Bahl A, Rudman S et al. ( 2015 ) . Is there an antiandrogen withdrawal syndrome with enzalutamide? . BJU International vol. 115 , ( 3 ) 373 - 380 .

Gurung PMS, Veerakumarasivam A, Williamson M, Counsell N, Douglas J, Tan WS, Feber A, Crabb SJ et al. ( 2015 ) . Loss of expression of the tumour suppressor gene AIMP3 predicts survival following radiotherapy in muscle-invasive bladder cancer . International Journal of Cancer vol. 136 , ( 3 ) 709 - 720 .

Albiges L, Choueiri T, Escudier B, Galsky M, George D, Hofmann F, Lam T, Motzer R et al. ( 2015 ) . A systematic review of sequencing and combinations of systemic therapy in metastatic renal cancer . Eur Urol vol. 67 , ( 1 ) 100 - 110 .

Kollmannsberger C, Tandstad T, Bedard PL, Cohn-Cedermark G, Chung PW, Jewett MA, Powles T, Warde PR et al. ( 2015 ) . Patterns of relapse in patients with clinical stage I testicular cancer managed with active surveillance . Journal of Clinical Oncology vol. 33 , ( 1 ) 51 - 57 .

Mather SJ, Nock BA, Maina T, Gibson V, Ellison D, Murray I, Sobnack R, Colebrook S et al. ( 2014 ) . GRP receptor imaging of prostate cancer using [(99m)Tc]Demobesin 4: a first-in-man study . Mol Imaging Biol vol. 16 , ( 6 ) 888 - 895 .

Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, Bellmunt J, Burris HA et al. ( 2014 ) . MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer . Nature vol. 515 , ( 7528 ) 558 - 562 .

Escudier B, Porta C, Powles T, Eisen T, Sternberg CN, Mehmud F, Cella D ( 2014 ) . Reply to S. Barni et Al and M. Sun et Al . J Clin Oncol vol. 32 , ( 33 ) 3783 - 3784 .

Xiao Y, Rabe C, Kowanetz M, Powles T, Vogelzang NJ, Petrylak DP, Loriot Y, Denker M et al. ( 2014 ) . Myeloid cell biology and inhibition of anti-tumor immune responses by MPDL3280A in urothelial bladder cancer . Journal for ImmunoTherapy of Cancer vol. 2 , ( Suppl 3 )

Choueiri TK, Escudier B, Pal SK, Jonasch E, Heng D, Powles T, Arkenau HT, Clark E et al. ( 2014 ) . 395 cMet: Proof-of-concept clinical trial with volitinib in patients with advanced papillary renal cell cancer (PRCC) . European Journal of Cancer . vol. 50 , 126 - 127 .

Stewart GD, O'Mahony FC, Laird A, Rashid S, Martin SA, Eory L, Lubbock ALR, Nanda J et al. ( 2014 ) . Carbonic anhydrase 9 expression increases with vascular endothelial growth factor-targeted therapy and is predictive of outcome in metastatic clear cell renal cancer . Eur Urol vol. 66 , ( 5 ) 956 - 963 .

Dabestani S, Marconi L, Hofmann F, Stewart F, Lam TBL, Canfield SE, Staehler M, Powles T et al. ( 2014 ) . Local treatments for metastases of renal cell carcinoma: A systematic review . The Lancet Oncology vol. 15 , ( 12 ) e549 - e561 .

Ghazaly E, Perry J, Kitromilidou C, Powles T, Joel S ( 2014 ) . Development and validation of an ultra-high performance LC-MS/MS assay for intracellular SN-38 in human solid tumour cell lines: comparison with a validated HPLC-fluorescence method . J Chromatogr B Analyt Technol Biomed Life Sci vol. 969 , 213 - 218 .

McDermott DF, Kluger HM, Sosman JA, Infante JR, Soria J-C, Hamid O, Delord J-P, Fasso M et al. ( 2014 ) . Immune correlates and long-term follow-up of a Phase Ia study of MPDL3280A, an engineered PD-L1 antibody, in patients with metastatic renal cell carcinoma (mRCC) . BJU INTERNATIONAL . vol. 114 , 12 - 12 .

Berlato C, Kahn MN, Schioppa T, Thompson R, Maniati E, Canosa M, Kulbe H, Sheldon C et al. ( 2014 ) . Abstract 1076: Antagonists of the chemokine receptor CCR4 reverse the tumor-promoting microenvironment of renal cancer . Conference: Tumor Biology1076 - 1076 .

McDermott DF, Sznol M, Sosman JA, Soria J-C, Gordon MS, Hamid O, Delord J, Fasso M et al. ( 2014 ) . 809OIMMUNE CORRELATES AND LONG TERM FOLLOW UP OF A PHASE IA STUDY OF MPDL3280A, AN ENGINEERED PD-L1 ANTIBODY, IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC) . Ann Oncol vol. 25 , ( suppl_4 )

Powles T, Hawkins R, Ralph C, Larkin J, Jones RJ, Chowdhury S, Boleti E, Fife K et al. ( 2014 ) . LBA24 A Randomised Phase Ii Study of Cediranib with or Without Src Inhibition (Saracatinib) in Metastatic Clear Cell Renal Cancer (Rcc) Patients Resistant to Vegf Targeted Therapy . Annals of Oncology . vol. 25 ,

Powles T, Foreshew S-JS, Shamash J, Sarwar N, Crabb S, Sahdev A, Nixon J, Lim L et al. ( 2014 ) . A phase Ib study investigating the combination of everolimus and dovitinib in vascular endothelial growth factor refractory clear cell renal cancer . Eur J Cancer vol. 50 , ( 12 ) 2057 - 2064 .

Powles T, Davies R, Rini B ( 2014 ) . Mammalian target of rapamycin inhibitors: the beginning of the end or the end of the beginning? . Eur Urol vol. 66 , ( 2 ) 282 - 283 .

Bellmunt J, Pons F, Foreshew A, Fay AP, Powles T, Porta C, Bracarda S, Lampron ME et al. ( 2014 ) . Sequential Targeted Therapy After Pazopanib Therapy in Patients With Metastatic Renal Cell Cancer: Efficacy and Toxicity . CLINICAL GENITOURINARY CANCER vol. 12 , ( 4 ) 262 - 269 .

Stewart GD, Harrison DJ, Berney DM, Powles T ( 2014 ) . The molecular biology of renal cancer: another piece of the puzzle . Eur Urol vol. 66 , ( 1 ) 85 - 86 .

Powles T, Oudard S, Escudier BJ, Brown JE, Hawkins RE, Castellano DE, Ravaud A, Staehler MD et al. ( 2014 ) . A randomized phase II study of GDC-0980 versus everolimus in metastatic renal cell carcinoma (mRCC) patients (pts) after VEGF-targeted therapy (VEGF-TT) . Journal of Clinical Oncology . vol. 32 , 4525 - 4525 .

Galsky MD, Harshman LC, Crabb SJ, Wong Y-N, Yu EY, Chowdhury S, Powles T, Pal SK et al. ( 2014 ) . Comparative effectiveness of gemcitabine plus cisplatin (GC) versus methotrexate, vinblastine, doxorubicin, plus cisplatin (MVAC) as neoadjuvant therapy for muscle-invasive bladder cancer (MIBC) . Journal of Clinical Oncology . vol. 32 , 4512 - 4512 .

Powles T, Vogelzang NJ, Fine GD, Eder JP, Braiteh FS, Loriot Y, Cruz Zambrano C, Bellmunt J et al. ( 2014 ) . Inhibition of PD-L1 by MPDL3280A and clinical activity in pts with metastatic urothelial bladder cancer (UBC) . Journal of Clinical Oncology . vol. 32 , 5011 - 5011 .

Jones RJ, Chester JD, Dixon-Hughes J, Alexander L, Bahl A, Hussain SA, Birtle A, Jagdev S et al. ( 2014 ) . Pazopanib versus paclitaxel in relapsed urothelial tumors: A randomized phase II study investigating pazopanib versus weekly paclitaxel in relapsed or progressive transitional cell carcinoma of the urothelium (PLUTO) . Journal of Clinical Oncology . vol. 32 , tps4589 - tps4589 .

Choueiri TK, Escudier BJ, Powles T, Cella D, Ru QC, Scheffold C, Motzer RJ ( 2014 ) . Phase 3 randomized study of cabozantinib (XL184) versus everolimus in subjects with clear cell renal cell carcinoma (METEOR) . Journal of Clinical Oncology vol. 32 , ( 15_suppl ) tps4601 - tps4601 .

Beaumont JL, Diaz J, Deen KC, McCann L, Powles T, Hackshaw MD, Motzer RJ, Cella D ( 2014 ) . Q-TWiST analysis of patients with metastatic renal cell carcinoma (mRCC) randomized to pazopanib (PAZ) or sunitinib (SUN) . Journal of Clinical Oncology . vol. 32 , 4581 - 4581 .

Cuzick JM, Brentnall A, Segal C, Sestak I, Kealy R, Howell A, Powles TJ, Orr N et al. ( 2014 ) . Use of a SNP panel to refine risk estimates in women at high risk of breast cancer: Results from two randomized tamoxifen prevention trials . Journal of Clinical Oncology . vol. 32 , 1519 - 1519 .

Escudier B, Porta C, Bono P, Powles T, Eisen T, Sternberg CN, Gschwend JE, De Giorgi U et al. ( 2014 ) . Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study . J Clin Oncol vol. 32 , ( 14 ) 1412 - 1418 .

Bex A, Fournier L, Lassau N, Mulders P, Nathan P, Oyen WJG, Powles T ( 2014 ) . Assessing the response to targeted therapies in renal cell carcinoma: technical insights and practical considerations . Eur Urol vol. 65 , ( 4 ) 766 - 777 .

Powles T, Grp GGGCT, EBMT S ( 2014 ) . ROLE OF AUTOLOGOUS TRANSPLANTATION IN GERM CELL TUMOR (GCT). OVERVIEW OF TIGER STUDY . BONE MARROW TRANSPLANTATION . vol. 49 , S98 - S98 .

Bharwani N, Miquel ME, Powles T, Dilks P, Shawyer A, Sahdev A, Wilson PD, Chowdhury S et al. ( 2014 ) . Diffusion-weighted and multiphase contrast-enhanced MRI as surrogate markers of response to neoadjuvant sunitinib in metastatic renal cell carcinoma . Br J Cancer vol. 110 , ( 3 ) 616 - 624 .

Fitzpatrick AM, Greenwood M, Foreshew A, Nixon J, Sahdev A, Sarwar N, Lim L, Jones RJ et al. ( 2014 ) . A phase Ib study exploring the combination of everolimus and dovitinib in VEGF-refractory clear cell renal cancer . JOURNAL OF CLINICAL ONCOLOGY . vol. 32 ,

Kwan A, Shamash J, Powles T, Ansell W, Chowdhury S, Harland SJ, Lamont A, Wade R et al. ( 2014 ) . An audit of adjuvant carboplatin in patients with stage I testicular seminoma (Anglian Germ Cell Cancer Group, UK) . JOURNAL OF CLINICAL ONCOLOGY . vol. 32 ,

Choueiri TK, Figueroa DJ, Liu Y, Gagnon RC, Deen KC, Carpenter C, Bartlett-Pandite AN, De Souza P et al. ( 2014 ) . Correlation of PDL1 tumor expression and treatment outcomes in patients with renal cell carcinoma (RCC) receiving tyrosine kinase inhibitors: COMPARZ study analysis . JOURNAL OF CLINICAL ONCOLOGY . vol. 32 ,

Rodriguez-Vida A, Bianchini D, Hughes S, Lorente D, Crawley D, Van Hemelrijck M, Voskoboynik M, Chau NM et al. ( 2014 ) . Is there an anti-androgen withdrawal effect with enzalutamide? . JOURNAL OF CLINICAL ONCOLOGY . vol. 32 ,

Stewart G, Laird A, O'Mahony F, Eory L, Lubbock A, Nanda J, O'Donnell M, Mackay A et al. ( 2014 ) . The effect of sunitinib on biomarkers and tumor heterogeneity in metastatic clear cell renal cancer . JOURNAL OF CLINICAL ONCOLOGY . vol. 32 ,

Gurung PM, Veerakumarasivam A, Williamson M, Counsell N, Douglas J, Tan WS, Feber A, Crabb SJ et al. ( 2014 ) . Loss of expression of the tumour suppressor gene AIMP3 predicts survival following radiotherapy in muscle-invasive bladder cancer . International Journal of Cancer

Patel N, Arya M, Muneer A, Powles T, Sullivan M, Hines J, Kelly J ( 2014 ) . Molecular aspects of upper tract urothelial carcinoma . Urol Oncol vol. 32 , ( 1 ) 28.e11 - 28.e20 .

Sharpe K, Stewart GD, Mackay A, Van Neste C, Rofe C, Berney D, Kayani I, Bex A et al. ( 2013 ) . The effect of VEGF-targeted therapy on biomarker expression in sequential tissue from patients with metastatic clear cell renal cancer . Clin Cancer Res vol. 19 , ( 24 ) 6924 - 6934 .

Choueiri TK, Escudier B, Powles T, Cella D, Lee Y, Laird DA, Scheffold C, Motzer RJ ( 2013 ) . A phase 3 randomized study of cabozantinib (XL184) vs everolimus in subjects with clear cell renal cell carcinoma (METEOR) . BJU INTERNATIONAL . vol. 112 , 4 - 4 .

Powles T, Kelly J ( 2013 ) . Innovation: London Cancer-multidisciplinary approach to urological cancer . Nat Rev Clin Oncol vol. 10 , ( 11 ) 609 - 610 .

Nichols CR, Roth B, Albers P, Einhorn LH, Foster R, Daneshmand S, Jewett M, Warde P et al. ( 2013 ) . Active Surveillance Is the Preferred Approach to Clinical Stage I Testicular Cancer . JOURNAL OF CLINICAL ONCOLOGY vol. 31 , ( 28 ) 3490 - 3493 .

Crusz SM, Tang YZ, Sandev A, Kayani I, Harris L, Beltran L, Peters J, Swanton C et al. ( 2013 ) . Heterogeneous response and progression patterns of renal cell carcinoma metastases in individual patients reveal intra-tumour heterogeneity of anti-angiogenic drug resistance . EUROPEAN JOURNAL OF CANCER . vol. 49 , S641 - S641 .

Lim L, Mathias J, Lampron M, Fehr M, Gruenwald V, Khan M, Crabb S, Choueiri T et al. ( 2013 ) . Liver toxicity in patients with metastatic renal cell carcinoma treated with pazopanib therapy . EUROPEAN JOURNAL OF CANCER . vol. 49 , S660 - S660 .

Hodi FS, Powles T, Cassier P, Kowanetz M, Herbst RS, Soria JC, Mokatrin A, Stroh M et al. ( 2013 ) . MPDL3280A (anti-PDL1): Clinical activity, safety and biomarkers of an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors . EUROPEAN JOURNAL OF CANCER . vol. 49 , S184 - S184 .

Mulder P, De Santis M, Fizazi K, Whitmore J, Sheikh N, McCoy C, Stubbs A, Powles T ( 2013 ) . Preliminary product parameters from P11-1, a Phase 2, open-label trial of sipuleucel-T in European men with metastatic castrate-resistant prostate cancer (mCRPC) . EUROPEAN JOURNAL OF CANCER . vol. 49 , S696 - S696 .

Powles T ( 2013 ) . The mechanism of resistance to targeted therapy . EUROPEAN JOURNAL OF CANCER . vol. 49 , S38 - S38 .

Bhattacharyya M, Powles T, Mutsvangwa K, Wilson P, Oliver T, Shamash J ( 2013 ) . A phase II study of mitomycin, fluorouracil, folinic acid, and irinotecan (MFI) for the treatment of transitional cell carcinoma of the bladder . Urol Oncol vol. 31 , ( 6 ) 878 - 882 .

Powles T, Kayani I, Sharpe K, Lim L, Peters J, Stewart GD, Berney D, Sahdev A et al. ( 2013 ) . A prospective evaluation of VEGF-targeted treatment cessation in metastatic clear cell renal cancer . Ann Oncol vol. 24 , ( 8 ) 2098 - 2103 .

Rini BI, Powles T ( 2013 ) . Biology and Treatment of Advanced Renal Cell Carcinoma: A Global Perspective . SEMINARS IN ONCOLOGY vol. 40 , ( 4 ) 419 - 420 .

Powles T, Bascoul-Mollevi C, Kramar A, Lorch A, Beyer J ( 2013 ) . Prognostic impact of LDH levels in patients with relapsed/refractory seminoma . JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY vol. 139 , ( 8 ) 1311 - 1316 .

Jamal-Hanjani M, Karpathakis A, Kwan A, Mazhar D, Ansell W, Shamash J, Harper P, Rudman S et al. ( 2013 ) . Bone metastases in germ cell tumours: lessons learnt from a large retrospective study . BJU INTERNATIONAL vol. 112 , ( 2 ) 176 - 181 .

Tookman L, Rashid S, Matakidou A, Phillips M, Wilson P, Ansell W, Jamal-Hanjani M, Chowdhury S et al. ( 2013 ) . Carboplatin AUC 10 for IGCCCG good prognosis metastatic seminoma . Acta Oncol vol. 52 , ( 5 ) 987 - 993 .

Galsky MD, Hahn NM, Powles T, Hellerstedt BA, Lerner SP, Gardner TA, Yu M, O'Rourke M et al. ( 2013 ) . Gemcitabine, Cisplatin, and Sunitinib for Metastatic Urothelial Carcinoma and as Preoperative Therapy for Muscle-Invasive Bladder Cancer . CLINICAL GENITOURINARY CANCER vol. 11 , ( 2 ) 175 - 181 .

Cho DC, Sosman JA, Sznol M, Gordon MS, Hollebecque A, Hamid O, McDermott DF, Delord J-P et al. ( 2013 ) . Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with metastatic renal cell carcinoma (mRCC) . JOURNAL OF CLINICAL ONCOLOGY . vol. 31 ,

Cho DC, Sosman JA, Sznol M, Gordon MS, Hollebecque A, Hamid O, McDermott DF, Delord J-P et al. ( 2013 ) . Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with metastatic renal cell carcinoma (mRCC) . Journal of Clinical Oncology vol. 31 , ( 15_suppl ) 4505 - 4505 .

Powles T, Sarwar N, Stockdale A, Boleti E, Jones RJ, Protheroe A, Chowdhury S, Peters J et al. ( 2013 ) . Pazopanib prior to planned nephrectomy in metastatic clear cell renal cancer: A clinical and biomarker study . JOURNAL OF CLINICAL ONCOLOGY . vol. 31 ,

Powles T, Sarwar N, Stockdale A, Boleti E, Jones RJ, Protheroe A, Chowdhury S, Peters J et al. ( 2013 ) . Pazopanib prior to planned nephrectomy in metastatic clear cell renal cancer: A clinical and biomarker study . Journal of Clinical Oncology vol. 31 , ( 15_suppl ) 4508 - 4508 .

Galsky MD, Chowdhury S, Bellmunt J, Wong Y-N, Recine F, Pal SK, Moshier EL, Ladoire S et al. ( 2013 ) . Treatment patterns and outcomes in "real world" patients (pts) with metastatic urothelial cancer (UC) . JOURNAL OF CLINICAL ONCOLOGY . vol. 31 ,

Powles T, Crusz SM ( 2013 ) . Sequencing Systemic Therapies in Advanced RCC: Is There a Best Strategy? . American Society of Clinical Oncology Educational Book ( 33 ) e172 - e174 .

Beyer J, Albers P, Altena R, Aparicio J, Bokemeyer C, Busch J, Cathomas R, Cavallin-Stahl E et al. ( 2013 ) . Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer . ANNALS OF ONCOLOGY vol. 24 , ( 4 ) 878 - 888 .

Hardt A, Wilson P, Powles T, Shamash J ( 2013 ) . The Outcome of Brain Metastases in Patients with Metastatic Germ Cell Tumours - Is Cranial Irradiation Necessary? . CLINICAL ONCOLOGY vol. 25 , ( 4 ) E70 - E71 .

Pal P, Roy A, Moore G, Muzslay M, Lee E, Alder S, Wilson P, Powles T et al. ( 2013 ) . Keypad mobile phones are associated with a significant increased risk of microbial contamination compared to touch screen phones . Journal of Infection Prevention vol. 14 , ( 2 ) 65 - 68 .

Powles T, Sarwar N, Jones R, Wilson P, Boleti E, Protheroe A, Crabb S, Shamash J et al. ( 2013 ) . The hazards of cross comparing the drug toxicity results from different trials in metastatic renal cancer: in response to a letter from Dr. Catalá-López . Eur J Cancer vol. 49 , ( 4 ) 986 - 987 .

Powles T, Sharpe K, Berney D, Kayani I, Doshi R, Stewart GD, Reynolds A, Bex A et al. ( 2013 ) . Dynamic molecular changes with VEGF targeted therapy in metastatic clear cell renal cancer . JOURNAL OF CLINICAL ONCOLOGY . vol. 31 ,

Powles T, Bex A ( 2013 ) . Integration of surgery in metastatic renal cancer . Renal Cell Carcinoma: Clinical Management ,

Kroon BK, de Bruijn R, Prevoo W, Horenblas S, Powles T, Bex A ( 2013 ) . Probability of Downsizing Primary Tumors of Renal Cell Carcinoma by Targeted Therapies Is Related to Size at Presentation . UROLOGY vol. 81 , ( 1 ) 111 - 115 .

Powles T, Crusz SM ( 2013 ) . Sequencing systemic therapies in advanced RCC: is there a best strategy? . Am Soc Clin Oncol Educ Book

Powles T, Kollmannsberger C, Feldman DR ( 2013 ) . The conundrum of clinical trials in adult germ-cell tumours . Lancet Oncol vol. 14 , ( 1 ) 14 - 15 .

O'Mahony FC, Nanda J, Laird A, Mullen P, Caldwell H, Overton IM, Eory L, O'Donnell M et al. ( 2013 ) . The use of reverse phase protein arrays (RPPA) to explore protein expression variation within individual renal cell cancers . Journal of visualized experiments : JoVE ( 71 )

Welti JC, Powles T, Foo S, Gourlaouen M, Preece N, Foster J, Frentzas S, Bird D et al. ( 2012 ) . Contrasting effects of sunitinib within in vivo models of metastasis . ANGIOGENESIS vol. 15 , ( 4 ) 623 - 641 .

Powles T, Albers P ( 2012 ) . Management of favorable-risk patients with metastatic renal cell carcinoma: when to start and when to stop targeted therapy . Clin Genitourin Cancer vol. 10 , ( 4 ) 213 - 218 .

Lim L, Powles T ( 2012 ) . The management of low-stage non-seminomatous germ cell tumors . Oncology Reviews vol. 6 , ( 2 ) 153 - 157 .

Powles T, Sarwar N, Jones R, Wilson P, Boleti E, Protheroe A, Crabb SJ, Shamash J et al. ( 2012 ) . An indirect comparison of the toxicity of sunitinib and pazopanib in metastatic clear cell renal cancer . Eur J Cancer vol. 48 , ( 17 ) 3171 - 3176 .

Stewart GD, O'Mahony FC, Eory L, Nanda J, Laird A, O'Donnell M, Mullen P, Riddick ACP et al. ( 2012 ) . Proteomic analysis of pre- and postsunitinib treated renal cancer tissue to assess tumour heterogeneity and differential protein expression . SCOTTISH MEDICAL JOURNAL vol. 57 , ( 4 ) 245 - 246 .

Sharpe K, Lu Y, Berney D, Rofe C, Powles T ( 2012 ) . 501 Preclinical Data Investigating the Use of Saracatinib in Renal Cell Carcinoma . Annals of Oncology vol. 23 ,

Powles TB, Jones RJ, Crabb S, Sarker S, Boleti E, Shamash J, Sarwar N, Chowdhury S ( 2012 ) . 822P A Phase I Dose Escalation Study Investigating Dovitinib and Everolmus in Combination in Metastatic Clear Cell Renal Cancer Patients who have Previously Failed VEGF Targeted Therapy . Annals of Oncology vol. 23 ,

Lim FL, Shamash J, Wilson P, Powles T ( 2012 ) . 880 Liver Toxicity in Patients with Metastatic Renal Cell Carcinoma Treated with Pazopanib Therapy . Annals of Oncology vol. 23 ,

Powles TB, Jones RJ, Crabb S, Sarker S, Boleti E, Shamash J, Sarwar N, Chowdhury S ( 2012 ) . A PHASE I DOSE ESCALATION STUDY INVESTIGATING DOVITINIB AND EVEROLMUS IN COMBINATION IN METASTATIC CLEAR CELL RENAL CANCER PATIENTS WHO HAVE PREVIOUSLY FAILED VEGF TARGETED THERAPY . ANNALS OF ONCOLOGY . vol. 23 , 272 - 272 .

Meeks JJ, Bellmunt J, Bochner BH, Clarke NW, Daneshmand S, Galsky MD, Hahn NM, Lerner SP et al. ( 2012 ) . A Systematic Review of Neoadjuvant and Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer . EUROPEAN UROLOGY vol. 62 , ( 3 ) 523 - 533 .

Powles T, Hutson TE ( 2012 ) . Difficulty in predicting survival in metastatic renal cancer . Lancet Oncol vol. 13 , ( 9 ) 859 - 860 .

Lim FL, Shamash J, Wilson P, Powles T ( 2012 ) . LIVER TOXICITY IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA TREATED WITH PAZOPANIB THERAPY . ANNALS OF ONCOLOGY . vol. 23 , 290 - 290 .

Porta C, Tortora G, Linassier C, Papazisis K, Awada A, Berthold D, Maroto JP, Powles T et al. ( 2012 ) . Maximising the duration of disease control in metastatic renal cell carcinoma with targeted agents: an expert agreement . MEDICAL ONCOLOGY vol. 29 , ( 3 ) 1896 - 1907 .

Birtle AJ, Lewis R, Chester J, Donovan J, Johnson M, Jones RJ, Kockelbergh R, Powles TB et al. ( 2012 ) . PERI-OPERATIVE CHEMOTHERAPY OR SURVEILLANCE IN UPPER TRACT UROTHELIAL CANCER ( POUT - CRUK/11/027) - A NEW RANDOMISED CONTROLLED TRIAL TO DEFINE STANDARD POST-OPERATIVE MANAGEMENT . ANNALS OF ONCOLOGY . vol. 23 , 292 - 292 .

Sharpe K, Lu Y, Berney D, Rofe C, Powles T ( 2012 ) . PRECLINICAL DATA INVESTIGATING THE USE OF SARACATINIB IN RENAL CELL CARCINOMA . ANNALS OF ONCOLOGY . vol. 23 , 172 - 172 .

Pons Valladares F, Choueiri TK, Hutson TE, Powles TB, Porta C, Bracarda S, Lampron ME, Cerbone L et al. ( 2012 ) . SEQUENTIAL TARGETED THERAPY FOLLOWING PAZOPANIB (PZ) IN PATIENTS (PTS) WITH METASTATIC RENAL CELL CANCER (MRCC): EFFICACY AND TOXICITY . ANNALS OF ONCOLOGY . vol. 23 , 278 - 278 .

Porta C, Powles T ( 2012 ) . Sequential therapy in metastatic renal cell carcinoma: what comes next? . MEDICAL ONCOLOGY vol. 29 , ( 3 ) 1914 - 1915 .

Blick C, Hall P, Pwint T, Al-Terkait F, Crew J, Powles T, Macaulay V, Munro N et al. ( 2012 ) . Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (AMVAC) as neoadjuvant chemotherapy for patients with muscle-invasive transitional cell carcinoma of the bladder . CANCER vol. 118 , ( 16 ) 3920 - 3927 .

Thillai K, Allan S, Powles T, Rudman S, Chowdhury S ( 2012 ) . Neoadjuvant and adjuvant treatment of renal cell carcinoma . EXPERT REVIEW OF ANTICANCER THERAPY vol. 12 , ( 6 ) 765 - 776 .

Powles T ( 2012 ) . Second-line therapy after VEGF targeted therapy in metastatic renal cancer: a law of diminishing returns . Clin Genitourin Cancer vol. 10 , ( 2 ) 67 - 68 .

Bex A, Powles T ( 2012 ) . Selecting patients for cytoreductive nephrectomy in advanced renal cell carcinoma: who and when . EXPERT REVIEW OF ANTICANCER THERAPY vol. 12 , ( 6 ) 787 - 797 .

Rashid S, Lim L, Powles T ( 2012 ) . Treatment of relapsed/refractory germ cell tumours: an equipoise between conventional and high dose therapy . Curr Treat Options Oncol vol. 13 , ( 2 ) 201 - 211 .

Bex A, Powles T, Blank CU, Chowdhury S, Horenblas S, Peters J, Boleti E, Haanen JBAG ( 2012 ) . Outcome of rapid disease progression in the treatment break following cytoreductive nephrectomy (CN) after presurgical sunitinib in patients with primary metastatic renal cell carcinoma (RCC) . JOURNAL OF CLINICAL ONCOLOGY . vol. 30 ,

Badreldin W, Chowdhury S, Harland SJ, Mazhar D, Powles T, Wilson P, Shamash J ( 2012 ) . The efficacy of irinotecan, paclitaxel, and oxaliplatin (IPO) in relapsed germ cell tumours: A non-cisplatin-based regimen . JOURNAL OF CLINICAL ONCOLOGY . vol. 30 ,

Kitromilidou C, McDonald D, Cutillas P, Ghazaly E, Perry J, Csaba B, Joel S, Powles T ( 2012 ) . Abstract 1792: The potential role of targeting HER1-4 in bladder cancer . Cancer Research vol. 72 , ( 8_Supplement ) 1792 - 1792 .

Shamash J, Jacob J, Agrawal S, Powles T, Mutsvangwa K, Wilson P, Stebbing J ( 2012 ) . Whole blood stem cell reinfusion and escalated dose melphalan in castration-resistant prostate cancer: a phase 1 study . Clin Cancer Res vol. 18 , ( 8 ) 2352 - 2359 .

Kitromilidou C, Ghazaly E, Joel S, Powles T ( 2012 ) . COMBINING HER1-4 TARGETED THERAPIES AND CHEMOTHERAPY IN BLADDER CANCER . ANNALS OF ONCOLOGY . vol. 23 , 35 - 35 .

Stewart GD, O'Mahony F, Eory L, Nanda J, Laird A, O'Donnell M, Mullen P, Riddick A et al. ( 2012 ) . Proteomic analysis of pre- and post-sunitinib treated renal cancer tissue to assess tumor heterogeneity and differential protein expression . JOURNAL OF CLINICAL ONCOLOGY vol. 30 , ( 5 )

Karpathakis A, Jamal-Hanjani M, Kwan A, Mazhar D, Rudman SM, Powles T, Shamash J, Chowdhury S ( 2012 ) . Testicular germ cell tumors with bony metastases: Diagnosis, management, and outcomes (a case series) . JOURNAL OF CLINICAL ONCOLOGY vol. 30 , ( 5 )

Boleti E, Sarwar N, Jones RR, Chowdhury S, Crabb SJ, Shamash J, Peters J, Oades G et al. ( 2012 ) . The safety and efficacy of pazopanib prior to planned nephrectomy in metastatic clear cell renal cancer . JOURNAL OF CLINICAL ONCOLOGY vol. 30 , ( 5 )

Doshi R, O'Donnel M, Bex A, Beltran L, Sahdev A, Peters J, Harrison DJ, Stewart GD et al. ( 2012 ) . Renal Cell Carcinoma before and after Sunitinib Therapy. Morphological and Molecular Changes . LABORATORY INVESTIGATION . vol. 92 , 201A - 201A .

Gurung PMS, Williamson M, West C, Counsell N, Ahmed A, Benthani F, Feber A, Dewinter P et al. ( 2012 ) . The tumour suppressor gene, AIMP3 sensitises bladder cancer to chemo/radiotherapy in vitro and is a prognostic marker for overall survival in patients treated with radiotherapy for muscle invasive disease . EUROPEAN UROLOGY SUPPLEMENTS vol. 11 , ( 1 ) E669 - U430 .

Lim L, Powles T ( 2012 ) . New prognostic models in metastatic renal cancer . Translational Andrology and Urology vol. 1 , ( 3 ) 144 - 145 .

Shaw GL, Hussain M, Nair R, Bycroft J, Beltran L, Green JSA, Powles T, Peters JL ( 2012 ) . Performing Cytoreductive Nephrectomy following Targeted Sunitinib Therapy for Metastatic Renal Cell Carcinoma: A Surgical Perspective . UROLOGIA INTERNATIONALIS vol. 89 , ( 1 ) 83 - 88 .

Kalin M, Cima I, Schiess R, Fankhauser N, Powles T, Wild P, Templeton A, Cerny T et al. ( 2011 ) . Novel Prognostic Markers in the Serum of Patients With Castration-Resistant Prostate Cancer Derived From Quantitative Analysis of the Pten Conditional Knockout Mouse Proteome . EUR UROL vol. 60 , ( 6 ) 1235 - 1243 .

Josephs D, Hutson TE, Cowey CL, Pickering LM, Larkin JM, Gore ME, Van Hemelrijck M, McDermott DF et al. ( 2011 ) . Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with severe renal impairment or on haemodialysis . BJU INT vol. 108 , ( 8 ) 1279 - 1283 .

Josephs D, Hutson TE, Cowey CL, Pickering LM, Larkin JM, Gore ME, Van Hemelrijck M, McDermott DF et al. ( 2011 ) . Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with severe renal impairment or on haemodialysis . BJU Int vol. 108 , ( 8 ) 1279 - 1283 .

Stephenson AJ, Aprikian AG, Gilligan TD, Oldenburg J, Powles T, Toner GC, Waters WB ( 2011 ) . Management of Low-stage Nonseminomatous Germ Cell Tumors of Testis: SIU/ICUD Consensus Meeting on Germ Cell Tumors (GCT), Shanghai 2009 . UROLOGY vol. 78 , ( 4 ) S444 - S455 .

Kayani I, Avril N, Bomanji J, Chowdhury S, Rockall A, Sahdev A, Nathan P, Wilson P et al. ( 2011 ) . Sequential FDG-PET/CT as a biomarker of response to Sunitinib in metastatic clear cell renal cancer . Clin Cancer Res vol. 17 , ( 18 ) 6021 - 6028 .

Rimmer Y, Chester J, Joffe J, Stark D, Shamash J, Powles T, White J, Wason J et al. ( 2011 ) . Accelerated BEP: a phase I trial of dose-dense BEP for intermediate and poor prognosis metastatic germ cell tumour . BRIT J CANCER vol. 105 , ( 6 ) 766 - 772 .

Bex A, Powles T ( 2011 ) . Reply from Authors re: Simon P. Kim, R. Houston Thompson. Sunitinib Prior to Planned Cytoreductive Nephrectomy: Is This the New Litmus Test for Metastatic Renal Cell Carcinoma? Eur Urol 2011;60:455-6 . EUR UROL vol. 60 , ( 3 ) 456 - 457 .

Powles T, Blank C, Chowdhury S, Horenblas S, Peters J, Shamash J, Sarwar N, Boleti E et al. ( 2011 ) . The outcome of patients treated with sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer . Eur Urol vol. 60 , ( 3 ) 448 - 454 .

Bex A, Powles T ( 2011 ) . Reply to The sequence of cytoreductive nephrectomy: glass half empty or glass half full? . ANN ONCOL vol. 22 , ( 7 ) 1691 - 1691 .

Lorch A, Bascoul-Mollevi C, Kramar A, Einhorn L, Necchi A, Massard C, De Giorgi U, Flechon A et al. ( 2011 ) . Conventional-Dose Versus High-Dose Chemotherapy As First Salvage Treatment in Male Patients With Metastatic Germ Cell Tumors: Evidence From a Large International Database . J CLIN ONCOL vol. 29 , ( 16 ) 2178 - 2184 .

Powles T ( 2011 ) . Stage I nonseminomatous germ cell tumor of the testis: more questions than answers? . Hematol Oncol Clin North Am vol. 25 , ( 3 ) 517 - viii .

Lerner SP, Powles T, Hahn NM, Gardner T, Cheng L, Green J, Berney D, Taber D et al. ( 2011 ) . A phase II trial of neoadjuvant cisplatin (C), gemcitabine (G), and sunitinib (S) in muscle-invasive urothelial carcinoma (miUC): Results from Hoosier Oncology Group GU07-123 trial . JOURNAL OF CLINICAL ONCOLOGY vol. 29 , ( 15 )

Fizazi K, Powles T, George DJ, Poehlein CH ( 2011 ) . A randomized, controlled phase III global trial comparing sipuleucel-T plus androgen deprivation therapy versus androgen deprivation therapy alone in men with metastatic androgen dependent (hormone sensitive) prostate cancer . JOURNAL OF CLINICAL ONCOLOGY vol. 29 , ( 15 )

Chen GJ, Sonpavde G, Vale CL, Fisher D, Powles T, ABCMAC ( 2011 ) . Association of progression-free survival (PFS) at 2 or 3 years with overall survival (OS) at 5 years for locally advanced bladder cancer (BC): Evaluation of individual patient data (IPD) from seven randomized trials comparing local therapy with or without neoadjuvant chemotherapy (NC) . JOURNAL OF CLINICAL ONCOLOGY vol. 29 , ( 15 )

Shamash J, Jacob J, Powles T, Agrawal S, Mutsvangwa K, Saunders N, Wilson P, Stebbing J ( 2011 ) . Melphalan and whole-blood stem cell reinfusion in castration-resistant prostate cancer (CRPC): A phase I/II study . JOURNAL OF CLINICAL ONCOLOGY vol. 29 , ( 15 )

Powles T, Mollevi C, Kramar A, Lorch A, Beyer J, IPFSG ( 2011 ) . The prognostic significance of LDH levels in patients with relapsed/refractory seminoma and their predictive value of the new international prognostic score . JOURNAL OF CLINICAL ONCOLOGY vol. 29 , ( 15 )

Powles T, Kayani I, Blank C, Chowdhury S, Horenblas S, Peters J, Shamash J, Sarwar N et al. ( 2011 ) . The safety and efficacy of sunitinib before planned nephrectomy in metastatic clear cell renal cancer . Annals of Oncology vol. 22 , ( 5 ) 1041 - 1047 .

Stewart GD, O'Mahony FC, Powles T, Riddick ACP, Harrison DJ, Faratian D ( 2011 ) . What can molecular pathology contribute to the management of renal cell carcinoma? . NAT REV UROL vol. 8 , ( 5 ) 255 - 265 .

Powles T, Chowdhury S, Shamash J, Bazeos A, Gillessen S, Saunders N, Lim L, Sarwar N et al. ( 2011 ) . Increased haematopoietic progenitor cells are associated with poor outcome in patients with metastatic renal cancer treated with sunitinib . Ann Oncol vol. 22 , ( 4 ) 815 - 820 .

Welti JC, Gourlaouen M, Powles T, Kudahetti SC, Wilson P, Berney DM, Reynolds AR ( 2011 ) . Fibroblast growth factor 2 regulates endothelial cell sensitivity to sunitinib . Oncogene vol. 30 , ( 10 ) 1183 - 1193 .

Hussain M, Nair R, Bycroft J, Green JSA, Powles T, Peters JL ( 2011 ) . A COMPARISON OF OPEN RADICAL NEPHRECTOMY COMPLICATION RATES IN PATIENTS TREATED WITH NEOADJUVANT SUNITINIB FOR METASTATIC RENAL CELL CARCINOMA VERSUS NON-METASTATIC RENAL CELL CARCINOMA . EUR UROL SUPPL vol. 10 , ( 2 ) 103 - 103 .

Blick C, Hall P, Pwint T, Munro N, Crew J, Powles T, Macaulay VM, Al-Terkait F et al. ( 2011 ) . Accelerated MVAC as neoadjuvant chemotherapy for patients with muscle-invasive transitional cell carcinoma of the bladder . JOURNAL OF CLINICAL ONCOLOGY vol. 29 , ( 7 )

Powles T, Chowdhury S, Avril N, Bomanji J, Shamash J, Sarwar N, Rockall A, Sahdev A et al. ( 2011 ) . Sequential FDG-PET/CT as a surrogate marker of response to sunitinib in metastatic clear cell renal cancer . JOURNAL OF CLINICAL ONCOLOGY vol. 29 , ( 7 )

Powles T, Chowdhury S, Avril N, Bomanji J, Shamash J, Sarwar N, Rockall A, Sahdev A et al. ( 2011 ) . Sequential FDG-PET/CT as a surrogate marker of response to sunitinib in metastatic clear cell renal cancer . J Clin Oncol vol. 29 , ( 7_suppl )

Powles T, Chowdhury S, Jones R, Mantle M, Nathan P, Bex A, Lim L, Hutson T ( 2011 ) . Sunitinib and other targeted therapies for renal cell carcinoma . Br J Cancer vol. 104 , ( 5 ) 741 - 745 .

Powles T, Blank C, Chowdhury S, Peters J, Haanen J, O'Brien T, Rockall AR, Sahdev AS et al. ( 2011 ) . THE OUTCOME OF PATIENTS TREATED WITH UPFRONT SUNITINIB PRIOR TO NEPHRECTOMY IN METASTATIC CLEAR CELL RENAL CANCER . EUR UROL SUPPL vol. 10 , ( 2 ) 102 - 103 .

Shamash J, Powles T, Sarker SJ, Protheroe A, Mithal N, Mills R, Beard R, Wilson P et al. ( 2011 ) . A multi-centre randomised phase III trial of Dexamethasone vs Dexamethasone and diethylstilbestrol in castration-resistant prostate cancer: immediate vs deferred Diethylstilbestrol . BRIT J CANCER vol. 104 , ( 4 ) 620 - 628 .

Feldman DR, Huddart R, Hall E, Beyer J, Powles T ( 2011 ) . Is High Dose Therapy Superior to Conventional Dose Therapy as Initial Treatment for Relapsed Germ Cell Tumors? The TIGER Trial . JOURNAL OF CANCER vol. 2 , 374 - 377 .

Powles T, Chowdhury S, Bower M, Saunders N, Lim L, Shamash J, Sarwar N, Sadev A et al. ( 2011 ) . The Effect of Sunitinib on Immune Subsets in Metastatic Clear Cell Renal Cancer . UROL INT vol. 86 , ( 1 ) 53 - 59 .

Bex A, Jonasch E, Kirkali Z, Mejean A, Mulders P, Oudard S, Patard JJ, Powles T et al. ( 2010 ) . Integrating Surgery with Targeted Therapies for Renal Cell Carcinoma: Current Evidence and Ongoing Trials . EUR UROL vol. 58 , ( 6 ) 819 - 828 .

Lorch A, Beyer J, Kramar A, Einhorn LH, Necchi A, Massard C, De Giorgi U, Flechon A et al. ( 2010 ) . Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy . Journal of Clinical Oncology vol. 28 , ( 33 ) 4906 - 4911 .

LaCroix AZ, Powles T, Osborne CK, Wolter K, Thompson JR, Thompson DD, Allred DC, Armstrong R et al. ( 2010 ) . Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women . J Natl Cancer Inst vol. 102 , ( 22 ) 1706 - 1715 .

Gerlinger M, Wilson P, Powles T, Shamash J ( 2010 ) . Elevated LDH predicts poor outcome of recurrent germ cell tumours treated with dose dense chemotherapy . Eur J Cancer vol. 46 , ( 16 ) 2913 - 2918 .

Poffiri E, Miscoria M, Lim L, Shamash J, Chowdhury S, Powles T ( 2010 ) . THE OUTCOME OF PATIENTS WHO FAIL SUNITINIB AND DO NOT HAVE ACCESS TO SUNITINIB THERAPY . ANNALS OF ONCOLOGY . vol. 21 , 292 - 292 .

Oliver T, Chung PWM, Powles T, Jewett MAS ( 2010 ) . Treatment: Seminoma: Stage I . Cancer of the Testis ,

Shamash J, Stebbing J, Sweeney C, Sonpavde G, Harland S, Dawkins G, Brock C, Abelman W et al. ( 2010 ) . A validated prognostic index predicting response to dexamethasone and diethylstilbestrol in castrate-resistant prostate cancer . Cancer vol. 116 , ( 15 ) 3595 - 3602 .

Gillessen S, Powles T, Lim L, Wilson P, Shamash J ( 2010 ) . Low-dose induction chemotherapy with Baby-BOP in patients with metastatic germ-cell tumours does not compromise outcome: a single-centre experience . Ann Oncol vol. 21 , ( 8 ) 1589 - 1593 .

Matakidou A, Mutsvangwa K, Ansell W, Lim L, Powles TB, Oliver RT, Shamash J ( 2010 ) . Single-agent carboplatin AUC10 for metastatic seminoma with IGCCCG good prognosis disease; a feasibility study of the Orchid Clinical Trials Group . Ann Oncol vol. 21 , ( 8 ) 1730 - 1731 .

Powles T, Jones R, Chowdhury S, Shamash J, Mantle M, Lim L, Hutson T ( 2010 ) . The application of the National Institute of Clinical Excellence guidelines for treatment of metastatic renal cell carcinoma in the United Kingdom: friend or foe? . BJU Int vol. 106 , ( 4 ) 453 - 457 .

Noel EE, Yeste-Velasco M, Mao X, Perry J, Kudahetti SC, Li NF, Sharp S, Chaplin T et al. ( 2010 ) . The association of CCND1 overexpression and cisplatin resistance in testicular germ cell tumors and other cancers . Am J Pathol vol. 176 , ( 6 ) 2607 - 2615 .

Avril N, Dambha F, Murray I, Shamash J, Powles T, Sahdev A ( 2010 ) . The clinical advances of fluorine-2-D-deoxyglucose--positron emission tomography/computed tomography in urological cancers . Int J Urol vol. 17 , ( 6 ) 501 - 511 .

Escudier BJ, Cella D, Gschwend JE, Powles T, Sternberg CN, Hodge R, Lau M, Neary M et al. ( 2010 ) . A randomized double-blind cross-over patient preference study of pazopanib versus sunitinib in treatment-naive locally advanced or metastatic renal cell carcinoma (mRCC) . JOURNAL OF CLINICAL ONCOLOGY vol. 28 , ( 15 )

Chowdhury S, O'Brien TS, Sarwar N, Shamash J, McGrath S, Agrawal S, Lim L, Rudman SM et al. ( 2010 ) . The effect of sunitinib on immune parameters and haemopoetic stem cell markers in patients with untreated cleat cell renal cancer . JOURNAL OF CLINICAL ONCOLOGY vol. 28 , ( 15 )

Powles T, Kayani I, Blank CU, Chowdhury S, Horenblas S, Sarwar N, Nathan PD, Boleti E et al. ( 2010 ) . The safety and efficacy of sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer . Journal of Clinical Oncology vol. 28 , ( 15_suppl ) 4603 - 4603 .

Bharwani N, Miquel M, Sahdev A, Powles T, Reznek R, Rockall A ( 2010 ) . Diffusion-Weighted MRI in the Assessment of Tumor Response to Novel Targeted Therapies in Metastatic Renal Cell Carcinoma . AMERICAN JOURNAL OF ROENTGENOLOGY . vol. 194 ,

Powles T, Peters J, Horenblas S, Meinhardt W, O'Brien T, Sahdev A, Lim L, Green J et al. ( 2010 ) . 101 PRESURGICAL SUNITINIB IN METASTATIC CLEAR CELL RENAL CANCER (MRCC): SURGICAL SAFETY AND EFFECT ON THE PRIMARY TUMOUR . European Urology Open Science . vol. 9 , 64 - 65 .

El-Hariry I, Powles T, Lau MR, Sternberg CN, Ravaud A, von der Maase H, Zantl N, Harper P et al. ( 2010 ) . Amplification of epidermal growth factor receptor gene in renal cell carcinoma . EUR J CANCER vol. 46 , ( 5 ) 859 - 862 .

Perry J, Ghazaly E, Kitromilidou C, McGrowder EH, Joel S, Powles T ( 2010 ) . A Synergistic interaction between lapatinib and chemotherapy agents in a panel of cell lines is due to the inhibition of the efflux pump BCRP . Molecular Cancer Therapeutics vol. 9 , ( 12 ) 3315 - 3321 .

Chowdhury S, Harper P, Powles T ( 2010 ) . Castration Refractory Prostate Cancer: Cinderella Finally Comes to the Ball . ONKOLOGIE vol. 33 , ( 12 ) 655 - 656 .

Matakidou A, Mutsvangwa K, Ansell W, Powles T, Oliver T, Shamash J ( 2009 ) . Single-agent Carboplatin AUC10 for Metastatic Seminoma with IGCCCG Good Prognosis Disease; a Feasibility Study of the Orchid Clinical Trials Group . CLIN ONCOL-UK vol. 21 , ( 10 ) 800 - 800 .

Perry J, Powles T, Shamash J, Veerupillai A, McGrowder E, Noel E, Lu Y-J, Oliver T et al. ( 2009 ) . The relative activity of cisplatin, oxaliplatin and satraplatin in testicular germ cell tumour sensitive and resistant cell lines . Cancer Chemother Pharmacol vol. 64 , ( 5 ) 925 - 933 .

Murugaesu N, Powles T, Bestwick J, Oliver RTD, Shamash J ( 2009 ) . Long-term follow-up of testicular cancer patients shows no predisposition to osteoporosis . Osteoporos Int vol. 20 , ( 9 ) 1627 - 1630 .

Josephs DH, Hutson TE, Pickering LM, Larkin JM, Choueiri TK, Patel TV, Mcdermott DF, Powles T et al. ( 2009 ) . Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma (mRCC) with severe renal impairment or on haemodialysis . JOURNAL OF CLINICAL ONCOLOGY . vol. 27 ,

Josephs DH, Hutson TE, Pickering LM, Larkin JM, Choueiri TK, Patel TV, Mcdermott DF, Powles T et al. ( 2009 ) . Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma (mRCC) with severe renal impairment or on haemodialysis . J Clin Oncol vol. 27 , ( 15_suppl )

Hahn NM, Powles T, Sweeney CJ ( 2009 ) . Development of novel agents for bladder cancer . Update on Cancer Therapeutics vol. 3 , ( 4 ) 160 - 169 .

Perry J, Kitromilidou C, McGrowder E, Madadi L, Joel S, Powles T ( 2009 ) . Lapatinib combination studies in solid tumor cell lines . CANCER RESEARCH . vol. 69 ,

Nathan P, Wagstaff J, Porfiri E, Powles T, Eisen T ( 2009 ) . UK guidelines for the systemic treatment of renal cell carcinoma . BRIT J HOSP MED vol. 70 , ( 5 ) 284 - 286 .

Powles T, Robinson D, Stebbing J, Nelson M, Mandalia S, Moller H, Gazzard B, Bower M ( 2009 ) . Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection . HIV MED vol. 10 , 4 - 4 .

Powles T, Stebbing J, Bazeos A, Hatzimichael E, Mandalia S, Nelson M, Gazzard B, Bower M ( 2009 ) . The role of immune suppression and HHV-8 in the increasing incidence of HIV-associated multicentric Castleman's disease . Ann Oncol vol. 20 , ( 4 ) 775 - 779 .

Gerlinger M, Wilson P, Powles T, Oliver RTD, Shamash J ( 2009 ) . ESTABLISHED PROGNOSTIC MODELS FAIL TO PREDICT THE OUTCOME OF DOSE DENSE CHEMOTHERAPY FOR THE TREATMENT OF RECURRENT GERM CELL TUMOURS (GCTS) . EUR UROL SUPPL vol. 8 , ( 4 ) 358 - 358 .

Powles T, Robinson D, Stebbing J, Shamash J, Nelson M, Gazzard B, Mandelia S, Moller H et al. ( 2009 ) . Highly Active Antiretroviral Therapy and the Incidence of Non-AIDS-Defining Cancers in People With HIV Infection . J CLIN ONCOL vol. 27 , ( 6 ) 884 - 890 .

Stancliffe M, Powles T, Bower M ( 2009 ) . HIV-related lung cancer in the age of HAART . Multidisciplinary Respiratory Medicine vol. 4 , ( 3 ) 225 - 228 .

Stebbing J, Powles T, McPherson K, Shamash J, Wells P, Sheaff MT, Slater S, Rudd RM et al. ( 2009 ) . The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma . Lung Cancer vol. 63 , ( 1 ) 94 - 97 .

Nelson M, Powles T, Zeitlin A, Sen P, Scourfield A, Bower M, Gazzard B, Stebbing J ( 2009 ) . Thyroid dysfunction and relationship to antiretroviral therapy in hiv-positive individuals in the HAART era . Journal of Acquired Immune Deficiency Syndromes vol. 50 , ( 1 ) 113 - 114 .

Oliver T, Powles T, Nargund V, Berney D ( 2008 ) . Spontaneous regression of renal cell carcinoma and the role of prognostic factors . Clinical Management of Renal Tumors ,

Oliver T, Shamash J, Powles T, Reznek R, Badenoch D, Nargund V ( 2008 ) . POD-2.08: Chemotherapy for Testis Conservation in Patients with Germ Cell Cancer (GCC): Is It Safe and Could Combination with Tumour Enucleation Increase the Frequency of Success? . Urology vol. 72 , ( 5 ) s35 - s36 .

Jones R, Nelson M, Bower M, Powles T, Mandalia S, Gazzard B, Stebbing J ( 2008 ) . Triple-class antiretroviral agent resistance in a large cohort: Prevalence and clinical outcomes . ARCH INTERN MED vol. 168 , ( 17 ) 1926 - 1927 .

Gaughan EM, Dezube BJ, Aboulafia D, Bower M, Strebbing J, Powles T, Pantanowitz L ( 2008 ) . Human immunodeficiency virus-associated renal cell carcinoma: A transatlantic case series . CLIN GENITOURIN CANC vol. 6 , ( 2 ) 86 - 90 .

Bazoes A, Bower M, Powles T ( 2008 ) . Smoke and mirrors: HIV-related lung cancer . Curr Opin Oncol vol. 20 , ( 5 ) 529 - 533 .

Powles T, McFaul S, Stebbing J, Wilson P, Oliver T, Tranter N, Shamash J ( 2008 ) . The efficacy and safety of irinotecan cisplatin and mitomycin chemotherapy in sunitinib pre-treated metastatic clear cell renal cancer . Onco Targets Ther vol. 1 , 35 - 39 .

Bower M, Collins S, Cottrill C, Cwynarski K, Montoto S, Nelson M, Nwokolo N, Powles T et al. ( 2008 ) . British HIV Association guidelines for HIV-associated malignancies 2008 . HIV MED vol. 9 , ( 6 ) 336 - 388 .

Perry J, Nsubuga E, Joel S, Shamash J, El-Hariry I, Powles T ( 2008 ) . A synergistic interaction between lapatinib and topoisomerase I inhibitors in cisplatin sensitive and resistant cancer cell lines . JOURNAL OF CLINICAL ONCOLOGY vol. 26 , ( 15 )

Gerlinger M, Wilson P, Powles T, Shamash J ( 2008 ) . Non-castrate status at the end of chemotherapy for metastatic hormone-resistant prostate cancer (HRPC) correlates with a better overall survival . JOURNAL OF CLINICAL ONCOLOGY vol. 26 , ( 15 )

Bower M, Stebbing J, Tuthill MH, Krell J, Campbell V, Nelson M, Gazzard B, Powles T ( 2008 ) . Recovery of cellular immunity following chemotherapy for AIDS related non Hodgkin's lymphoma . JOURNAL OF CLINICAL ONCOLOGY vol. 26 , ( 15 )

Bazeos A, Powles T, Stebbing J, Mandalia S, Bower M ( 2008 ) . The increasing incidence of HIV-associated multicentric Castlemans disease . JOURNAL OF CLINICAL ONCOLOGY vol. 26 , ( 15 )

Stebbing J, Powles T, Mandalia S, Nelson M, Gazzard B, Bower M ( 2008 ) . Use of antidepressants and risk of cancer in individuals infected with HIV . J CLIN ONCOL vol. 26 , ( 14 ) 2305 - 2310 .

Bower M, Stebbing J, Tuthill M, Campbell V, Krell J, Holmes P, Ozzard A, Nelson M et al. ( 2008 ) . Immunologic recovery in survivors following chemotherapy for AIDS-related non-Hodgkin lymphoma . BLOOD vol. 111 , ( 8 ) 3986 - 3990 .

Sonpavde G, Ross R, Powles T, Sweeney CJ, Hahn N, Hutson TE, Galsky MD, Lerner SP et al. ( 2008 ) . Novel agents for muscle-invasive and advanced urothelial cancer . BJU INT vol. 101 , ( 8 ) 937 - 943 .

Macdonald DC, Nelson M, Bower M, Powles T ( 2008 ) . Hepatocellular carcinoma, human immunodeficiency virus and viral hepatitis in the HAART era . WORLD J GASTROENTERO vol. 14 , ( 11 ) 1657 - 1663 .

Krege S, Beyer J, Souchon R, Albers P, Albrecht W, Algaba F, Bamberg M, Bodrogi I et al. ( 2008 ) . European consensus conference on diagnosis and treatment of germ cell cancer: A report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): Part I . EUR UROL vol. 53 , ( 3 ) 478 - 496 .

Krege S, Beyer J, Souchon R, Albers P, Albrecht W, Alyaba F, Bamberg M, Bodrogi I et al. ( 2008 ) . European consensus conference on diagnosis and treatment of germ cell cancer: A report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): Part II . EUR UROL vol. 53 , ( 3 ) 497 - 513 .

Powles T, Robinson D, Shamash J, Moller H, Tranter N, Oliver T ( 2008 ) . The long-term risks of adjuvant carboplatin treatment for stage I seminoma of the testis . ANN ONCOL vol. 19 , ( 3 ) 443 - 447 .

Stebbing J, Powles T, Bower M ( 2008 ) . AIDS-associated Kaposi's sarcoma associated with a low viral load and a high CD4 cell count . AIDS vol. 22 , ( 4 ) 551 - 552 .

Shamash J, Davies A, Ansell W, Mcfaul S, Wilson P, Oliver T, Powles T ( 2008 ) . A phase II study investigating the re-induction of endocrine sensitivity following chemotherapy in androgen-independent prostate cancer . BRIT J CANCER vol. 98 , ( 1 ) 22 - 24 .

Krege S, Beyer J, Souchon R, Albers P, Albrecht W, Algaba F, Bamberg M, Bodrogi I et al. ( 2008 ) . Corrigendum to: "European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer . European Urology vol. 54 , ( 2 )

Liu WM, Scott KA, Shamash J, Joel S, Powles TB ( 2008 ) . Enhancing the in vitro cytotoxic activity of Delta(9)-tetrahydrocannabinol in leukemic cells through a combinatorial approach . LEUKEMIA LYMPHOMA vol. 49 , ( 9 ) 1800 - 1809 .

Berney DM, Warren AY, Verma M, Kudahetti S, Robson JM, Williams MW, Neal DE, Powles T et al. ( 2008 ) . Malignant germ cell tumours in the elderly: a histopathological review of 50 cases in men aged 60 years or over . Mod Pathol vol. 21 , ( 1 ) 54 - 59 .

Waters L, Nelson M, Mandalia S, Bower M, Powles T, Gazzard B, Stebbing J ( 2008 ) . The risks and incidence of K65R and L74V mutations and subsequent virologic responses . CLIN INFECT DIS vol. 46 , ( 1 ) 96 - 100 .

Bower M, Powles T, Williams S, Davis TN, Atkins M, Montoto S, Orkin C, Webb A et al. ( 2007 ) . Brief communication: rituximab in HIV-associated multicentric Castleman disease . Ann Intern Med vol. 147 , ( 12 ) 836 - 839 .

Sonpavde G, Chi KN, Powles T, Sweeney CJ, Hahn N, Hutson TE, Galsky MD, Berry WR et al. ( 2007 ) . Neoadjuvant therapy followed by prostatectomy for clinically localized prostate cancer . Cancer vol. 110 , ( 12 ) 2628 - 2639 .

Powles T, Stebbing J, Montoto S, Nelson M, Gazzard B, Orkin C, Webb A, Bower M ( 2007 ) . Rituximab as retreatment for rituximab pretreated HIV-associated multicentric Castleman disease [4] . Blood vol. 110 , ( 12 ) 4132 - 4133 .

Davies CL, Chinn R, Nelson M, Rasanesan M, Gazzard B, Powles T, Bower M, Stebbing J ( 2007 ) . Outcome in AIDS-related systemic non-Hodgkin lymphoma and leptomeningeal disease is not predicted by a CT brain scan . AM J NEURORADIOL vol. 28 , ( 10 ) 1988 - 1990 .

Shamash J, Stebbing J, Powles T ( 2007 ) . Germ-cell tumors . NEW ENGL J MED vol. 357 , ( 17 ) 1771 - 1772 .

Shamash J, Powles T, Ansell W, Berney D, Stebbing J, Mutsvangwa K, Wilson P, Asterling S et al. ( 2007 ) . Erratum: GAMEC - A new intensive protocol for untreated poor prognosis and relapsed or refractory germ cell tumours (British Journal of Cancer (2007) 97, (308-314) DOI: 10.1038/6603865) . British Journal of Cancer vol. 97 , ( 8 )

Young AM, Powles T, Holmes P, Wang J, Nelson M, Anderson J, Bower MD, Brock CS ( 2007 ) . An HIV-associated mediastinal germ cell tumour complicated by acute myeloid leukaemia . Journal of HIV Therapy vol. 12 , ( 3 ) 68 - 71 .

Bazeos A, Powles T, Stebbing J ( 2007 ) . HIV-associated multicentric Castleman's disease: From case reports to evidence . Journal of HIV Therapy vol. 12 , ( 3 ) 61 - 62 .

Walters Z, Shamash J, Powles T ( 2007 ) . Prostate cancer in HIV-positive individuals: what we know and what we don't . J HIV Ther vol. 12 , ( 3 ) 66 - 67 .

Stebbing J, Nathan B, Jones R, McKenna A, Powles T, Bower M, Holmes P, Gazzard B et al. ( 2007 ) . Virological failure and subsequent resistance profiles in individuals exposed to atazanavir . AIDS vol. 21 , ( 13 ) 1826 - 1828 .

Shamash J, Powles T, Ansell W, Stebbing J, Mutsvangwa K, Wilson P, Asterling S, Liu S et al. ( 2007 ) . GAMEC - a new intensive protocol for untreated poor prognosis and relapsed or refractory germ cell tumours . BRIT J CANCER vol. 97 , ( 3 ) 308 - 314 .

Bower M, Powles T, Williams S, Newsom-Davis T, Atkins M, Stebbing J, Montoto S, Nelson M et al. ( 2007 ) . Rituximab induces long-term remissions in patients with HIV-associated multicentric Castleman's disease . Journal of Clinical Oncology vol. 25 , ( 18_suppl ) 8049 - 8049 .

Powles T, Oliver T, Ostrowski M, Levay J, Shamash J, Williams M ( 2007 ) . The long term side effects of adjuvant carboplatin for stage 1 seminoma . JOURNAL OF CLINICAL ONCOLOGY . vol. 25 ,

Powles T, Murray I, Brock C, Oliver T, Avril N ( 2007 ) . Molecular positron emission tomography and PET/CT imaging in urological malignancies . Eur Urol vol. 51 , ( 6 ) 1511 - 1520 .

Stebbing J, Sanitt A, Teague A, Powles T, Nelson M, Gazzard B, Bower M ( 2007 ) . Prognostic significance of immune subset measurement in individuals with AIDS-associated Kaposi's sarcoma . J CLIN ONCOL vol. 25 , ( 16 ) 2230 - 2235 .

Shamash J, Powles T, Mutsvangwa K, Wilson P, Ansell W, Walsh E, Berney D, Stebbing J et al. ( 2007 ) . A phase II study using a topoisomerase I-based approach in patients with multiply relapsed germ-cell tumours . ANN ONCOL vol. 18 , ( 5 ) 925 - 930 .

Powles T, Ell PJ ( 2007 ) . Does PET imaging have a role in renal cancers after all? . LANCET ONCOL vol. 8 , ( 4 ) 279 - 281 .

Stebbing J, Powles T ( 2007 ) . Stress in the workplace amongst medical professionals . J POSTGRAD MED vol. 53 , ( 2 ) 83 - 84 .

Powles T, Savage PM, Stebbing J, Short D, Young A, Bower M, Pappin C, Schmid P et al. ( 2007 ) . A comparison of patients with relapsed and chemo-refractory gestational trophoblastic neoplasia . BRIT J CANCER vol. 96 , ( 5 ) 732 - 737 .

Powles T, Perry J, Shamash J, Liu W, Oliver T, Joel S ( 2007 ) . A comparison of the platinum analogues in bladder cancer cell lines . UROL INT vol. 79 , ( 1 ) 67 - 72 .

Powles T, Young A, Sanitt A, Stebbing J, Short D, Bower M, Savage PM, Seckl MJ et al. ( 2006 ) . Erratum: The significance of the time interval between antecedent pregnancy and diagnosis of high-risk gestational trophoblastic tumours (British Journal of Cancer (2006) 95, (1145-1147) DOI: 10.1038/sj.bjc.6603416) . British Journal of Cancer vol. 95 , ( 12 )

Powles T, Young A, Sanitt A, Stebbing J, Short D, Bower M, Savage PM, Seckl MJ et al. ( 2006 ) . The significance of the time interval between antecedent pregnancy and diagnosis of high-risk gestational trophoblastic tumours . Br J Cancer vol. 95 , ( 9 ) 1145 - 1147 .

Powles T, Macdonald D, Nelson M, Stebbing J ( 2006 ) . Hepatocellular cancer in HIV-infected individuals: tomorrow's problem? . EXPERT REV ANTICANC vol. 6 , ( 11 ) 1553 - 1558 .

Powles T, Oliver T, Bower M ( 2006 ) . Non-AIDS-defining cancers in people with HIV infection: a sleeping giant? . J HIV Ther vol. 11 , ( 3 ) 57 - 60 .

Stebbing J, Powles T, Nelson M, Bower M ( 2006 ) . Significance of variation within HIV, EBV, and KSHV subtypes . Journal of the International Association of Physicians in AIDS Care vol. 5 , ( 3 ) 93 - 102 .

Bower M, Powles T, Nelson M, Mandalia S, Gazzard B, Stebbing J ( 2006 ) . Highly active antiretroviral therapy and human immunodeficiency virus - Associated primary cerebral lymphoma . Journal of the National Cancer Institute vol. 98 , ( 15 ) 1088 - 1091 .

Oliver R, Powles T, Ell P, Somasundram U, Shamash J ( 2006 ) . 22 year phase 1/2 study of single agent carboplatin in metastatic seminoma: Potential for acceleration by a new surrogate end point, 72 hr PET scan response? . J Clin Oncol vol. 24 , ( 18_suppl )

Powles T, Young A, Short D, Savage P, Pappin C, Schmid P, Seckl M ( 2006 ) . The outcome of patients with relapsed gestational trophoblastic neoplasm (GTN) after the completion of chemotherapy . JOURNAL OF CLINICAL ONCOLOGY . vol. 24 , 263S - 263S .

Stebbing J, Sanitt A, Nelson M, Powles T, Gazzard B, Bower M ( 2006 ) . A prognostic index for AIDS-associated Kaposi's sarcoma in the era of highly active antiretroviral therapy . Lancet vol. 367 , ( 9521 ) 1495 - 1502 .

Liu WM, Powles TB ( 2006 ) . Cannabinoids: Do they have a role in cancer therapy? . LETT DRUG DES DISCOV vol. 3 , ( 2 ) 76 - 82 .

Powles T, Savage P, Short D, Young A, Pappin C, Seckl MJ ( 2006 ) . Residual lung lesions after completion of chemotherapy for gestational trophoblastic neoplasia: should we operate? . BRIT J CANCER vol. 94 , ( 1 ) 51 - 54 .

Liu WM, Baird R, Sarker D, Powles T ( 2005 ) . Antiapoptotic effect of growth factors in leukemia [1] . Journal of Clinical Oncology vol. 23 , ( 3 )

Bhardwa JM, Powles T, Berney D, Baithun S, Nargund VH, Oliver RTD ( 2005 ) . Assessing the size and stage of testicular germ cell tumours: 1984-2003 . BJU Int vol. 96 , ( 6 ) 819 - 821 .

Waterston AM, Gumbrell L, Bratt T, Waller S, Gustav-Aspland J, L'Hermenier C, Bellenger K, Campbell M et al. ( 2005 ) . Phase I study of TNFα AutoVaccine in Patients with metastatic cancer . Cancer Immunology, Immunotherapy vol. 54 , ( 9 ) 848 - 857 .

Bower M, Gazzard B, Mandalia S, Newsom-Davis T, Thirlwell C, Dhillon T, Young AM, Powles T et al. ( 2005 ) . A prognostic index for systemic AIDS-related non-Hodgkin lymphoma treated in the era of highly active antiretroviral therapy . Annals of Internal Medicine vol. 143 , ( 4 )

Stebbing J, Mandalia S, Young AM, Dhillon T, Newshom-Davis T, Thirlwell C, Powles T, Nelson M et al. ( 2005 ) . A new prognostic index for systemic AIDS-related lymphoma . JOURNAL OF CLINICAL ONCOLOGY . vol. 23 , 844S - 844S .

Shamash J, Powles T, Mutsangwa K, Cotton L, Oliver T ( 2005 ) . A phase II study of irinotecan, paclitaxel and oxaliplatin (IPO) in patients with multiply relapsed germ cell tumours (GCT) . Journal of Clinical Oncology vol. 23 , ( 16_suppl ) 4527 - 4527 .

Shamash J, Powles T, Mutsangwa K, Cotton L, Oliver T ( 2005 ) . A phase II study of irinotecan, paclitaxel and oxaliplatin (IPO) in patients with multiply relapsed germ cell tumours (GCT) . JOURNAL OF CLINICAL ONCOLOGY . vol. 23 , 384S - 384S .

Powles TB, Bhardwa J, Shamash J, Mandalia S, Oliver T ( 2005 ) . The changing presentation of germ cell tumours of the testis between 1983 and 2002 . BJU INT vol. 95 , ( 9 ) 1197 - 1200 .

Berney DM, Argyle K, Cheang M, Powles T, Oliver RTD ( 2005 ) . Erythropoietin and erythropoietin receptor expression in renal cell carcinomas . JOURNAL OF PATHOLOGY . vol. 205 , 14 - 14 .

Bower M, Powles T, Stebbing J, Thirlwell C ( 2005 ) . Potential antiretroviral drug interactions with cyclophosphamide, doxorubicin, and etoposide [10] . Journal of Clinical Oncology vol. 23 , ( 6 ) 1328 - 1329 .

Shamash J, Powles T, Wilson P, Ansell W, Oliver T ( 2005 ) . Prognostic factors in cytokine-refractory renal cell carcinoma treated with irinotecan, cisplatin, and mitomycin chemotherapy . J CLIN ONCOL vol. 23 , ( 6 ) 1323 - 1325 .

Powles T, te Poele R, Shamash J, Chaplin T, Propper D, Joel S, Oliver T, Liu WM ( 2005 ) . Cannabis-induced cytotoxicity in leukemic cell lines: the role of the cannabinoid receptors and the MAPK pathway . Blood vol. 105 , ( 3 ) 1214 - 1221 .

Bower M, Powles T, Newsom-Davis T, Thirlwell C, Stebbing J, Mandalia S, Nelson M, Gazzard B ( 2004 ) . HIV-associated anal cancer: Has highly active antiretroviral therapy reduced the incidence or improved the outcome? . Journal of Acquired Immune Deficiency Syndromes vol. 37 , ( 5 ) 1563 - 1565 .

Marvin V, Stebbing J, Powles T, Bower M ( 2004 ) . The pharmacogenomics of anti-cancer chemotherapy . Minerva Biotecnologica vol. 16 , ( 3 ) 181 - 188 .

Oliver T, Shamash J, Powles T, Somasundram U ( 2004 ) . 20 year phase 1/2 study of single agent carboplatin in metastatic seminoma: Could it have been accelerated by 72 hr PET scan response? . JOURNAL OF CLINICAL ONCOLOGY . vol. 22 , 447S - 447S .

Powles T, Shamash J, Ong J, MacDonald D, Kyle F, Palmiera C, Moller H, Oliver T ( 2004 ) . The rising incidence of stage I seminoma; a reflection of earlier diagnosis of germ cell cancer of the testis in last 20 years . JOURNAL OF CLINICAL ONCOLOGY . vol. 22 , 387S - 387S .

Powles T, Bower M, Shamash J, Stebbing J, Ong J, Daugaard G, De Ruiter A, Johnson M et al. ( 2004 ) . Outcome of patients with HIV-related germ cell tumours: a case-control study . BRIT J CANCER vol. 90 , ( 8 ) 1526 - 1530 .

Powles T, Powles J, Nelson M, Sandison A, Peston D, Buchannan J, Mandalia S, Gazzard B et al. ( 2004 ) . Head and neck cancer in patients with human immunodeficiency virus-1 infection: incidence, outcome and association with Epstein-Barr virus . J LARYNGOL OTOL vol. 118 , ( 3 ) 207 - 212 .

Liu WM, Powles T, Shamash J, Propper D, Oliver T, Joel S ( 2004 ) . Effect of haemopoietic growth factors on cancer cell lines and their role in chemosensitivity . Oncogene vol. 23 , ( 4 ) 981 - 990 .

Powles T, Shamash J, Liu W ( 2004 ) . Erythropoietin to treat anaemia in patients with head and neck cancer . LANCET vol. 363 , ( 9402 ) 82 - 82 .

Kaanders JHAM, Van Der Kogel AJ, Haddad R, Posner M, Leyland-Jones B, Mahmud S, Blumberg N, Heal JM et al. ( 2004 ) . Erythropoietin to treat anaemia in patients with head and neck cancer [2] (multiple letters) . Lancet vol. 363 , ( 9402 ) 78 - 79 .

Powles T, Bower M ( 2004 ) . HIV and the risk of lung cancer . Journal of Clinical Oncology vol. 22 , ( 7 ) 1348 - 1349 .

Powles T, Nelson M, Bower M ( 2003 ) . HIV-related lung cancer - A growing concern? . International Journal of STD and AIDS vol. 14 , ( 10 ) 647 - 651 .

Powles T, Shamash J, Berney D, Oliver RTD ( 2003 ) . Irinotecan in patients with relapsed or cisplatin-refractory germ cell cancer: a phase II study of the German Testicular Cancer Study Group . BRIT J CANCER vol. 89 , ( 6 ) 1140 - 1141 .

Powles T, Thirwell C, Newsom-Davis T, Nelson M, Shah P, Cox S, Gazzard B, Bower M ( 2003 ) . Does HIV adversely influence the outcome in advanced non-small-cell lung cancer in the era of HAART? . British Journal of Cancer vol. 89 , ( 3 ) 457 - 459 .

Powles T, Thirlwell C, Nelson M, Bower M ( 2003 ) . Immune reconstitution inflammatory syndrome mimicking relapse of AIDS related lymphoma in patients with HIV 1 infection . Leukemia and Lymphoma vol. 44 , ( 8 ) 1417 - 1419 .

Powles T, Liu W, Shamash J, Oliver T, Joel S ( 2003 ) . The effect of recombinant erythropoeitin on renal cancer cell lines and its role in chemosensitivity . BRITISH JOURNAL OF CANCER . vol. 88 , S66 - S66 .

Powles T, Shamash J, Joel S, Oliver T, Liu W ( 2003 ) . The role of CB1 and CB2 receptors in cannabis induced apoptosis in vitro . BRITISH JOURNAL OF CANCER . vol. 88 , S25 - S25 .

Powles T, Bower M, Daugaard G, Shamash J, De Ruiter A, Johnson M, Fisher M, Anderson J et al. ( 2003 ) . Multicenter study of human immunodeficiency virus-related germ cell tumors . J CLIN ONCOL vol. 21 , ( 10 ) 1922 - 1927 .

Bower M, Powles T, Nelson M, Shah P, Cox S, Mandelia S, Gazzard B ( 2003 ) . HIV-related lung cancer in the era of highly active antiretroviral therapy . AIDS vol. 17 , ( 3 ) 371 - 375 .

Cuzick J, Powles T, Veronesi U, Forbes J, Edwards R, Ashley S, Boyle P ( 2003 ) . Overview of the main outcomes in breast-cancer prevention trials . Lancet vol. 361 , ( 9354 ) 296 - 300 .

Powles T, Nelson M, Bower M ( 2003 ) . HIV-related testicular cancer . International Journal of STD and AIDS vol. 14 , ( 1 ) 24 - 27 .

Stebbing J, Wildfire A, Portsmouth S, Powles T, Thirlwell C, Hewitt P, Nelson M, Patterson S et al. ( 2003 ) . Paclitaxel for anthracycline-resistant AIDS-related Kaposi's sarcoma: Clinical and angiogenic correlations . Annals of Oncology vol. 14 , ( 11 ) 1660 - 1666 .

Powles T, Daugaard G, Nelson M, Oliver T, Fisher M, Stebbing J, Johnson M, Gazzard B et al. ( 2002 ) . Multi-centre cohort study of testicular, cancer in men with HIV . BRIT J CANCER vol. 86 , S19 - S19 .

Powles T, Imami N, Nelson M, Gazzard BG, Bower M ( 2002 ) . Effects of combination chemotherapy and highly active antiretroviral therapy on immune parameters in HIV-1 associated lymphoma . AIDS vol. 16 , ( 4 ) 531 - 536 .

Powles T, Bower M, Nelson M, Oliver RTD ( 2002 ) . HIV related testicular cancer . GERM CELL TUMOURS V . Editors: Harden, P, Joffe, JK, Jones, WG , 51 - 52 .

Powles T, Matthews G, Bower M ( 2000 ) . AIDS related systemic non-Hodgkin's lymphoma . Sexually Transmitted Infections vol. 76 , ( 5 ) 335 - 341 .

Matthews GV, Bower M, Mandalia S, Powles T, Nelson MR, Gazzard BG ( 2000 ) . Changes in acquired immunodeficiency syndrome-related lymphoma since the introduction of highly active antiretroviral therapy . Blood vol. 96 , ( 8 ) 2730 - 2734 .

Powles T, Bower M ( 2000 ) . HIV-associated Hodgkin's disease . International Journal of STD and AIDS vol. 11 , ( 8 ) 492 - 494 .

Kaltsas GA, Powles TB, Evanson J, Plowman PN, Drinkwater JE, Jenkins PJ, Monson JP, Besser GM et al. ( 2000 ) . Hypothalamo-pituitary abnormalities in adult patients with Langerhans cell histiocytosis: Clinical, endocrinological, and radiological features and response to treatment . Journal of Clinical Endocrinology and Metabolism vol. 85 , ( 4 ) 1370 - 1376 .

Gill J, Powles T, Bower M ( 2000 ) . The molecular genetics of human herpesvirus 8 . Hospital Medicine vol. 61 , ( 5 ) 306 - 309 .